Novel Mechanisms of Antihelminth Immunity by Entwistle, Lewis James
 1 
 




Lewis James Entwistle 
 
 
The Francis Crick Institute, 
London 
 
University College London 
 
PhD Supervisor: Mark S. Wilson 
 






I, Lewis James Entwistle, confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 




Intestinal helminths are highly prevalent worldwide, infecting approximately a third of 
the world’s population, causing significant host morbidity. With no current vaccines, 
a limited number of effective chemotherapeutic drugs available and the emergence 
of drug-resistant helminths, it is essential to further our understanding of the 
mechanisms of antihelminth immunity. Our current understanding of antihelminth 
immunity places the type 2 immune response at the forefront of protection, with type 
2 cytokines orchestrating and activating a plethora of immune and non-immune cells 
to mediate parasite expulsion. The naturally occurring intestinal helminth 
Heligmosomoides polygyrus establishes a chronic infection in many inbred naïve 
mice, with resistance to a challenge infection established following drug-cure. This 
experimental model allows us to identify novel mechanisms of drug-induced 
resistance, relative to susceptibility. 
In this thesis, we utilised next generation sequencing technology to identify two novel 
mechanisms of antihelminth immunity. Firstly, we determined that the enzyme 
phospholipase A2 group 1B (PLA2g1B) is an endogenous anthelmintic, upregulated 
in intestinal epithelial cells of resistant mice. We demonstrated that PLA2g1B was 
essential for resistance to H. polygyrus and that PLA2g1B directly cleaves 
phospholipids off infective H. polygyrus larvae. Secondly, we identified that the 
microRNAs miR-99a-5p, miR-148a-3p and miR-155-5p were upregulated in mice 
resistant to H. polygyrus during infection and were also essential for functional 
immunity. In summary, we have identified and characterised two novel mechanisms 
of antihelminth immunity and propose a model of tissue memory, essential for 





The analysis, discovery and insight presented in this thesis further our understanding 
of antihelminth immunity. Utilising RNA sequencing, we identified and describe two 
novel mechanisms of immunity to intestinal helminth infection. These findings have 
the potential to benefit other basic, translational and clinical researchers in the fields 
of parasitology and immunology. Furthermore, these findings may also impact the 
pharmaceutical industry and improve human health by providing new therapeutic 
opportunities in the rational design of anthelmintic drugs and/or the manipulation of 
microRNA (miRNA) expression. 
Specifically, the vast RNA sequencing datasets created and analysed in this thesis 
provide an abundance of high quality, high resolution data from mice susceptible and 
resistant to an experimental intestinal helminth infection. These datasets are 
publically available and knowledge of this will be disseminated upon publishing of 
these results in scientific journals. Further mining of these transcriptomic datasets 
has the potential for the discovery of further novel mechanisms of antihelminth 
immunity. This will therefore benefit basic and translational researchers in the field 
of antihelminth immunity. 
The discovery that phospholipase A2 group 1B (PLA2g1B) acts as an endogenous 
anthelmintic and is critical for protective immunity to intestinal helminth infection 
furthers our understanding of important antihelminth responses. Furthermore, the 
demonstration that PLA2g1B cleaves phospholipids from infective larvae has 
revealed a completely new mechanism of antihelminth immunity. This discovery 
should spur interest in identifying the specific roles of larval phospholipids in infection, 
host-parasite interaction and larval development amongst the basic parasitology and 
immunoparasitology research communities. Moreover, further elucidation of 
PLA2g1B’s effect on intestinal helminths and the role of parasite-phospholipids in 
helminth infection and health would be of interest in the pharmaceutical industry. 
Specifically, in the design of synthetic helminth-specific molecules to recapitulate the 
effects of endogenous PLA2g1B, leading to the generation of new anthelmintics. The 
discovery of PLA2g1B as an endogenous anthelmintic could therefore impact 
treatment strategies of intestinal helminth infection, thus improving human health. 
 5 
 
As part of this thesis, we may have identified a discrepancy between pharmacological 
inhibition of miRNAs and genetic deletion studies of miRNAs. This discrepancy is 
particularly important in the translation of basic research using genetic miRNA-
deficient models into pharmacological inhibition for potential use in the clinic. We also 
demonstrate that inhibition of a suite of miRNAs abrogated protective immunity to 
intestinal helminth infection, whereas individual miRNA inhibition did not. This 
highlights the complex nature of miRNAs in vivo cooperating to regulate specific 
biological functions and pathways. These insights into miRNA-regulated antihelminth 
immunity will benefit basic researchers with interests in immunoparasitology, 
immunology and miRNA biology. 
Finally, our data provides insights into the phenomenon of ‘tissue memory’ being 
both present and essential in protection against intestinal helminth infection. Our 
findings should stimulate important questions in the realm of ‘tissue memory’ that are 
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Chapter 1. Introduction 
1.1 Intestinal helminths 
Helminths are a class of large, multicellular organisms that are both free-living and 
parasitic. Intestinal helminth infections are highly prevalent worldwide, infecting 
approximately a third of the world’s population, and represent a large part of the 17 
neglected tropical diseases (NTDs) (WHO, 2012). As well as humans, intestinal 
helminth infections are also extremely common in livestock. As a result, intestinal 
helminth infections are responsible for significant health and economic burdens 
(Bartsch et al., 2016, Fitzpatrick, 2013, Bethony et al., 2006). There are two main 
phyla of helminths: the nematodes (also known as roundworms) and the 
platyhelminths (also known as flatworms). The nematodes comprise of the intestinal 
worms (often referred to as soil-transmitted helminths) and the filarial worms that 
cause lymphatic filariasis and onchocerciasis. The platyhelminths comprise of the 
flukes (or trematodes), such as the schistosomes, and tapeworms (or cestodes) 
(Hotez et al., 2008). 
 
1.1.1 Soil-transmitted helminthiasis 
Soil-transmitted helminthiasis (STH) is highly prevalent in tropical and subtropical 
areas and often associated with impoverished conditions and poor sanitation, 
contributing to transmission by faecal contamination. The most common human soil-
transmitted helminths are Ascariasis lumbrocoides (roundworm), Trichuris trichiura 
(whipworm), Necator americanus (hookworm), Ancylostoma duodenale (Hookworm) 
and Strongyloides stercoralis (threadworm); with many individuals often 
polyparasitised (infected with more than one species of parasitic worm) (Hotez et al., 
2008). Left untreated, intestinal helminths often establish chronic, multi-year 
infections, despite not replicating in the host (with the exception of Strongyloides 
stercoralis).  
In 2015, The World Health Organisation estimated that 883 million children are in 
need of treatment for STH (2011). Despite rarely inducing host mortality, many host 
morbidities are associated with chronic STH, causing an estimated global loss of 5.3 
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million Disease Adjusted Life Years (DALYs) (2016). Morbidities, including anaemia, 
growth stunting, malnutrition, fatigue and poor cognitive development, can be more 
severe and have a greater impact on children, particularly in reducing school 
attendance and impairing educational performance (Miguel and Kremer, 2004). 
These morbidities are primarily due to parasitism by the intestinal worms, feeding on 
the host’s intestinal mucosa, submucosa, blood and ingested food. 
STH is currently treated with chemotherapeutic anthelmintic drugs, such as 
ivermectin, albendazole and praziquantel. Many countries and global programmes 
have adopted mass deworming strategies, outlined by the WHO, in an attempt to 
control human helminthiases and eliminate morbidity. However, chemotherapeutic 
treatment is not prophylactic, only curing current infections, therefore failing to 
provide long lasting immunity. In addition, drug-resistant helminths have been 
identified in livestock (Kaplan and Vidyashankar, 2012), highlighting the danger of 
mass drug administration. 
With no current licenced preventative vaccines, the development of antihelminth 
vaccines are essential in providing long lasting, prophylactic protection against 
infection. Unfortunately, the pipeline of antihelminth vaccine antigens are profoundly 
modest. This is a reflection of the huge scientific challenge to successfully identify 
relevant helminth antigens, with significant problems including limitations in the 
mining of helminth genomes, lack of translation in current animal models and the 
absence of strong correlates of protection for accelerating clinical development 
(Hotez et al., 2016). Despite these difficulties, there are currently two hookworm 
antigens and three schistosome antigens in clinical trials for antihelminth vaccines 
(Hotez et al., 2016).  
With an over reliance on chemotherapeutic drugs, the emergence of drug-resistant 
helminths and stalling vaccine efforts, it is essential that we further our understanding 
of antihelminth immunity in the hope of identifying new therapeutic targets and 
treatment strategies. 
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1.1.2 Animal models of soil-transmitted helminthiasis 
Much of our understanding of intestinal helminth infection has originated from the 
use of laboratory animal models. In particular, mouse models of Heligmosomoides 
polygyrus, Nippostrongylus brasiliensis, Trichuris muris and Trichinella spiralis have 
been studied extensively. In addition, intestinal helminths of larger mammals, such 
as sheep and pigs, have also been studied.  
Each of the mouse intestinal helminths studied in the laboratory have different routes 
of infections, life cycles and niches, but all at some point reside in the intestinal tract, 
where they mature, become sexually active and produce eggs. The subtleties 
between the different helminth models have enabled the identification and 
description of fundamental immune responses to helminth infections, as well as 
highlight differences between specific species. Our current understanding of the 
immune response to intestinal helminth infection is outlined in section 1.2. 
 
1.1.2.1 Heligmosomoides polygyrus 
Heligmosomoides polygyrus is a naturally occurring intestinal helminth of the mouse, 
first isolated from wild mice in 1939 (Spurlock, 1943). It shares the same 
phylogenetic Order, Strongylida, as the human hookworm parasites N. americanus 
and A. duodenale as well as the ruminant parasites Haemonchus contortus and 
Teladorsagia circumcincta (Gouy de Bellocq et al., 2001). Heligmosomoides 
polygyrus has been referred to by a variety of names over the past 70 years, such 
as Nematospiroides dubius, Heligmosomoides polygyrus bakeri and 
Heligmosomoides polygyrus polygyrus, but here will be referred to as H. polygyrus 
throughout. 
H. polygyrus is a strictly enteric helminth and is subsequently transmitted by the 
faecal-oral route (Ehrenford, 1954). H. polygyrus eggs, measuring approximately 77 
microns long by 45 microns wide, are secreted in the host faeces at the 8-16 cell 
stage, becoming fully embryonated after 8-10 hours before hatching after a further 
16 hours at temperatures of 23-28oC (Ehrenford, 1954). The first stage (L1) larvae, 
undergo two developmental moults (or ecdysis) to become L2 then infective L3 
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larvae, measuring 480-563 microns long. The final ecdysis, from L2 to L3 larvae, is 
not complete outside the host as the L3 larvae retain the cuticle from the L2 larvae 
as a protective sheath, marking the transition from the free living to the parasitic 
stage (Sommerville, 1957, Ehrenford, 1954). Following oral infection with L3 H. 
polygyrus larvae, the larvae enter the digestive tract where they are exsheathed in 
the stomach of host, losing the cuticle retained from the L2 stage (Sommerville and 
Bailey, 1973). The L3 larvae then pass into the small intestine where they penetrate 
the intestinal mucosa and embed into the muscularis externa within 48 hours of 
infection (Camberis et al., 2003, Ehrenford, 1954). Here the larvae undergo rapid 
growth, resulting in two developmental moults (into the L4 then L5 stage), and re-
emerge into the lumen as adult L5 worms after approximately 10 days to feed on 
host intestinal tissue (Camberis et al., 2003, Bansemir and Sukhdeo, 1994). In the 
lumen the adult worms wrap around the villi to anchor themselves, favouring the 
duodenum and anterior jejunum due to increased villus length (Bansemir and 
Sukhdeo, 1996). Adult females are significantly larger than adult male H. polygyrus 
worms, measuring 18-21 and 8-10 mm respectively (Ehrenford, 1954). In the lumen, 
adult worms form mating pairs and produce eggs which are released into the 
environment in the host’s faeces, thus continuing the life cycle (Ehrenford, 1954, 
Camberis et al., 2003). The life cycle of H. polygyrus is summarised in Figure 1.1. 
H. polygyrus is frequently used as a model to investigate host immunity to intestinal 
helminth infections in an attempt to delineate mechanisms of susceptibility and 
resistance (Allen and Maizels, 2011, Maizels et al., 2012b). Unlike the mouse-
adapted rat parasite N. brasiliensis, H. polygyrus establishes a chronic infection in 
susceptible strains of mice (Ehrenford, 1954), enabling the modelling of human 
chronic STH in an evolutionary adapted host. With a strictly enteric lifecycle, H. 
polygyrus is also a suitable model for studying the development of intestinal immune 
response in isolation, without the complexity of immune responses in other organs 
(such as the lung following N. brasiliensis infection or the muscle following T. spiralis 
infection). 
Following primary (1o) infection of H. polygyrus, the length of time the infection can 
persist is dependent upon the strain of mouse. SJL and SWR mice are able to clear 
1o H. polygyrus infection most rapidly, in 4-6 weeks of infection; BALB/c, DBA/2 and 
NIH mice in 6-8 weeks; C57BL/6, C57BL/10 and 129/J mice in 8-20 weeks; whilst 
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CBA C3H, SL and A/J mice take more than 20 weeks to expel 1o infection (Ben-
Smith et al., 2003, Reynolds et al., 2012) as well as failing to mount a protective 
response to secondary (2o) challenge infection (Enriquez et al., 1988). Genetic 
comparison of these strains identified the major histocompatibility complex (MHC) H-
2 loci as a significant genetic factor which mediates differences in susceptibility 
(Behnke and Robinson, 1985). Specifically, studies with H-2 congenic C57BL/10 
mouse strains elegantly demonstrate that mice with H-2s, H-2d or H-2q haplotypes 
expelled H. polygyrus 1o infection more rapidly, whereas mice with H-2b or H-2k 
haplotypes, backcrossed onto the fast expelling BALB/c background, were unable to 
expel as quickly (Behnke and Wahid, 1991). Importantly, establishment of 1o 
infection after two weeks was equal between all strains (Behnke and Wahid, 1991), 
suggesting that protective immune response and expulsion mechanisms were 
generated at different rates depending on haplotype. A study comparing the fast 
expelling SWR and slow expelling CBA strains identified significant candidate genes 
associated with resistance using quantitative trait loci mapping, including MHC, Il9 
(encoding Interleukin (IL)-9), Mcp6, Mcp7 (encoding mast cell protease 6 and 7, 
respectively) and several trefoil factors (Behnke et al., 2003). Gender also influences 
susceptibility to H. polygyrus infection, with female mice of all strains clearing 1o and, 
to a lesser extent, 2o infections quicker than male mice (Van Zandt et al., 1973, 
Dobson and Owen, 1978, Wahid and Behnke, 1993). 
If 1o H. polygyrus infection is cleared using anthelmintic drugs, such as Pyrantel 
Embonate, the majority of mouse strains are resistant to 2o challenge infection due, 
in part, to the generation of an effective memory immune response (Finkelman et al., 
1997). Interestingly, during 2o infection the majority of parasites are trapped and 
killed in the intestinal wall during development (acquired resistance) (Chaicumpa et 
al., 1977), unlike in 1o infection where more resistant strains clear the infection once 
the adult worms have emerged into the intestinal lumen (natural resistance) (Behnke 
and Wahid, 1991). The mechanisms of killing and expulsion in both acquired and 
natural resistance may be subtly different as the parasite is located in two distinct 
areas of the intestine. 
A third model of resistance to H. polygyrus has also been developed, utilising 
vaccination. Mice are able to elicit sterile immunity to 1o infection following 
immunisation with H. polygyrus excretory-secretory antigens (HES) alongside an 
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alum adjuvant, trapping and killing the parasites in the intestinal wall (Hewitson et 
al., 2011, Hewitson et al., 2015). 
Intestinal helminths have immunomodulatory properties, enabling establishment of 
chronic infection by defusing host immune responses and without inducing host 
mortality. H. polygyrus has been used as a mouse model to study the 
immunomodulatory properties of intestinal helminths as it has evolved to establish 
chronic infection in the mouse. A TGF-like protein is secreted by H. polygyrus which 
induces the differentiation of regulatory T cells (Tregs) which dampen the immune 
response to H. polygyrus, allowing a chronic infection to establish (Maizels et al., 
2012a, Grainger et al., 2010, Rausch et al., 2009). Furthermore, adult H. polygyrus 
secrete exosomes containing parasite-derived miRNAs which are transferred to the 
host to supress type 2 immunity (Buck et al., 2014) (see section 1.3.3.4). 
 
1.1.2.2 Nippostrongylus brasiliensis 
N. brasiliensis is a naturally occurring intestinal helminth of rats, which has been 
adapted for use in mice, and is used in the laboratory as an acute model of human 
hookworm infection. 
Unlike H. polygyrus, N. brasiliensis penetrates the skin and migrates through the lung 
before traveling up the trachea, down the oesophagus and finally reside in the small 
intestine. Eggs are secreted in the host faeces into the environment at the 16-21-cell 
stage (Camberis et al., 2003). In the environment, the eggs hatch after 24 hours and 
undergo two developmental moults from L1 to L2 larvae after a further 24 hours and 
L2 to infective L3 larvae within a further 24 hours (Camberis et al., 2003). The 
infective L3 larvae undergo full ecdysis in the environment and therefore do not retain 
a protective sheath, unlike H. polygyrus (Camberis et al., 2003). The infective L3 
larvae penetrate the skin within five minutes of contact, although the majority of 
experimental infections are given by subcutaneous injection, and burrow into the 
epidermis before migrating into the bloodstream (Haley, 1962, Camberis et al., 
2003). Within 11 hours of infection the L3 larvae can be found in the lung after 
migrating through the pulmonary blood vessels. Here, in the lung, the larvae undergo 
another developmental moult into L4 larvae where they remain until approximately 
Chapter 1 Introduction 
24 
 
4-5 days post infection (Haley, 1962, Camberis et al., 2003). At this point, the L4 
larvae migrate up the airways of the lung and trachea, down the oesophagus and 
through the stomach before establishing in the duodenum and jejunum. In the small 
intestine, the L4 larvae undergo their final developmental moult into L5 adult worms 
which feed on host tissue, mate and produce eggs (Camberis et al., 2003) (Haley, 
1962). Eggs are found in the host faeces from 6 days-post infection, peaking 
between days 8 and 9 before declining as the worms are expelled by day 11 
(Camberis et al., 2003). 
For experimental use, mice are normally infected with 200-500 L3 larvae by 
subcutaneous injection. Bolus infections greater than 1000 L3 larvae in a 1o infection 
causes significant host morbidity and occasional mortality (Camberis et al., 2003). 
However, mice can cope with infections greater than 1000 L3 larvae upon 2o infection 
(Camberis et al., 2003), as most worms are killed. 
 
1.1.2.3 Trichuris muris 
T. muris is a naturally occurring intestinal helminth of the mouse and is used in the 
laboratory to model Trichuris trichiura infections in humans.  
T. muris is also a strictly enteric helminth and has no free living larval stages, unlike 
H. polygyrus and N. brasiliensis. Infection occurs upon host ingestion of infective 
eggs. T. muris eggs accumulate in the cecum and after ninety minutes post infection 
the L1 larvae hatch from the eggs. The interaction of the host microbiota is critical 
for the induction of egg hatching, with bacterial type 1 fimbrae being essential (Hayes 
et al., 2010). Upon hatching, L1 larvae penetrate into the wall of the proximal colon, 
including the cecum, where it resides in the epithelial layer and undergoes three 
more developmental moults to the L4 stage (Klementowicz et al., 2012). By 32 days-
post infection, adult worms are present, at which point eggs are secreted and can be 
found in the host faeces (Klementowicz et al., 2012). During the course of 
development, the parasite gets larger and the posterior of the whipworm extends into 
the lumen of the gut. The anterior part of the whipworm remains buried in parasite-
modified epithelial cells, in contact with the epithelial cell cytoplasm from where they 
absorb nutrients (Tilney et al., 2005). Eggs secreted in the host faeces require 
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approximately 2 months to embryonate and become infective (Klementowicz et al., 
2012). 
Mice with different genetic backgrounds vary in susceptibility to T. muris infection. 
Similar to genetic susceptibility to H. polygyrus, the H-2 allele of the MHC influences 
susceptibility to T. muris; with H-2k and H-2d haplotypes being more susceptible than 
the H-2q and H-2b haplotypes, which expel the parasites faster (Else et al., 1990, Else 
and Wakelin, 1988). 
Infective dose size can also influence the balance between susceptibility and 
resistance to T. muris infection through altering the polarisation of the immune 
response. Specifically, low dose infections of less than 40 eggs develop a chronic 
infection due to the development of a susceptible-associated type 1 immune 
response (Bancroft et al., 1994). Whereas a high dose infection of more than 200 
eggs are expelled through the initiation of a type 2 immune response (Bancroft et al., 
1994). Moreover, a high dose infection also renders mice resistant to subsequent 
high or low dose infections through the generation of a memory Th2 response 
(Bancroft et al., 2001). 
 
1.2 Immunity to intestinal helminth infection 
Our current understanding of the immune response to intestinal helminths, 
underpinning susceptibility and resistance, has developed predominantly from 
observations made in laboratory animal models as well as clinical observations. 
These observations have placed type 2 immunity at the forefront of protection against 
intestinal helminth infection. In this section, the immune response to intestinal 
helminths is outlined, drawing on information gathered using mouse models of H. 
polygyrus, N. brasiliensis and T. muris infection (Figure 1.2). 
Upon entry into the intestine, helminth presence and damage to local tissue is 
detected by intestinal epithelial cells, which secrete a variety of alarmin-type 
cytokines, including IL-25, IL-33 and TSLP, which activate immune cells and initiate 
immunity (Zaph et al., 2007, Gerbe et al., 2016, von Moltke et al., 2016, Howitt et al., 
2016). These alarmin cytokines support the activation and expansion of a suite of 
innate and adaptive immune cells (Fallon et al., 2006, Saenz et al., 2008, Saenz et 
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al., 2010). Both group 2 innate lymphoid cells (ILC2s) and antigen sampling dendritic 
cells (DCs) process and present helminth antigens and promote T helper (Th)2 cell 
differentiation. CD4+ Th2 cells are essential in orchestrating an effector type 2 
immune response (Grencis et al., 1991, Hashimoto et al., 2009, Urban et al., 1991a) 
in the small intestine through the secretion of the type 2 cytokines IL-4, IL-5 and IL-
13 (Oeser et al., 2015). These cytokines act on a plethora of immune and stromal 
cells, inducing immunological and physiological changes. IL-4 and IL-13 driven 
alternatively activated macrophages contribute significantly to various aspects, 
including helminth trapping, immune cell activation and wound healing (Anthony et 
al., 2006, Esser-von Bieren et al., 2015, Herbert et al., 2004, Gratchev et al., 2001). 
Similarly, the activation of mast cells (Hepworth et al., 2012) and basophils (Herbst 
et al., 2012, Schwartz et al., 2014) and the mobilisation of granulocytes, such as 
eosinophils (Patel et al., 2009, Morimoto et al., 2004) and neutrophils (Sutherland et 
al., 2014, Chen et al., 2014, Morimoto et al., 2004), contribute to parasite trapping 
and support cytokine-mediated effector pathways. The development of memory Th2 
cells, as well as IL-4, IL-5 and IL-13 induced B cell expansion, class switching and 
the production of parasite specific antibodies (McCoy et al., 2008), are essential for 
long-lived immunological memory and immunity to subsequent infection. IL-4 and IL-
13 driven physiological changes culminate in a ‘weep and sweep’ response in an 
attempt to physically remove the parasite from the intestinal lumen, involving 
increased epithelial turnover (Cliffe et al., 2005), goblet cell hyperplasia with mucus 
hypersecretion (Hasnain et al., 2011, Hasnain et al., 2010) and smooth muscle 
contraction (Vallance et al., 1997). Although the exact mechanism of helminth killing 
is unclear, epithelial cell-derived Relm was shown to have direct antihelminth 
effects, inhibiting the feeding of adult worms in the intestine (Herbert et al., 2009).  
 
1.2.1 Adaptive immunity 
1.2.1.1 T cells 
T lymphocytes (T cells) develop from common lymphoid progenitor (CLP) cells in the 
bone marrow, before exiting through the lymphatic system into the thymus. Here, the 
CLP cells undergo multiple stages of development, leading to the formation of 
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functional α and β T cell receptors (TCRs) (mediated by RAG genes), commitment 
to CD4 or CD8 fate and establish central tolerance (reviewed in (Shah and Zuniga-
Pflucker, 2014)) producing a constant supply of peripheral T cells. Mature, naïve 
CD4+ T cells exit the thymus and migrate through lymphatic vessels to tissue-
draining lymph nodes, such as the intestine-draining mesenteric lymph nodes (mLN). 
Naïve T cell differentiation into specialised T helper (Th) subsets requires 
presentation of an antigen on MHC class II molecules from an antigen presenting 
cell (APC) to the αβTCR, co-receptor stimulation (T cell CD28 interacting with 
CD80/86 receptors on the APC) and a cytokine signal, usually from a primed innate 
immune cell, to direct the differentiation to a specific Th subtype. Th2 cell 
differentiation requires exogenous IL-4, enabling the secretion of the canonical Th2 
cytokines IL-4, IL-5 and IL-13 (Le Gros et al., 1990). 
CD4+ cells are essential for immunity to both H. polygyrus (Urban et al., 1991a), N. 
brasiliensis (Urban et al., 1995) and T. muris (Koyama et al., 1995, Else and Grencis, 
1996), with CD4+ Th2 cell differentiation observed upon intestinal helminth infection 
(Svetic et al., 1993, Rausch et al., 2008, Bancroft et al., 1994). Both gene expression 
and protein secretion of Th2-associated cytokines were seen to be increased in the 
mLN following H. polygyrus infection (Finney et al., 2007, Svetic et al., 1993), T. 
muris infection (Faulkner et al., 1998, Grencis et al., 1991, Bancroft et al., 1994) and 
N. brasiliensis infection (Ishikawa et al., 1998). The production of the type 2 cytokines 
IL-4 and IL-13 are essential in orchestrating the protective immune response to 
intestinal helminth infection. 
Resistance to 2o H. polygyrus challenge infection is reduced upon administration of 
an IL-4 blocking antibody and completely abolished upon blocking the IL-4 receptor 
(IL-4R), suggesting a partial or compensatory role for IL-13 mediated-protection 
(Urban et al., 1991b). Administration of IL-4 in complex with anti-IL-4 antibody, to 
extend the half-life of IL-4, is sufficient to induce expulsion of 1o H. polygyrus infection 
in BALB/c and SCID mice, which lack T and B cells (Urban et al., 1995). This data 
indicates that the protective effect of exogenous IL-4 complex treatment was not to 
potentiate Th2 cells, but rather to increase the IL-4Rα-dependent innate effector 
responses and activate IL-4Rα-driven pathways in stromal cells, outlined in section 
1.2. 
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Resistance to T. muris infection was also abolished upon genetic deletion of IL-4 in 
C57BL/6 mice (Bancroft et al., 1998, Bancroft et al., 2000) and upon genetic deletion 
of IL-13 in 129 mice (Bancroft et al., 1998). However, when IL-4 was deleted in the 
more resistant BALB/c mouse, resistance to T. muris was maintained in an IL-13 
dependent manner (Bancroft et al., 2000).  
Interestingly, despite IL-4 complex rescuing immunity to N. brasiliensis infection 
following CD4 depletion (Urban et al., 1995), IL-4 is dispensable for resistance to N. 
brasiliensis mouse infection (Urban et al., 1998). Instead, IL-13 production in Il4-
deficient mice and signalling through IL-4Rα and Stat6 confer resistance (Urban et 
al., 1998, McKenzie et al., 1998).  
Despite IL-4 being essential for Th2 differentiation (Le Gros et al., 1990), as a type 
2 effector cytokine, IL-13 has been described to be equally or more important in 
mediating type 2 effector responses through IL-4Rα (Zhu et al., 1999, Li et al., 1999, 
Finkelman et al., 1999). The observations seen in T. muris and N. brasiliensis mouse 
infection models suggest that, in particular intestinal helminth infections, IL-13 is 
sufficient for resistance to infection. 
The Th2 cytokine IL-5, which supports eosinophilia, is not required for protective 
immunity to intestinal helminth infections. Blocking of IL-5 with an antibody did not 
compromise immunity to H. polygyrus or N. brasiliensis (Urban et al., 1991b) and 
genetic deletion of IL-5 did not abrogate resistance to T. muris infection (Dixon et al., 
2006). 
H. polygyrus infection also induces hybrid Th1/2 cells, expressing both Gata-3 and 
T-bet and capable of producing IL-4, IL-13 and IFNγ (Peine et al., 2013). These Th1/2 
hybrid cells are stably maintained as memory cells in vivo and resist reprogramming 
into classic Th1 or Th2 cells. Functionally, Th1/2 hybrid cells can support both 
inflammatory type 1 and type 2 immune responses but cause significantly reduced 
immunopathology than Th1 or Th2 cells, respectively (Peine et al., 2013). Whether 
Th1/2 hybrid cells are important in resistance to intestinal helminth infection is 
currently unclear. However, these cells are likely to be beneficial to intestinal 
helminths as they prevent excessive host pathology and therefore may contribute in 
the establishment of chronic infection. 
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As well as inducing effector T cells, Tregs are also induced upon intestinal helminth 
infection. This phenomenon has been predominantly studied in the laboratory using 
H. polygyrus, with infection potently inducing Tregs (Wilson et al., 2005, Finney et 
al., 2007, Rausch et al., 2008, Pelly et al., 2017). The induction of Tregs during 
intestinal helminth infection is thought to limit the host’s Th2 response, otherwise 
directed at the parasite, and preventing intestinal pathology, collectively establishing 
a chronic infection (Rausch et al., 2009). However, Treg depletion did not induce 
expulsion of H. polygyrus during a 1o infection, despite an increase in Th2 cells and 
their associated cytokines, IL-4 and IL-13 (Rausch et al., 2009). 
 
1.2.1.2 B cells 
B lymphocytes (B cells), like T cells, also develop from common lymphoid progenitor 
(CLP) cells in the bone marrow. They exit the bone marrow into the circulatory 
system as immature B cells and migrate to the spleen to continue their development. 
In the spleen, immature B cells differentiate in to naïve, follicular or marginal zone B 
cells. The maturation of B cells requires the rearrangement of their antigen-specific 
receptor, the B cell receptor (BCR), which is also mediated by RAG genes. Marginal 
zone B cells develop into short lived plasma cells upon contact with antigen, whereas 
follicular B cells develop into memory B cells or plasma cells in the germinal centre 
(reviewed in (Pieper et al., 2013)). 
B cells are responsible for producing antibodies that facilitate the clearance of a 
variety of pathogens and antigens. They also regulate immune responses through 
antibody-independent mechanisms. Upon activation through Toll-like receptor (TLR) 
stimulus, B cells express costimulatory molecules and can act as APCs, up-taking 
specific antigens via their BCR before processing and presenting the antigen to CD4+ 
T cells via MHC class II (Linton et al., 2003, Linton et al., 2000). B cells are therefore 
capable of shaping the primary and memory T cell response through antigen 
presentation (Lund et al., 2006). B cells can also influence immunity through the 
secretion of the cytokines, such as TNFα, IL-6 and IL-10 (Shen and Fillatreau, 2015). 
Elevated IL-4 levels during intestinal helminth infections promote B cell class 
switching and production of IgE and IgG1 antibodies (Katona et al., 1991, Urban et 
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al., 1991a, McCoy et al., 2008). In B cell-deficient mice, resistance is abrogated to 
1o T. muris infection in normally resistant C57BL/6 mice and to 2o challenge infection 
of both H. polygyrus and T. muris (Blackwell and Else, 2001, Liu et al., 2010, 
Wojciechowski et al., 2009). The mechanism by which B cells are protective in 2o H. 
polygyrus infection is currently unclear: two studies demonstrate that in B cell-
deficient mice, protective immunity is not defective due to impairment of a Th2 
response (Liu et al., 2010, McCoy et al., 2008); however, the findings of another 
study suggested that B cell-deficient mice had an impaired Th2 response following 
H. polygyrus infection, with the H. polygyrus-specific memory Th2 response reliant 
upon B cells-derived IL-2 and TNFα (Wojciechowski et al., 2009). Similar conclusions 
were drawn in regard to 1o T. muris infection in B cell-deficient mice, with B cell 
deficiency compromising the Th2 response (Blackwell and Else, 2001). Interestingly, 
B cells are dispensable in mediating protection from 1o or 2o infection with N. 
brasiliensis mouse infection, with B cell-deficient mice still mounting a strong Th2 
response (Liu et al., 2010).  
The role of antibodies in mediating protection against intestinal helminth infection 
remains incompletely understood. Clinical vaccine efforts are currently stalling as 
identifying relevant antigens is proving to be a difficult challenge (Hotez et al., 2016). 
The role of antibodies in mediating protection against laboratory intestinal helminth 
infection differs between animal models. Despite the induction of IgE in WT mice, 
protective immunity was still intact in B cell-deficient mice following N. brasiliensis 
infection (Liu et al., 2010), suggesting that antibodies do not play a critical role in 
expulsion of N. brasiliensis.  
T. muris infection also induces antibody production, with IgM, IgG, IgA and T. muris-
specific IgG1 antibodies seen from 14 days-post infection (Koyama et al., 1999, 
Blackwell and Else, 2002). Despite abrogated resistance to T. muris infection in B 
cell-deficient mice being restored by adoptive transfer of IgG from previously infected 
resistant donor mice (Blackwell and Else, 2001), adoptive transfer of CD4+ T cells 
alone into SCID mice (lacking T and B cells) results in expulsion of T. muris (Else 
and Grencis, 1996). This suggests that antibodies can confer resistance to T. muris 
infection, but they are not essential. 
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Antibodies are essential in mediating protection against H. polygyrus, with infection 
inducing IgA, IgE and IgG1 isotype production (McCoy et al., 2008, Hewitson et al., 
2011). H. polygyrus-induced IgE and IgG1 required MHC class II-dependent CD4+ T 
cell help prior to class switching (McCoy et al., 2008). 1o H. polygyrus infection also 
induces a nonspecific, polyclonal antibody response, whereas 2o infection induces 
H. polygyrus-specific antibodies (McCoy et al., 2008). Nonspecific, polyclonal IgG 
functions to limit parasite fecundity, whereas affinity matured, parasite-specific IgG1 
and IgA promote protective immunity upon passive transfer to naïve mice (McCoy et 
al., 2008, Wojciechowski et al., 2009). Despite the production of both H. polygyrus-
specific and nonspecific IgE following infection, both IgE and IgM have no role in 
protective immunity (McCoy et al., 2008, Wojciechowski et al., 2009). Vaccination of 
naïve mice with HES and an alum adjuvant induces the generation of HES-specific 
IgG1 antibodies which promote sterile immunity to subsequent H. polygyrus infection 
(Hewitson et al., 2015, Hewitson et al., 2011). It is unclear whether similar titres of 
HES-specific antibodies develop naturally and contribute to resistance. 
Parasite-specific IgG1 antibodies are believed to confer protection to H. polygyrus 
through the trapping of L3/L4 larvae in the intestinal wall. H. polygyrus-specific 
antibodies were shown to promote adherence of macrophages to L3 larvae in vitro, 
reducing larval motility, and promote larval trapping in the intestinal wall in vivo 
(Esser-von Bieren et al., 2013). Antibody-mediated trapping of larvae in the tissue 
was dependent on CD11b (involved in complement-mediated immune complex 
binding (Sanchez-Madrid et al., 1983)) and IgG receptor FcγRI (CD64) expression 
on macrophages, with CD11b mediating macrophage adherence to the larvae and 
FcγRI promoting macrophage IL-4-independent expression of Arginase 1 (Arg1) 
(Esser-von Bieren et al., 2015, Esser-von Bieren et al., 2013). However, FcγR-
deficient mice and complement component C3-deficient mice are still able to expel 
2o challenge H. polygyrus infection (McCoy et al., 2008), therefore suggesting this 
mechanism of helminth trapping is not essential for protective immunity. Data from 
the vaccine-induced immunity model to H. polygyrus suggests that the protective 
effects of parasite-specific IgG1 are not mediated by activation of FcγRI, but instead 
rely on IL-4Rα- and IL-25-dependent effector cells (Hewitson et al., 2015).  
These data suggest that the role of H. polygyrus-specific antibodies differs between 
vaccine-mediated and acquired immunity: IgG1-mediated binding of larvae by 
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macrophages is not essential for vaccine-induced immunity; instead IgG1 is critical 
for sequestering HES products which allows for effector immune cells to promote H. 
polygyrus expulsion. 
 
1.2.2 Innate immunity 
1.2.2.1 Innate lymphoid cells 
Innate lymphoid cells (ILCs) differentiate from the common innate lymphoid 
progenitor (CILP) in the bone marrow and are present in mucosal tissues, such as 
the lung and gut (Geiger et al., 2014, Zook and Kee, 2016). ILCs mirror CD4+ Th cell 
subtypes, both in transcription factor expression and their cytokine secretion profile. 
However, ILCs are distinguished from Th cells by their expression of the thymocyte 
marker Thy1.2 and their lack of common lymphocyte lineage markers, such as 
somatically rearranged antigen receptors (e.g. TCR or BCR) (Zook and Kee, 2016). 
Group 1 (ILC1), group 2 (ILC2) and group 3 (ILC3) innate lymphoid cells make up 
the ILC family, including lymphoid tissue inducer (LTi) cells and conventional natural 
killer (NK) cells (reviewed in detail in (Zook and Kee, 2016)). 
ILC2s, first described as nuocytes and innate helper type 2 cells, populate mucosal 
sites as well as the tissue draining lymph nodes (Neill et al., 2010, Fallon et al., 2006, 
Pelly et al., 2016). Unlike other ILCs, ILC2s express Sca-1 and KLRG1 which 
correlate with Gata-3 expression (Zook and Kee, 2016). They also express the IL-25 
receptor (Il17rb) and IL-33 receptor (ST2/Il1rl1), making them responsive to epithelial 
alarmin cytokines (Fallon et al., 2006, Zook and Kee, 2016). ILC2s also express MHC 
class II, allowing them to present antigen (Neill et al., 2010). Upon IL-25 or IL-33 
stimulation, ILC2s produce the type 2 cytokines IL-5 and IL-13 (Neill et al., 2010, 
Walker et al., 2013), and IL-4 following leukotriene D4 stimulation (Pelly et al., 2016), 
placing ILC2s in the centre of type 2 immunity. 
Indeed, ILC2s contribute to the protective type 2 immune response to intestinal 
helminths. In response to N. brasiliensis infection, Il25-deficient mice fail to activate 
ILC2s, correlating with delayed worm expulsion in the intestine (Fallon et al., 2006). 
In T cell-deficient mice, recombinant IL-25-dependent activation of ILC2s was 
sufficient to mediate accelerated expulsion of N. brasiliensis (Fallon et al., 2006). 
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Activated ILC2 survival is dependent upon IL-9, with IL-9R-deficient mice displaying 
reduced numbers of ILC2s following N. brasiliensis infection which result in impaired 
type 2 cytokine production and delayed worm expulsion (Turner et al., 2013). In 
addition, trefoil factor 2 (Tff2)-deficient mice, which do not produce IL-33 protein from 
epithelial cells or inflammatory DCs upon N. brasiliensis infection, fail to efficiently 
expel the parasite (Wills-Karp et al., 2012). Although the authors attribute this 
delayed expulsion to ineffective Th2 differentiation and cytokine production from 
CD4+ T cells to drive type 2 effector responses (Wills-Karp et al., 2012), it is also 
plausible that abrogation of an IL-33 response to N. brasiliensis infection prevented 
ILC2 expansion and activation and ILC2-derived type 2 cytokine release (Neill et al., 
2010), although this was not addressed. Nevertheless, ILC2s are essential for 
efficient expulsion of N. brasiliensis mouse infection. 
Treatment with recombinant IL-25 or IL-33 promoted expulsion of T. muris in mice 
genetically susceptible to T. muris infection (Owyang et al., 2006, Humphreys et al., 
2008). However, the effect of IL-25 or IL-33 was dependent on T cells as 
susceptibility was maintained in SCID mice treated with recombinant IL-25 (Owyang 
et al., 2006, Humphreys et al., 2008). Whether IL-25- or IL-33-dependent activation 
of ILC2s was required for protective Th2 differentiation during T. muris infection is 
unclear.  
In contrast to N. brasiliensis infection, the expansion of ILC2s in T and B cell-deficient 
mice was only able to provide partial immunity to H. polygyrus infection, despite 
significant production of type 2 cytokines and initiation of downstream type 2 effector 
responses (Pelly et al., 2016). ILC2 expansion and activation by mast cell-derived 
IL-33 may be responsible for this protection (Shimokawa et al., 2017). During 1o H. 
polygyrus infection in WT C57BL/6 mice, ILC2s facilitate Th2 differentiation in the 
small intestine, through the secretion of both IL-4 and IL-2 (Pelly et al., 2016), which 
is essential for immunity to H. polygyrus (Urban et al., 1991a, Urban et al., 1991b). 
 
1.2.2.2 Macrophages 
Macrophages are mononuclear, phagocytic myeloid cells which function to clear 
apoptotic cells, cellular debris and pathogens. Macrophages are found in almost all 
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tissues throughout the body, but are particularly prominent at mucosal sites, such as 
the lung and intestine. The majority of macrophages are derived from embryonic 
progenitors, which are seeded in peripheral tissues of the foetus to give rise to tissue-
resident macrophages that self-maintain throughout life, with each population 
specifically adapted to their niche (Guilliams et al., 2014). The development and 
survival of macrophages is dependent on their expression of colony-stimulating 
factor 1 receptor (CSF1R, also known as macrophage colony stimulating factor 
receptor (M-CSFR)) and the cognate ligands colony stimulating factor 1 (CSF1, also 
known as macrophage colony-stimulating factor 1 (M-CSF)) and IL-34 (Greter et al., 
2012, Wang et al., 2012). Despite presence of tissue-resident macrophages, during 
inflammation circulating monocytes, from the bone marrow, infiltrate inflamed tissues 
where they differentiate into monocyte-derived macrophages to participate in 
pathogen killing or tissue repair (Guilliams et al., 2014). In specific tissues and under 
the appropriate conditions, monocytes can differentiate into tissue-resident 
macrophages to replenish the population after an inflammatory event. Macrophage 
development and origins are thoroughly reviewed in (Guilliams et al., 2014) and 
(Guilliams and Scott, 2017). 
The alternate activation of macrophages is a hallmark of the type-2 immune 
response to helminth infections. The type 2 cytokines IL-4 and IL-13 alternatively 
activate macrophages, inducing the expression of Arg1 (gene encoding Arginase 1), 
Chi3l3 (gene encoding Chitinase-like 3, also known as Ym1) and Retnla (Relmα, 
encodes Resistin-like alpha, also known as Fizz1) via IL-4R-STAT6 dependent 
signalling (Goerdt and Orfanos, 1999, Rodriguez-Sosa et al., 2002, Dasgupta et al., 
2011, Raes et al., 2002). Alternatively activated macrophages (aaMϕs) are believed 
to have three distinct functions: regulation of the immune response, wound healing 
and resistance to parasite invasion. In regard to regulating the immune response, 
parasite elicited aaMϕs have been shown to downregulate helminth-induced Th1 
cells and subsequent immunopathology (Herbert et al., 2004).  
Given the relatively large size of H. polygyrus, significant damage occurs when the 
L3 larvae penetrate into the wall of the duodenum. It is thought that aaMϕs contribute 
to tissue repair and wound healing by clearing debris and upregulating genes 
associated with tissue remodelling, such as fibronectin, matrix metalloproteases 
(MMPs), tissue inhibitors of MMPs (TIMPs) and several collagen types (Gratchev et 
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al., 2001, Sandler et al., 2003, Wilson et al., 2007). Chi3l3 expression has also been 
implicated in wound healing (Liu et al., 2004b). AaMϕs accumulate around H. 
polygyrus larvae in the wall of the intestine, forming cysts or granulomas around the 
invading larvae (Morimoto et al., 2004, Anthony et al., 2006). IL-4Rα signalling is 
sufficient for the expansion of tissue-resident macrophages in the small intestine 
upon H. polygyrus infection, independent of CSF1 (Jenkins et al., 2013). The 
presence of memory Th2 cell-induced aaMϕs is essential for immunity against H. 
polygyrus as depletion of macrophages with clodronate-loaded liposomes prevented 
expulsion upon 2o infection (Anthony et al., 2006). Specifically, Arginase 1 derived 
from aaMϕs is essential in protective immunity to H. polygyrus: Arginase inhibition 
with S-(2-boronoethyl)-1-cysteine (BEC) abrogated the protection during 2o infection 
(Anthony et al., 2006); however direct antiparasitic activity has been difficult to 
elucidate. Chitinase, chitinase-like proteins (such as Chi3l3) and resistin-like family 
members are secreted by aaMϕs and were hypothesised to have direct effects on 
tissue-dwelling helminths through enzymatic degradation of helminth-specific 
proteins. However, direct antiparasitic effects of these aaMϕ-associated proteins 
have not been discovered. Instead, roles have been described in mediating type 2 
immune responses (Nair et al., 2009, Cai et al., 2009). An early study identified that 
macrophages isolated from mice infected with H. polygyrus were shown to adhere 
to and damage exsheathed L3 larvae in vitro, resulting in reduced infectivity in vivo 
(Chaicumpa and Jenkin, 1978). IL-33 can also directly induce alternate activation of 
macrophages and IL-13 production in vitro and in vivo (Yang et al., 2013). 
Furthermore, adoptive transfer of in vitro IL-33-induced aaMϕs promoted resistance 
to H. polygyrus infection, correlating with enhanced smooth muscle hyper-
contractility and increased in situ IL-13 production (Yang et al., 2013). 
The infiltration of aaMϕs and the expression of their associated markers are also 
observed in the small intestine upon infection with N. brasiliensis (Zhao et al., 2008). 
Interestingly, the accumulation of macrophages in the small intestine following 
infection was not dependent upon T or B cells, whereas the alternate activation was. 
Administration of recombinant IL-13 rescued alternate activation in SCID mice (Zhao 
et al., 2008). Clodronate-loaded liposome depletion of both resident and recruited 
macrophages in the small intestine abrogated immunity to N. brasiliensis (Zhao et 
al., 2008). Whether aaMϕs and their associated molecules have any direct 
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antihelminth activity in this model is unclear. N. brasiliensis-induced smooth muscle 
hyper-contractility and increased muscle thickness was inhibited when macrophages 
were depleted or when Arginase was inhibited with BEC (Zhao et al., 2008), 
suggesting that aaMϕs may regulate the effects of type 2 immunity on smooth muscle 
cell function. 
Infection with T. muris increased the accumulation of macrophages in the large 
intestine, with a greater number of infiltrating macrophages seen in resistant strains 
(Little et al., 2005). A protective role for macrophages has yet to be conclusively 
proven in T. muris infection. However, if a protective role does exist, it is not through 
the expression of Arginase 1 in aaMϕ as both genetic deletion and BEC treatment 
had no effect on worm burden, immune response or intestinal pathology following T. 
muris infection (Bowcutt et al., 2011). 
 
1.2.2.3 Dendritic cells 
Dendritic cells (DCs) are professional antigen presenting cells critical in priming the 
adaptive immune system. DCs differentiate from common DC precursors (CDPs), 
which originate from adult haematopoietic stem cells (HSCs), distinct from that of 
monocytes (Guilliams et al., 2014). Mature DC populations are broadly subdivided in 
to three groups based on their distinct developmental pathways: classical type 1 DCs 
(cDC1s), which are dependent on Batf3 expression; classical type 2 DCs (cDC2s), 
which are dependent on IRF4 expression; and plasmacytoid DCs (pDCs), which are 
dependent on E2-2 expression (reviewed in (Guilliams et al., 2014)). 
DCs are present at all mucosal sites and environmental interfaces, such as the 
intestine, where they are able to sample their environment and detect pathogens. 
Upon activation by various stimuli, such as alarmin cytokines or TLR ligands, DCs 
uptake antigen and migrate to the local draining lymph nodes where they present 
antigen on MHC class II molecules to naïve CD4+ T cells (MacDonald and Maizels, 
2008). Presentation of the antigen to the αβTCR of the naïve T cell alone is not 
sufficient for T cell differentiation, but requires both co-receptor stimulation (T cell 
CD28 interacting with CD80/86 receptors on the DC) and a cytokine signal, such as 
IL-4 for Th2 cell differentiation (Le Gros et al., 1990, Kapsenberg, 2003). The source 
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of IL-4 is likely to originate from innate immune cells, with ILC2s, mast cells and 
eosinophils shown to be capable of producing IL-4 (Pelly et al., 2016, Gessner et al., 
2005, Voehringer et al., 2004). These data have prompted a continuing debate 
regarding the cellular source of IL-4 required for Th2 differentiation.  
Although the evidence presented in previous sections suggests that type 2 immune 
responses to intestinal helminth infection can be driven in the absence of the 
adaptive immune system, CD4+ Th2 cells are fundamentally important for immunity 
to some intestinal helminths, such as H. polygyrus and T. muris (Urban et al., 1991a, 
Urban et al., 1991b, Koyama et al., 1995, Else and Grencis, 1996), indicating that 
DCs, or any other APCs, are critical for their activation.  
CD11c+ DCs are essential for the initiation and maintenance of Th2 cells in vivo 
(Phythian-Adams et al., 2010). However, following depletion of CD11c+ DCs, type 2 
effector responses, such as alternative activation of macrophages, were still intact 
despite abrogation of Th2 differentiation and Th2 cytokine release (Smith et al., 2012, 
Smith et al., 2011). Unlike our understanding of viral and bacterial sensing and 
activation of DCs, the manner in which DCs sense helminth infection is not 
completely understood. Helminth products have been shown to modulate TLR4 
signalling in DCs, inhibiting both IL-12p40 and p70 protein production and promoting 
Th2 cell differentiation (Goodridge et al., 2004). Interestingly, deletion of MyD88, 
which is an essential signalling adaptor protein for TLR and IL-1 family members, 
had heightened protective immune responses following H. polygyrus infection, 
mounting a stronger Th2 response. These data suggest that MyD88 signalling can 
promote susceptibility to H. polygyrus (Reynolds et al., 2014a). Whether heightened 
immunity seen in MyD88-deficient mice is attributable to MyD88-deficient DCs is 
unclear. It is interesting to speculate that MyD88-deficiency prevents DC activation 
by TLR ligands, thus preventing IL-12 induction and therefore promoting Th2 
differentiation. Promoting Th2 differentiation is essential for protective immunity to T. 
muris infection, however restriction of MHC class II expression to DCs was not 
sufficient to generate Th2 differentiation and cytokine production, abrogating 
resistance to T. muris (Perrigoue et al., 2009). Immunity was restored in mice with 
MHC class II expression restricted to DCs when IFNγ was neutralised (Perrigoue et 
al., 2009), suggesting that DCs promote Th2 responses, only if Th1 development is 
blocked. 
Chapter 1 Introduction 
38 
 
Tumour progression locus 2(Tpl-2, also known as Map3k8 and Cot) kinase activity 
activates the Mek-Erk Mapk signalling pathway in response to TLR, TNFR1 and IL-
1R stimulation in innate immune cells (Gantke et al., 2011). Mice with Tpl-2-deficient 
CD11c+ DCs were resistant to 1o H. polygyrus infection, with Tpl-2-deficient DCs 
producing more of the chemokine Ccl24. Increased Ccl24 stimulated increased 
accumulation of innate immune cells and Th2 cells in the small intestine, promoting 
acceleration of type 2 effector responses which leads to killing of the invading larvae 
(Kannan et al., 2017). 
Taken together, these data demonstrate that DCs are essential in initiating and 
maintaining Th2 cell differentiation in response to intestinal helminth infections. 
 
1.2.2.4 Mast cells 
Mast cells are long-lived granulocytes which, upon appropriate stimulation, undergo 
degranulation and release a range of inflammatory molecules. Mast cells mature 
from mast cell progenitors (MCPs) in peripheral tissues, which themselves are 
derived from the bone marrow. Following development, MCPs enter into the 
circulatory system and migrate to tissues in an immature state in a regulated process 
that is stimulated by inflammation, leading to an increase in local tissue MCPs 
(reviewed in (Dahlin and Hallgren, 2015)). Unlike the lung, the intestine contains 
many MCPs, even in germ-free mice or mice deficient in the Rag-2 gene either alone 
or in combination with the IL-receptor common gamma (γ) chain (Guy-Grand et al., 
1984, Gurish et al., 2001), suggesting they may play essential roles in maintaining 
gut homeostasis and responding to infection. Indeed, mastocytosis and activation is 
a hallmark of intestinal helminth infection. 
Mastocytosis and elevated Mcp1 correlate with expulsion of 1o H. polygyrus infection 
(Behnke et al., 1993, Wahid and Behnke, 1993, Ben-Smith et al., 2003, Hepworth et 
al., 2012). Mcp1 is hypothesised to disrupt the niche of adult H. polygyrus worms by 
increasing gut permeability by disrupting epithelial tight junction proteins (McDermott 
et al., 2003, Snoek et al., 2012). Mast cell-deficient mice harbour the same number 
of adult worms 21 days-post 1o H. polygyrus infection, but worms isolated from mast 
cell-deficient mice deposited more eggs in vivo and ex vivo (Hashimoto et al., 2010). 
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In support, mice with genetically induced intestinal mastocytosis were demonstrated 
to have a significantly lower egg burden following H. polygyrus infection (Morimoto 
and Utsumiya, 2011). Another study demonstrated that mast cell-deficient mice were 
defective in expulsion of 1o H. polygyrus infection, harbouring more intestinal worms 
21 days-post infection (Hepworth et al., 2012). The reason for this discrepancy is 
unclear.  
In addition, protective immunity was abrogated in mast cell-deficient mice following 
2o challenge infection (Hepworth et al., 2012). The protective role of mast cells in this 
study was attributed to their role in the priming of the Th2 response through 
promoting IL-25, IL-33 and TSLP release following infection (Hepworth et al., 2012). 
Supporting this type 2 priming role of mast cells, a more recent study has identified 
that mast cells are activated to produce IL-33 by ATP released from apoptotic 
epithelial cells following H. polygyrus infection. Mast cell-derived IL-33 promoted 
activation of IL-13 producing ILC2s and initiation of type 2 immune effector 
responses (Shimokawa et al., 2017). Taken together, these data suggest a role for 
mast cells in protective immunity to H. polygyrus. 
Upon infection with N. brasiliensis, intestinal mastocytosis correlates with the 
migration of the parasite to the intestine (Uber et al., 1980). However, mast cell-
deficient mice are able to expel N. brasiliensis (Uber et al., 1980). Similarly, following 
T. muris infection, mast cell numbers increase in the cecum (Guy-Grand et al., 1984), 
however antibody-mediated depletion of mast cells had no effect on worm expulsion 
(Betts and Else, 1999). As a result, mast cells are currently thought to be dispensable 
for protective immunity to N. brasiliensis and T. muris. 
 
1.2.2.5 Eosinophils 
Eosinophils are a subset of granulocytes generally associated with type 2 immune 
responses and are a hallmark of intestinal helminth infection. Eosinophils originate 
from HSCs in the bone marrow, which gives rise to eosinophil-restricted progenitors 
(EoPs) (Orkin and Zon, 2008). Gata1 expression and IL-5 are essential for EoP 
development into immature eosinophils, which subsequently leave the bone marrow 
and enter the bloodstream (Byström et al., 2004). IL-5 signalling triggers the 
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development of mature eosinophils, resulting in nucleus condensation and granule 
maturation (Willebrand and Voehringer, 2017). Eosinophils have a short lifespan in 
the circulation, however this is increased when eosinophils seed in peripheral 
tissues, such as the small intestine with IL-5 and, to a lesser extent, colony 
stimulating factor 2 (CSF2, also known as granulocyte-macrophage colony 
stimulating factor (GM-CSF)) being survival factors (Rothenberg, 2016, Schwartz et 
al., 2015). Eotaxin family proteins, eotaxin-1 (Ccl11), eotaxin-2 (Ccl24) and eotaxin-
3 (Ccl26) are chemokines which bind to the chemokine receptor Ccr3, which is 
expressed on eosinophils, drawing them to sites of inflammation (Pease, 2006). 
Eosinophil development and survival is reviewed in (Uhm et al., 2012) and 
(Willebrand and Voehringer, 2017). 
Despite induction of eosinophilia upon intestinal helminth infection (Dixon et al., 
2006, Rennick et al., 1990, Urban et al., 1991b) their precise roles remain elusive. 
Eosinophils are not critical mediators of protective immunity. In genetic mouse 
models of eosinophil deficiency, immunity to N. brasiliensis or T. muris was not 
impaired (Knott et al., 2007, Dixon et al., 2006). Furthermore, administration of anti-
IL-5 antibody, which reduces eosinophil numbers, did not impair expulsion of N. 
brasiliensis or 2o H. polygyrus infection, despite inhibiting eosinophilia (Khan et al., 
1995, Urban et al., 1991b). Moreover, helminth products have been shown to directly 
promote eosinophil chemotaxis (Dixon et al., 2006). Interestingly, early studies 
demonstrated that eosinophils isolated from infected mice can adhere to various 
developmental stages of H. polygyrus larvae/worms (Penttila et al., 1983) and cause 
damage to exsheathed L3 larvae in vitro, as measured by a loss of infectivity in vivo 
(Penttila et al., 1984). Taken together, these data suggest that eosinophils may 




Neutrophils, a subset of granulocytes and the most abundant immune cell 
population, play a crucial role in host defence. Neutrophils are characterised by their 
ability to act as phagocytic cells, to release lytic enzymes, produce reactive oxygen 
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species and other products with antimicrobial properties (reviewed in (Kruger et al., 
2015)). Neutrophils reside from HSCs in the bone marrow, which differentiate into 
granulocyte-monocyte myeloid precursors (GMPs), before developing into mature 
neutrophils which exit into the circulation (Coffelt et al., 2016). Colony-stimulating 
factor 3 (CSF3, also known as granulocyte colony stimulating factor (G-CSF)) is the 
master regulator of neutrophil generation (Lieschke et al., 1994, Liu et al., 1996).  
Neutrophils are present in the granulomas surrounding tissue-embedded larvae 
following both 1o and 2o H. polygyrus infection, however they are less prevalent in 2o 
infection (Anthony et al., 2006, Morimoto et al., 2004, Patel et al., 2009). The 
decrease in neutrophils upon 2o H. polygyrus infected mice suggests that they are 
not a critical cell in protective immunity, or they have undergone netosis to produce 
neutrophil extracellular traps (NETs) (Bonne-Annee et al., 2014, Branzk et al., 2014). 
Early studies demonstrated that neutrophils, as well as eosinophils, isolated from 
infected mice can both adhere to various developmental stages of H. polygyrus 
larvae/worms (Penttila et al., 1983) and cause damage to exsheathed L3 larvae 
(Penttila et al., 1984). Moreover, antibody-mediated neutrophil depletion was shown 
to partially compromise resistance to 2o H. polygyrus challenge infection (Penttila et 
al., 1985). However, antibody-mediated depletion of neutrophils during T. muris 
infection did not abrogate protective immunity (Zaph and Artis, 2015). A more recent 
study illustrated a role for neutrophils in infection with N. brasiliensis, with Chi3l3-
induced neutrophil recruitment limiting helminth survival at the cost of local tissue 
damage (Sutherland et al., 2014). Although the exact mechanism is unclear, these 
data demonstrate a protective role for neutrophils following helminth infection. 
Furthermore, following N. brasiliensis infection, neutrophils were shown to be 
essential for priming and maintaining long-lived effector aaMϕs, essential for 
heightened resistance to 2o N. brasiliensis infection (Chen et al., 2014). These 
neutrophils were shown to adopt a ‘type 2’ phenotype, upregulating expression of 
Il13, Il33, Igf1, Retnla and Chi3l3 and were essential in the alternate activation of 
macrophages (Chen et al., 2014). 
Overall, the role of neutrophils, and NETs, have not been fully elucidated in immunity 
to intestinal helminth infections. However, despite clear antihelminth properties, they 
appear not to be critical for protection against helminth infections. 




1.2.3 Stromal immunity 
1.2.3.1 Epithelial cells 
Epithelial cells line mucosal surfaces, such as the lung and intestine, and function as 
a barrier between the host and the environment. In the small intestine, there are 
many different subtypes of intestinal epithelial cell (IEC), all of which arise from Leu-
rich repeat-containing G protein-coupled receptor 5-expressing (Lgr5+) intestinal 
stem cells. Intestinal stem cells reside at the base of the crypts and continuously 
generate transit-amplifying (TA) cells. TA cells occupy the remainder of the crypt and 
reserve stem cells from the +4 position from the crypt base and can also repopulate 
the Lgr5+ stem cells following injury. TA cells differentiate into various functional cells 
to replace the IECs lost via anoikis at the tip of the villi, with complete IEC turnover 
occurring every 3-5 days in the small intestine. The main subtypes of IECs are 
enterocytes, enteroendocrine cells, tuft cells, goblet cells and paneth cells; each with 
specialised functions (reviewed in (Barker, 2014)). 
IECs are often in direct contact with intestinal helminths and therefore function both 
as critical initiators of immunity and effector cells. Epithelial cells secrete a suite of 
alarmin cytokines, IL-25, IL-33 and TSLP to initiate the type 2 immune response (Fort 
et al., 2001, Soumelis et al., 2002, Schmitz et al., 2005). Partial redundancy between 
these three alarmin cytokines in initiating type 2 immunity has been demonstrated 
(Vannella et al., 2016), although distinct roles have also been elucidated in the 
context of intestinal helminth infection. Mice with IL-25-deficiency or inhibition of IL-
33 signalling display impaired type 2 immune responses to N. brasiliensis infection, 
resulting in impaired worm expulsion (Fallon et al., 2006, Wills-Karp et al., 2012). 
Recent studies identified that tuft cells are able to sense intestinal helminths through 
the taste-chemosensory G-protein coupled receptors. Upon helminth detection, tuft 
cells secrete IL-25 which activates ILC2s to secrete IL-13, which feedback to 
promote tuft cell hyperplasia, thus providing a feed-forward mechanism to initiate 
type 2 immunity (Gerbe et al., 2016, von Moltke et al., 2016, Howitt et al., 2016). Tuft 
cells are key in initiating the type 2 immune response to intestinal helminths. Genetic 
deletion of tuft cells, or key signal transduction molecules in the taste-chemosensory 
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pathway, abrogated protective immunity to N. brasiliensis (Gerbe et al., 2016). Tuft 
cells have also been shown to undergo IL-4Rα-dependent hyperplasia following H. 
polygyrus infection (Gerbe et al., 2016, Howitt et al., 2016), however their role in 
protective immunity to this mouse intestinal helminth has not been determined. Both 
IL-25 and IL-33 are important in initiating protective immunity upon T. muris infection 
(Humphreys et al., 2008, Saenz et al., 2010). Specifically, IL-25 promotes the 
accumulation of type 2 multipotent progenitors (MPPstype2), similar to ILC2 cells, in 
the gut-associated lymphoid tissue (GALT), which can induce Th2 differentiation and 
expulsion of T. muris (Saenz et al., 2010). Similarly, IL-33 is expressed early 
following T. muris infection and promotes the production of Th2 cytokines, preventing 
an inappropriate Th1 response (Humphreys et al., 2008). Additionally, exogenous 
administration of IL-33 to susceptible mice promoted expulsion of T. muris and also 
induced increased intestinal pathology. However, IL-33 treatment could not induce 
T. muris expulsion if administered once chronic infection had established 
(Humphreys et al., 2008). Interestingly, mouse strains resistant to T. muris infection 
produce more IL-33 early in infection, when compared to susceptible strains 
(Humphreys et al., 2008). IL-33 has also been shown to induce the Th2-inducing 
alarmin cytokines TSLP from IECs (Humphreys et al., 2008). Abrogation of TSLP-
induced TSLP receptor (TSLPR) signalling prevented expulsion of T. muris infection, 
due to a defective Th2 response. Instead an ineffective Th1 response was induced, 
promoting severe intestinal inflammation (Taylor et al., 2009). Blockade of IFN or 
IL-12p40 rescued protective immunity in T. muris infected TSLPR-deficient mice, 
restoring the Th2 response (Massacand et al., 2009, Taylor et al., 2009). The 
induction of a protective type 2 immune response was not dependent on TSLP 
following infection with either H. polygyrus or N. brasiliensis, with TSLPR-deficient 
mice able to expel 2o H. polygyrus challenge infection (Massacand et al., 2009). The 
discrepancy in requiring TSLP for induction of type 2 immunity between these three 
intestinal helminths was due to their excretory-secretory (ES) products. ES products 
from both H. polygyrus and N. brasiliensis were able to supress DC production of IL-
12p40, therefore inhibit Th1 polarisation and promoting Th2 responses, whereas ES 
products from T. muris could not (Massacand et al., 2009).  
As well as sensing pathogens and initiating the immune response, IECs are also key 
effector cells in the type 2 immune response against helminth infections. The type 2 
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cytokines IL-4 and IL-13 signal via IL-4R on IECs induce vast changes in the 
architecture and physiology of the intestine. Following 2o H. polygyrus infection IL-
4R-dependent changes in small intestine physiology were identified; these included 
increased mucosal permeability, decreased ion absorption and increased 
prosecretory effects in response to inflammatory mediators (Shea-Donohue et al., 
2001, Madden et al., 2004). IEC-mediated changes in small intestine physiology are 
hypothesised to promote protective immunity by disrupting the niche of H. polygyrus, 
impairing their ability to coil around villi (Bansemir and Sukhdeo, 1996) and feed on 
host tissue (Bansemir and Sukhdeo, 1994). Mice resistant to T. muris infection have 
an increased proliferation and turnover of IECs. This increased turnover acts like an 
‘epithelial escalator’ where IECs move from the bottom to the top of the crypt to be 
shed, expelling the IEC-embedded T. muris worms (Cliffe et al., 2005). This 
increased IEC turnover is dependent upon IL-13 signalling, not IL-4, and is inhibited 
by the chemokine Cxcl10 (Cliffe et al., 2005). As described above, IL-4R-dependent 
tuft cell hyperplasia contributes to the tuft cell – ILC2 feedforward loop to amplify type 
2 immunity (Gerbe et al., 2016, von Moltke et al., 2016, Howitt et al., 2016). Whether 
tuft cells also possess any antihelminth effector response is unclear. IL-4R-
dependent goblet cell hyperplasia and mucus production is a well described feature 
of the antihelminth type 2 immune response. The increased volume of mucus has 
been postulated to both trap the luminal worms as well as disrupt their niche (Maizels 
and Holland, 1998). Indeed, susceptibility to T. muris infection is associated with 
mucus porosity, with resistant mice having a less permeable mucus barrier than 
susceptible mice (Hasnain et al., 2010). Specific molecules produced by goblet cells 
have been shown to be directly anthelmintic. As mentioned above, Relm is 
produced by goblet cells following intestinal helminth infection (Artis et al., 2004, 
Herbert et al., 2009) and has been demonstrated to bind to the tegument of the larval 
stages of both T. muris and the human intestinal helminth S. stercoralis, impairing 
larval chemosensory function and chemotaxis (Artis et al., 2004). In addition, Relm 
is essential in protective immunity to H. polygyrus and N. brasiliensis (Herbert et al., 
2009). Specifically, Relm was shown to inhibit the feeding of adult H. polygyrus 
worms in vivo, reducing their fitness ex vivo, measured by ATP and protein levels 
(Herbert et al., 2009). Whether this effect on H. polygyrus is mediated via disruption 
of chemosensation or other neuronal processes is unclear. Muc2 and Muc5ac are 
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mucus components upregulated in response to intestinal helminth infection 
(Hashimoto et al., 2009, Hasnain et al., 2010, Inagaki-Ohara et al., 2011). Increased 
Muc2 expression correlated with expulsion of both T. muris and N. brasiliensis, with 
Muc2-deficient mice having impaired worm expulsion following T. muris infection 
(Inagaki-Ohara et al., 2011, Hasnain et al., 2010). Despite not normally being 
expressed in the intestinal tract, Muc5ac expression was detected following T. muris 
infection shortly before worm expulsion, but was not induced upon H. polygyrus 
infection (Hasnain et al., 2011, Hasnain et al., 2010). Muc5ac-deficient mice failed to 
expel T. muris and N. brasiliensis (Hasnain et al., 2011). Intriguingly, unlike Muc2, 
Muc5ac directly impaired the health of T. muris in vitro, as measured by parasite ATP 
levels (Hasnain et al., 2011). This effect was dependent upon the polymerisation of 
Muc5ac, suggesting that the structure of this mucin is critical to its anthelmintic 
function. 
Enteroendocrine cells are rare in the intestinal epithelium, shown to mediate 
protection against the intestinal helminth Trichinella spiralis. Following infection, 
CD4+ T cells induced CCK+ enteroendocrine I cell hyperplasia and CCK 
hypersecretion, which in turn reduced leptin levels, an inflammatory adipokine. The 
reduced leptin levels heightened the protective type 2 immune response, whereas 
exogenous administration of leptin perturbed Th2 cytokine production and 
mastocytosis, abrogating parasite expulsion (Worthington et al., 2013). 
Taken together, these data indicate that epithelial cells are essential in protective 
immunity to intestinal helminth infection, by both initiating the appropriate immune 
response and producing key effector molecules. 
 
1.2.3.2 Smooth muscle 
The GI tract is made up of a series of organs that process ingested food, assimilate 
water and nutrients, and eliminate waste. Critical to moving the contents through the 
intestine are the smooth muscle tissues, tunica muscularis, via peristalsis. Smooth 
muscle cells are autonomous, generating spontaneous electrical rhythmicity and 
contractions, and form both electrical and mechanical junctions with neighbouring 
cells to coordinate intestinal motility (Sanders et al., 2012). 
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Type 2 cytokines have been demonstrated to modulate intestinal contractility (Zhao 
et al., 2003). Both H. polygyrus and N. brasiliensis infection increased intestinal 
hypercontractility ex vivo, which was dependent upon IL-4R-activated Stat6 
signalling, Protease-activated receptor 2 (Par2) expression and enteric nerve 
stimulation (Zhao et al., 2003, Shea-Donohue et al., 2010). Similarly, T, muris 
infection induced increased smooth muscle hypercontractility in resistant strains, 
however hypercontractility was instead dependent upon IL-9 and not Stat6 signalling 
(Khan et al., 2003). Administration of an immunosuppressive steroid could partially 
restore smooth muscle hypercontractility in susceptible mice (Motomura et al., 2010), 
further demonstrating that the immune system can mediate smooth muscle cell 
function. Induction of smooth muscle hypercontractility was also shown to be 
essential for expulsion of both N. brasiliensis and T. muris (Khan et al., 2003, 
Horsnell et al., 2007) however the role of smooth muscle contractility in H. polygyrus 
infection has not been determined. 
 
1.3 MicroRNAs 
MicroRNAs (miRNAs) are noncoding RNA molecules of approximately 21 
nucleotides (nt) in length which function to regulate messenger RNA (mRNA) 
translation (Ambros, 2003). miRNAs were first discovered in 1993 with the 
identification of lin-4 in Caenorhabditis elegans. The small, noncoding RNA lin-4 was 
identified to negatively regulate lin-14 mRNA translation into protein through a RNA-
RNA interaction (Lee et al., 1993). It was not until 2001 that further miRNA species 
were identified and demonstrated to be conserved from C. elegans to mammals (Lee 
and Ambros, 2001, Lagos-Quintana et al., 2001, Lau et al., 2001). Over the past 16 
years our understanding of miRNA biogenesis and function has improved 
dramatically, allowing us to further appreciate their importance in many different 
biological settings. 
 




Both canonical and non-canonical pathways of mature, functional miRNA molecule 
biogenesis have been described. Canonical biogenesis consists of several stages, 
each requiring key enzymes, before producing mature miRNAs. Initially, primary 
miRNA (pri-miRNA) molecules are transcribed from their respective gene by RNA 
polymerase II (Lee et al., 2004, Lee et al., 2002). The pri-miRNA molecule has an 
imperfect self-complementary region, forming a hairpin loop, with elongated 3’ and 
5’ tails. In some cases, several miRNA loci are in close proximity, creating 
polycistronic miRNA genes or clusters, and are transcribed as one cluster containing 
many pri-miRNAs (Lee et al., 2002). The pri-miRNA molecule remains in the nucleus 
where the RNA binding protein DiGeorge syndrome critical region gene 8 (Dgcr8) 
recognises its structure and recruits the RNase enzyme Drosha. Drosha cleaves the 
elongated 5’ and 3’ tails to form a precursor miRNA (pre-miRNA) molecule of 
approximately 70-nucleotides (nt), with a 2-nt 3’ overhang (Lee et al., 2003, Han et 
al., 2004, Denli et al., 2004, Gregory et al., 2004, Landthaler et al., 2004). This 3’ 
overhang is essential for recognition and binding of the high-resolution nuclear export 
factor Exportin-5. Exportin-5 facilitates the transport of the pre-miRNA out of the 
nucleus and into the cytoplasm via a RAN-GTP-dependent mechanism (Yi et al., 
2003). In the cytoplasm, the double stranded RNA binding protein TAR RNA-binding 
protein (TRBP), in complex with the RNase enzyme Dicer, binds and cleaves the 
hairpin loop of the pre-miRNA to produce the mature, double stranded miRNA 
molecule (Hutvagner et al., 2001, Ketting et al., 2001, Knight and Bass, 2001). The 
passenger strand (also known as miRNA*) dissociates from the complementary, 
mature guide miRNA strand after being recognised, and subsequently bound, by an 
Argonaute (Ago) protein (Chendrimada et al., 2005). In most instances, the mature 
strand is that which is most thermodynamically stable and the released passenger 
strand is degraded quickly (Khvorova et al., 2003, Schwarz et al., 2003). This results 
in an abundance bias toward the mature guide strand, although the passenger strand 
is still active and can be bound by Ago proteins. The miRNA-Ago complex is then 
incorporated into the RNA-induced silencing complex (RISC). In the RISC, the 
miRNA functions by guiding the complex to complementary sequences in the 3’ 
untranslatable region (UTR) of target messenger RNA to induce gene silencing 
(Maniataki and Mourelatos, 2005, MacRae et al., 2005, Gregory et al., 2005, 
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Martinez et al., 2002). The canonical miRNA biogenesis pathway is displayed in 
Figure 1.3. It is now clear that canonical miRNA processing cannot occur without 
Drosha, Dgcr8 and Dicer. 
Non-canonical miRNA biogenesis deviates from the canonical pathway by one or 
more steps. Dicer however is almost always indispensable in the generation of 
mature, functional miRNAs in both canonical and non-canonical pathways. Drosha 
and Dgcr8 are specific to canonical miRNA biogenesis, and therefore in their 
absence only non-canonical miRNA biogenesis can occur (Abdelfattah et al., 2014). 
One such Drosha/Dgcr8 independent non-canonical pathway is the mirtron pathway. 
This pathway mirrors the canonical in the cytoplasm (utilises Dicer) but does not 
require the Drosha/Dgcr complex in the nucleus. Pre-miRNA-sized short introns were 
discovered by deep sequencing of small RNAs, which are processed by 
spliceosomes and debranching enzymes within the nucleus to produce pre-miRNA-
like hairpins suitable for Dicer cleavage (Ruby et al., 2007, Okamura et al., 2007). 
These pre-miRNA-like hairpins are transported to the nucleus by Exportin-5. Mirtron-
derived miRNAs have been found in Drosha- or Dgcr8-deficient mice (Babiarz et al., 
2008, Chong et al., 2010).  
As well as mirtrons, other Dicer-dependent, non-canonical miRNA biogenesis 
pathways have been discovered but not fully elucidated. These include miRNAs from 
endogenous short hairpin RNAs (Babiarz et al., 2008) and transfer RNAs (tRNAs) 
(Cole et al., 2009). Both of these pathways generate miRNA hairpins that were able 
to be recognised and cleaved by Dicer to form mature miRNAs. 
Both the canonical and non-canonical miRNA biogenesis pathways highlight the 
importance of Dicer to produce functional, mature miRNA molecules. As a result, 
genetic deletion of Dicer results in embryonic lethality (Bernstein et al., 2003), 
highlighting the critical role played by miRNAs. Despite Dicer’s importance in miRNA 
processing, one miRNA has been discovered to be Drosha/Dgcr8 complex-
dependent and Dicer-independent (Cheloufi et al., 2010, Cifuentes et al., 2010). Pri-
miR-451 is cleaved in the nucleus by Drosha/Dgcr8 to generate an 18bp pre-miRNA. 
Upon export to the cytoplasm this pre-miRNA is too short to act as a substrate for 
Dicer, therefore Ago2 mediates the cleavage of pre-miR-451 to be loaded into the 
RISC (Cheloufi et al., 2010, Cifuentes et al., 2010). 
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1.3.2 Mechanism of action 
As described in section 1.3.1, miRNAs function as a guide, directing the RISC to the 
appropriate mRNA to inhibit translation into protein. Specifically, nucleotides 2-7 of 
the miRNA, referred to as the seed sequence, is crucial for target recognition, 
determining the binding to the 3’ UTR of mRNA (Krol et al., 2010). The downstream 
nucleotides are less important, but also contribute to base pairing and binding to 
target mRNAs (Ha and Kim, 2014). miRNAs are able to prevent mRNA translation 
into protein by both inducing degradation of mRNA and by inhibiting ribosomal 
translation (Eulalio et al., 2008). In mammals, there are four Ago proteins (Ago1-4). 
mRNA degradation was thought to be dependent upon Ago2, as Ago2 was the only 
Ago protein with catalytic slicer activity, whereas Argonaute1, 3 & 4 were thought to 
inhibit mRNA translation without mRNA degradation (Liu et al., 2004a, Meister et al., 
2004). Recently, slicer activity of Ago3 was described (Park et al., 2017). 
In humans, all four Ago proteins bind to miRNAs and have no discernible difference 
in their miRNA repertoire (Dueck et al., 2012), whether this is the case in other cells 
types and species is currently unclear. 
 
1.3.3 miRNA-mediated regulation of immune responses to intestinal helminth 
infection 
The ability of miRNAs to provide finite control over gene expression implicates them 
in almost every biological setting; from embryogenesis, physiological development 
to pathology. Regulation of the immune response requires coordinated control of 
specific gene expression in participating immune and stromal cells. As such, miRNAs 
have been demonstrated to be essential in many aspects of immunology and 
immunity to infection.  
Our current understanding of the role of miRNAs in regulating antihelminth immunity 
draws from studies investigating the type 2 immune response to intestinal helminths 
and other type 2 immune-driven diseases, such as allergic asthma. 
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1.3.3.1 miRNA-mediated regulation of adaptive immunity 
As described in section 1.2.1, the adaptive immune system is essential for the 
clearance of chronic intestinal helminth infection (Katona et al., 1991, Urban et al., 
1991a, Koyama et al., 1995, Else and Grencis, 1996). As outlined in section 1.2.1.1, 
Th2 cells and their type 2 cytokines promote resistance against intestinal helminth 
infection. Aberrant CD4+ T cell polarisation and cytokine production results in an 
ineffective immune response to intestinal helminth infection, best highlighted in 
immunity to T. muris (Bancroft et al., 1994). miRNAs regulate T cell polarisation and 
cytokine production. Specifically, Dicer-deficient T cells have a preference for the 
Th1 lineage, even under Th2 polarising conditions, as well as regulating proliferation 
and survival in vivo (Muljo et al., 2005, Cobb et al., 2005). Unsurprisingly, mice with 
Dicer-deficient T cells are fully susceptible to both H. polygyrus and T. muris infection 
as they fail to mount a protective type 2 immune response (unpublished 
observations, Wilson Lab). 
Further investigation of the miRNA profiles of CD4+ T cells has identified individual 
miRNAs enriched and essential for specific T helper subtype function (Baumjohann 
and Ansel, 2013). Studies investigating the miRNA transcriptomic landscape of CD4+ 
T helper cells identified a suite of miRNAs enriched in Th2 cells from both intestinal 
infection and allergic disease models. Interestingly, the Th2 cells isolated from 
intestinal helminth infection exhibited many similarities and distinct differences in 
their miRNAome when compared to Th2 cells derived from house dust mite-
challenged mice or in vitro polarised Th2 cells (Okoye et al., 2014). This highlights 
the heterogeneity of Th2 cells, potentially determined by anatomical location or 
disease setting. miR-155 expression was enriched in Th2 cells and was critical for 
protective immunity to H. polygyrus (Okoye et al., 2014). The authors demonstrate 
that miR-155 regulated the expression of S1pr1 (which encodes the protein 
Sphingosine-1-phosphate receptor 1) in Th2 cells, with S1pr1 downregulation 
previously demonstrated to be required for egress of lymphocytes from lymphoid 
tissue (Rivera et al., 2008).  
Many other T cell-intrinsic miRNAs influence T helper cell differentiation during type 
2 immune-mediated diseases. miR-21-deficiency promoted Th1 differentiation in a 
mouse model of allergic airway inflammation, leading to increased IFNγ levels and 
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reduced eosinophilia (Lu et al., 2011). Furthermore, miR-182 targeting of RUNX3 in 
human CD4+ T cells regulated Th1/Th2 differentiation, where overexpression of miR-
138 promoted Th2 differentiation and miR-138 inhibition induced Th1-related 
cytokines and transcription factor expression (Fu et al., 2015). miRNA clusters have 
also been shown to regulate T helper cell differentiation. Specifically, overexpression 
of the miRNA cluster miR-23~27~24 negatively impacts the differentiation of Th1, 
Th2, Th17 and iTreg lineages in vitro (Cho et al., 2016). Deletion of the miR-
23~27~24 cluster promoted Th2 cell differentiation and IL-4 expression in vitro and 
exacerbated eosinophilic airway inflammation and pathology in vivo (Cho et al., 
2016, Pua et al., 2016). Mechanistically, both miR-24 and miR-27 have been 
demonstrated to target a network of genes which regulate IL-4 production, such as 
Gata3, Cnot6 and Ikzf1 (Pua et al., 2016). Increased expression miR-19a, a member 
of the miR-17~92 cluster, was identified in both human and mouse Th2 cells, 
essential for promoting Th2 differentiation through the inhibition of Pten, Socs1 and 
A20 (Simpson et al., 2014). These observations suggest that miR-182, the miR-
23~27~24 cluster and/or the miR-17~92 cluster maybe implicated in the 
development and function of Th2 cells, critical for protective immunity to intestinal 
helminth infections. 
Tregs are a subset of CD4+T cells that are induced upon intestinal helminth infection 
which function as immunomodulatory cells, suppressing immunity and protecting 
against immune-mediated pathology (Abbas et al., 2013, Finney et al., 2007, 
Grainger et al., 2010) but at the cost of promoting chronic infection. miRNAs have 
been described to contribute to many aspects of Treg biology, from development and 
differentiation to function. Dicer or Drosha deletion, which abrogated miRNA 
biogenesis, compromises Treg maintenance and survival in vivo (Liston et al., 2008, 
Zhou et al., 2008, Chong et al., 2008). Despite many miRNAs being reported to 
contribute to Treg differentiation, survival and function (Li et al., 2015a, Li et al., 
2015b, Li et al., 2014, van der Geest et al., 2015, Pan et al., 2015, Zhou et al., 2015, 
Jiang et al., 2011, Rouas et al., 2009, Singh et al., 2015, Seddiki et al., 2012, Lu et 
al., 2010b, Lu et al., 2009), very few studies have investigated the role of miRNAs in 
Tregs in type 2 immunity, such as during intestinal helminth infection. In one such 
study, the authors observed miR-182 expression was elevated in Tregs isolated from 
helminth infected mice and that IL-4 increased miR-182 expression in Tregs in vitro 
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(Kelada et al., 2013). Interestingly, miR-182 expression was required in Tregs for 
suppression of Th2-mediated immune responses and not Th1 responses (Kelada et 
al., 2013). This suggests that distinct miRNAs maybe important in regulating the 
function of specific Treg subsets. 
B cells contribute to protection against intestinal helminth infection (Blackwell and 
Else, 2001, Liu et al., 2010, Wojciechowski et al., 2009, McCoy et al., 2008) and 
underpin the hopes in the development of an antihelminth vaccine. miR-155 and 
miR-182 are both essential for the generation of antigen specific, high affinity IgG1 
antibody production (Li et al., 2016, Vigorito et al., 2007, Thai et al., 2007), essential 
for immunity to H. polygyrus (McCoy et al., 2008). Specifically, miR-155-deficient B 
cells have impaired germinal centre and extra-follicular responses following 
immunisation and therefore failed to produce high affinity IgG1 antibodies (Vigorito 
et al., 2007, Thai et al., 2007). Later studies identified that miR-155 regulates B cell 
survival and function, with miR-155 targeting Jarid2, preventing B cell apoptosis 
(Nakagawa et al., 2016), and activation-induced cytidine deaminase (AID), essential 
for antibody affinity maturation (Teng et al., 2008). Although miR-182 deficiency did 
not affect B cell development, they exhibited impaired early generation of antigen-
specific IgM and IgG1 following immunisation, as well as a reduction of extra-
follicular plasma cells (Li et al., 2016). In addition to regulating antibody production, 
miRNAs are also essential for B cell survival (Tsai et al., 2015). For example, miR-
148 is the most abundantly expressed miRNA in plasma cells and critical for their 
differentiation and survival by targeting both Bach2 and Mitf, which repress Blimp-1 
and Irf4 (Porstner et al., 2015). Furthermore, IL-6 and stromal cell-derived factor 1 
induced plasma cell survival is dependent upon induction of miR-24-3p (Gabler et 
al., 2013), potentially by targeting Bim (Nguyen et al., 2013). Taken together, 
miRNAs are essential for regulating B cell survival and antibody generation, although 
the precise role of B cell-intrinsic miRNAs has not been investigated in the context 
of antihelminth immunity. 
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1.3.3.2 miRNA-mediated regulation of innate immunity 
Many innate immune cells are essential for protective immunity to intestinal helminth 
infection, contributing to the initiation of the type 2 immune response and acting as 
critical effector cells (see section 1.2.2). 
Macrophages are essential effector cells in mediating protection against intestinal 
helminth infection, outlined in section 1.2.2.2. Specifically, the alternate activation of 
macrophages is critical for immunity to H. polygyrus (Anthony et al., 2006). The IL-
4Rα-Stat6 signalling axis induces a miRNA signature that is conserved between 
mouse and human (Czimmerer et al., 2016), of which regulates the activation and 
function of aaMϕs. Specifically, macrophage-intrinsic expression of miR-223 is a 
critical regulator of macrophage polarisation. miR-223 inhibition of Pknox1 
translation suppressed classical activation (or M1 polarisation) and promoted 
alternate activation (Zhuang et al., 2012). Furthermore, mir-342-3p acts as a brake 
following alternate activation of macrophages, limiting aaMϕ survival by inhibiting an 
anti-apoptotic gene signalling network (Czimmerer et al., 2016). Likewise, miR-378-
3p functioned to limit excessive alternate activation and proliferation of macrophages 
by limiting the IL-4Rα/PI3K/Akt-signalling cascade through the targeting of Akt1 
(Ruckerl et al., 2012). One caveat of recent efforts to investigate the role of miRNAs 
in macrophage polarisation and function is that the majority of studies utilised in vitro 
model systems. It is therefore imperative to translate these findings in vivo to 
determine if these miRNA regulatory nodes are maintained in a complex, 
multicellular environment. Overall, with specific miRNAs demonstrated to both 
promote and limit aaMϕs, we would predict that these macrophage-intrinsic miRNAs 
maybe essential for immunity to intestinal helminth infections. 
DCs are also essential for T cell differentiation and for reactivation of the adaptive 
immune system (Banchereau and Steinman, 1998, Kapsenberg, 2003) (see section 
1.2.2.3). DC function is also regulated by miRNAs. For example, increased miR-23b 
expression in DCs prompted a tolerogenic phenotype through the inhibition of 
Notch1/NF-ϰB signalling pathways, resulting in an inhibition of IL-12 production, 
increased IL-10 production and an enhanced capability to induce Treg differentiation 
(Zheng et al., 2012). DC-intrinsic miR-155 expression is essential for their ability to 
promote Th2 differentiation. Specifically, miR-155 regulates DC-mediated activation 
Chapter 1 Introduction 
54 
 
of antigen-specific T cell responses through the targeting of Arg2 expression. 
Increased Arg2 prevented T cell activation and proliferation due to Arginase-2-
mediated arginine depletion in the extracellular milieu (Dunand-Sauthier et al., 2014). 
Furthermore, miR-155 regulates purinergic receptor signalling in DCs that are 
required for appropriate DC activation and DC-mediated Th2 cell differentiation 
(Zech et al., 2015). In corroboration with these findings, miR-155-deificent mice fail 
to expel a 2o H. polygyrus infection due to a defective type 2 immune response 
(Okoye et al., 2014). miR-106b also regulates DC function, preventing Th2 cell 
polarisation through inhibition of Egr2 (Tang et al., 2015). Interestingly, the cestode 
Taenia crassiceps can alter DC function through modulation of host miRNAs. T. 
crassiceps ES products regulated LPS-induced miRNA expression profile in human 
DCs, inhibiting LPS-induced Let-7i expression to reduce DC inflammatory cytokine 
production (Terrazas et al., 2013). Overall, at least two miRNAs, miR-155 and miR-
106b, have been identified to effect DC-mediated Th2 polarisation with other miRNAs 
regulating tolerogenic DC properties. It is therefore likely that miRNAs are critical in 
shaping DC-mediated antihelminth immunity. 
Mast cells play an important role in antihelminth immunity, contributing to early 
cytokine release and immune response initiation, as well as the production of 
inflammatory mediators (see section 1.2.2.4). miRNAs are essential for mast cell 
development in vivo, with mice harbouring a mast cell-specific Dicer-deletion having 
a profound mast cell depletion in all tissues (Oh et al., 2014). Upon activation of mast 
cells, their miRNA expression profile changes (Teng et al., 2015), suggesting that 
miRNAs mediate mast cell function. Indeed, miR-155 expression regulated mast cell 
function following activation by targeting components of the PI3K pathway. miR-155-
deficient mast cells had enhanced FcϵRI-mediated degranulation and release of 
TNFα, IL-13, and IL-6 (Biethahn et al., 2014). Furthermore, mast cell-intrinsic miR-
223 expression regulates IL-6 secretion through targeting Akt and Igf1 (Yang et al., 
2016). Expression of miR-221-3p in mast cells promotes the production of IL-4 by 
modulating the NF-ϰB signalling pathway by directly targeting Pten (Zhou et al., 
2016). With IL-4 essential for immunity to intestinal helminth infection (Urban et al., 
1991b, Bancroft et al., 2000, Bancroft et al., 1998), perhaps increasing IL-4 
production from mast cells through miRNA manipulation can promote antihelminth 
immunity. Overall, with miRNAs regulating a plethora of mast cell functions, it is 
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therefore likely that mast cell-intrinsic miRNAs contribute to mast cell-mediated 
antihelminth immunity. 
With the large secretion of protein mediators from ILCs, it is interesting to speculate 
that miRNAs are rapidly downregulated upon activation to permit such high rate if 
mRNA translation, ribosome activity and protein secretion. As yet, the role of miRNAs 
in ILCs remains an area of research currently understudied. As outlined in section 
1.2.2.1, ILC2s are important players in antihelminth immunity, secreting type 2 
cytokines IL-4, IL-5 and IL-13 to promote type 2 immunity (Moro et al., 2010, Neill et 
al., 2010, Pelly et al., 2016). Currently, the only miRNA studied in ILC2s is miR-155, 
with expression of miR-155 in ILC2s increased following activation and required for 
both proliferation and cytokine production (Johansson et al., 2017). Despite the exact 
mechanism of miR-155-mediated ILC2 inflammation being unclear, miR-155-
deficient ILC2s expressed less Gata3 and produced less IL-13 (Johansson et al., 
2017). Identifying other miRNAs that regulate ILC2 proliferation and type 2 cytokine 
secretion will be beneficial in further understanding their role in antihelminth 
immunity. 
 
1.3.3.3 miRNA-mediated regulation of stromal immunity 
As outlined in section 1.2.3, stromal cells are essential for antihelminth immunity. 
Epithelial cells are particularly important, detecting and initiating immune responses 
to intestinal helminths as well as acting as important effector cells (see section 
1.2.3.1). Genetic deletion of the miRNA processing enzyme Dicer in intestinal 
epithelial cells resulted in the disorganisation of intestinal architecture, reducing 
goblet cell numbers and decreasing barrier function (McKenna et al., 2010). 
Unsurprisingly, mice with Dicer-deficient IECs are susceptible to T. muris, unlike their 
WT counterparts, due to a failure to induce Relmβ expression and induce a futile Th1 
immune response (Biton et al., 2011). In WT mice, IL-13 signalling in IECs drives 
miR-375 expression, concomitant with an increase in TSLP mRNA and protein 
expression. miR-375-deficient mice partially phenocopied mice with Dicer-deficient 
IECs, with reduced goblet cell frequency and reduced expression of Relmβ and 
TSLP mRNA in the small intestine (Biton et al., 2011). Although the targets of miR-
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375 were not identified in this study, it is likely that miR-375 targets an inhibitor of IL-
13R-mediated signalling and that deletion of miR-375 allows for increased 
expression of the inhibitory pathway, thus increasing expression of TSLP. miR-375 
also negatively regulates enteroendocrine cell development (Knudsen et al., 2015), 
an IEC subtype critical for protection against T. spiralis (Worthington et al., 2013). 
Furthermore, patients with ulcerative colitis have reduced miR-375 expression (Wu 
et al., 2008), adding to the growing evidence that miR-375 may be an important 
miRNA regulating intestinal epithelial cell homeostasis and potentially in regulating 
immunity to intestinal helminth infections. 
Tuft cells are another subtype of IEC, which specialise in the detection of intestinal 
helminth and the subsequent initiation of type 2 immunity through release of IL-25 
(Gerbe et al., 2016, von Moltke et al., 2016, Howitt et al., 2016). Whether miRNAs 
are important for tuft cell differentiation and function is currently unclear. However, 
miR-20b has been demonstrated to directly target IL-25, with an inverse relationship 
between serum levels of miR-20b and IL-25 observed in myasthenia gravis patients 
(Chunjie et al., 2015). Furthermore, elevated levels of miR-20b have been observed 
in the colon of patients with ulcerative colitis (Coskun et al., 2013), who have 
previously been described to have reduced intestinal IL-25 (Caruso et al., 2009). The 
role of miR-20b has not been investigated in the context of antihelminth immunity, 
however, extrapolating previous research, reducing miR-20b expression may allow 
for increased IL-25 production and therefore enhance antihelminth immunity. 
Intestinal microfold cells (M cells) are a specialised IEC, which are located on the 
luminal surface of gut-associated lymphoid tissue (GALT). M cells are important 
transporters of luminal antigens from the intestinal lumen into the GALT and are likely 
to be important in the generation of adaptive immune responses following helminth 
infection, but have not yet been directly studied in this context. M cell maturation 
relies on functional miRNA expression, with Dicer deletion restricted to IECs 
significantly depleted of M cell numbers and impairing antigen uptake (Nakato et al., 
2016). 
The critical role of Dicer in epithelial cell biology, coupled with the essential functions 
of IECs in regulating intestinal homeostasis and antihelminth immunity, strongly 
suggest a role for IEC-intrinsic miRNAs in mediating protection against intestinal 
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helminth infection. The precise function of specific IEC-intrinsic miRNAs is currently 
understudied, but investigation could elucidate critical IEC genes and pathways in 
antihelminth immunity. 
 
1.3.3.4 Helminth-derived miRNAs 
Intestinal helminths have long been known to produce and secrete molecules and 
proteins that act on the host to influence immunity. Many of these molecules induce 
an immunoregulatory environment, dampening the host immune response, 
preventing immunopathology and promote chronic infection.  
More recently, intestinal helminths have been shown to produce miRNAs which are 
incorporated and act in host cells. Specifically, Buck and colleagues identified 
miRNA-filled exosomes that were secreted by H. polygyrus, which contain a miRNA 
profile distinct from that isolated form the total worm (Buck et al., 2014). 
Administration of H. polygyrus-derived exosomes to mice was able to supress type 
2 responses by targeting Il33r and Dusp1. This study suggests intestinal helminths 
may select particular miRNAs for secretion to contribute to their immunoregulatory 
effector properties. In addition, miRNAs were detected in exosome-like vesicles in 
the ES products of T. muris, although their ability to act on the host is unclear (Tritten 
et al., 2017). Furthermore, parasite-derived miRNAs have been found in the 
circulation of the host. For example, miRNAs were found in the host blood following 
infection with the filarial nematodes Litomosoides sigmodontis (mice), Onchocerca 
volvulus (human), Onchorcerca ochengi (cows), Loa loa (baboons) and Dirofilaria 
immitis (Dogs) (Buck et al., 2014, Tritten et al., 2014b, Tritten et al., 2014a). Whether 
these filarial nematode-derived miRNAs can target host mRNAs is unclear. However, 
it is interesting to speculate that parasite-derived miRNAs can modulate host 
immunity and influence susceptibility and chronicity of infection.  
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1.4 Phospholipase A2 (PLA2) 
1.4.1 PLA2 function and mechanism 
Phospholipase A2 (PLA2) enzymes are a large superfamily of enzymes consisting of 
5 distinct types, 15 groups and multiple isoforms. PLA2 enzymes hydrolyse fatty acid 
moieties from the sn-2 position of phospholipids, yielding nonesterified (unsaturated) 
fatty acids and lysophospholipids (Figure 1.4) (Leslie, 2004, Berg et al., 2001, Six 
and Dennis, 2000). Both the fatty acids and lysophospholipids produced lead to the 
induction of several downstream responses. The fatty acids released, such as 
arachidonic acid, can be metabolised to form various eicosanoids and other bioactive 
lipids and mediate a wide range of biological functions (Powell, 2005). 
Lysophospholipids, such as lysophosphatidylcholine (LPC), are bioactive, capable 
of inducing distinct biological effects (Kabarowski, 2009, Valentine et al., 2008). As 
a result, PLA2 enzymes contribute to a diverse array of biological events. 
 
1.4.2 PLA2 family members 
As mentioned above, the superfamily of PLA2 enzymes compasses 15 different 
groups that fall into 5 distinct types. PLA2 enzymes are separated into types based 
on their function, including secretory PLA2s, cytosolic PLA2s, calcium-independent 
PLA2s, lysosomal PLA2s and lipoprotein-associated PLA2s. Each PLA2 enzyme is 
assigned a group (I – XV), which is determined by their structure and characteristics. 
Each individual PLA2 isoform is then identified using a letter after the assigned group, 
for example PLA2 group IIA (PLA2g2A). The precise function of PLA2 varies between 
each individual member, often depending where they are expressed and their cellular 
location. Each family type is outlined below. 
 
1.4.2.1 Secretory PLA2s (sPLA2s) 
Secretory PLA2s (sPLA2s) were the first PLA2 enzymes to be identified. PLA2s 
enzymes were first discovered in snake venoms and characterised after the 
purification from both cobra and rattlesnake venom in the 1970’s. The two venoms 
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phospholipase enzymes have a large number of cysteines in the form of disulphide 
bonds, with six disulphide bonds in common but one bond located in a distinctly 
different location. These two venom PLA2s were designated as group I (cobra venom 
PLA2) and group II (rattlesnake venom PLA2) (Dennis et al., 2011). At the same time, 
studies on the pancreatic digestive enzymes identified a mammalian sPLA2 enzyme, 
with the same disulphide bonding pattern as that seen in the cobra venom. This 
sPLA2 was therefore designated as group IB. Another sPLA2 was discovered in the 
synovial fluids of arthritic joints which shared the disulphide bonding characteristics 
of the rattlesnake venom, therefore this sPLA2 was denoted as group IIA (Hara et al., 
1989). A sPLA2 purified from bee venom was named as a group III PLA2 due to 
further differences in its structure (Kuchler et al., 1989). A further sPLA2 was 
identified in macrophages, however this sPLA2 lacked a seventh disulphide bond and 
was subsequently named as a group V PLA2 (Dennis et al., 2011). More sPLA2 
enzymes have since been discovered, each with differing structures or disulphide 
bonding characteristics, giving rise to groups IX, X, XI, XII, XIII and XIV (Dennis et 
al., 2011, Murakami et al., 2015).  
Structurally, sPLA2s enzymes are closely related low-molecular weight molecules, 
with highly conserved calcium binding loop and conserved disulphide bonds. Each 
sPLA2 isoform has been demonstrated to distinct substrate specificity, determined 
by the polar head groups of the phospholipid (Mitsuishi et al., 2007). Many of the 
functions of sPLA2 enzymes have been identified using both knockout and 
overexpressing mice. Their functions are varied and differ between isoforms, such 
as membrane remodelling, modification of dietary lipids and degradation of microbe 
phospholipids. This breadth of functions highlights the distinct roles of each sPLA2 
isoform in vivo, likely due to their subtleties in different enzymatic properties, 
substrate specificity and tissue distribution. 
As well as mediating biological functions through their catalytic activity, sPLA2s can 
also act as ligands that interact with sPLA2 receptors (sPLA2Rs), independent of 
catalytic function (Granata et al., 2005, Triggiani et al., 2003, Mandal et al., 2001). 
Two types of sPLA2R have been described in mammals, the N-type and M-type 
receptors (Valentin and Lambeau, 2000). The N-type receptor is abundantly 
expressed in the brain whereas the M-type receptor is expressed in various tissues 
(Lambeau et al., 1991, Lambeau and Lazdunski, 1999). The M-type receptor exists 
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as both membrane bound and soluble receptor (Lambeau and Lazdunski, 1999). The 
membrane bound form can induce signalling cascades upon ligand activation 
(Granata et al., 2005) whereas the soluble receptor sequesters and clears 
extracellular sPLA2, demonstrated to be important in limiting inflammation (Tamaru 
et al., 2013). 
 
1.4.2.2 Calcium-dependent cytosolic PLA2s (cPLA2s) 
In 1992, two groups independently reported the purification and characterisation of 
the first human cytosolic PLA2 (cPLA2) from a macrophage cell line, whose sequence 
was unrelated to sPLA2 enzymes previously described and was therefore denoted 
as a group IV PLA2 (Sharp et al., 1991, Clark et al., 1991). There are 6 cPLA2s, all 
of which are group IV members and dependent upon calcium for their catalytic 
activity (Leslie, 2015). Each of the 6 isoforms exhibit slightly different properties, 
sharing only 30% homology (Ohto et al., 2005), specifically in substrate specificity 
and sensitivity to pharmacological inhibitors (Ghomashchi et al., 2010).  
Among the cPLA2 group IV family members, phospholipase A2 group IVA (PLA2g4A) 
is the most well characterised, highly conserved between mouse and human (Clark 
et al., 1991) and expressed in a wide range of cells throughout the body, such as 
mast cells, endothelial cells and lung fibroblasts (Nakatani et al., 2000, Ghosh et al., 
2004, Tanaka et al., 2011). cPLA2g4A activity is predominantly regulated by its 
intracellular location. Normally sequestered in the cytosol, translocation to 
membranes (cell or organelle) is induced by an increase in intracellular calcium ion 
concentration (Channon and Leslie, 1990, Gijón et al., 1999). Calcium is also 
essential for functional catalytic activity, although the binding domains of calcium 
differ to that required for membrane translocation (Xu et al., 1998). PLA2g4A 
activation is also dependent upon the calcium-independent binding of the lipid 
second messenger phosphatidylinositol-4,5-bisphosphate (PIP2) (Mosior et al., 
1998, Six and Dennis, 2003) and phosphorylation (Dennis et al., 2011). PLA2g4c has 
a specificity for arachidonic acid and is important for the generation of eicosanoids, 
such as prostaglandins (PGs) and leukotrienes (LTs), and bioactive 
lysophospholipids (Leslie, 2004).  
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Evidence of other roles of cPLA2s have also emerged. PLA2g4A also regulates both 
Golgi-membrane and intra-Golgi trafficking (San Pietro et al., 2009, Regan-Klapisz 
et al., 2009). Furthermore, PLA2g4C was discovered in the epithelium of lesions from 
psoriatic patients, where it is postulated to be involved in the generation of 
eicosanoid-mediated chronic inflammation and disease (Chiba et al., 2004, Ghosh 
et al., 2006). Despite the discovery of other cPLA2 isoforms, their biological roles 
have been difficult to elucidate and are still unknown. 
 
1.4.2.3 Calcium-independent cytosolic PLA2s (iPLA2s) 
In the 1994, another PLA2 was identified in the cytosol of macrophage-like cells, 
however the protein sequence differed from cPLA2s and its enzymatic activity was 
not dependent on calcium. It was therefore named as a calcium-independent PLA2 
(iPLA2) and designated as a group VI PLA2, isoform A (PLA2g6A) (Ackermann et al., 
1994, Tang et al., 1997). The iPLA2 family only encompasses group VI PLA2s despite 
the existence of other calcium-independent PLA2s, such as the lysosomal PLA2s 
(lPLA2s, section 1.4.2.4) and the cPLA2 PLA2g4C (section 1.4.2.2). There are 6 
members of the group VI iPLA2 family (A-F), all of which are catalytically active. The 
catalytic domain of iPLA2 enzymes is also called a patatin-like domain as it shares 
40% homology to patatin, another enzyme with lipase activity (Hsu et al., 2009). 
Although not regulated by calcium, PLA2g6A activity and function is regulated by ATP 
binding and caspase cleavage. PLA2g6A can be activated by ATP in the 
mitochondria of various cell types (Liou et al., 2005, Gadd et al., 2006), although ATP 
is not a substrate, but instead acts as a cofactor for PLA2g6A activity, likely inducing 
a conformational change (Lio and Dennis, 1998). Caspase proteolysis of the 
PLA2g6A enzyme during apoptosis results in a hyperactive, truncated protein 
(Atsumi et al., 2000, Atsumi et al., 1998), resulting in membrane damage and 
processing of lysophospholipids to initiate phagocytosis (Kim et al., 2002, Lei et al., 
2010).  
Like cPLA2s, iPLA2s are intracellular enzymes which are ubiquitously expressed and 
contribute to a variety of biological activities, such as fat catabolism, cell 
differentiation, mitochondrial maintenance, phospholipid remodelling and signal 
Chapter 1 Introduction 
62 
 
transduction (Ramanadham et al., 2015). As expected, dysregulation of iPLA2 
enzymes has been linked to a wide range of diseases. 
 
1.4.2.4 Lysosomal PLA2s (lPLA2s) 
In 1996, group XV PLA2 (PLA2g15) was discovered in the soluble and lysosomal 
fractions of Madin-Darby canine kidney (MDCK) cells (Abe et al., 1996) and 
subsequently identified to be ubiquitously expressed in every tissue (Abe et al., 
2004). PLA2g15 is the only member of the lysosomal PLA2 (lPLA2) family, with 
optimal enzymatic activity at pH 4.5 (Abe et al., 1996). The catalytic activity of 
PLA2g15 is not dependent upon calcium, but millimolar concentrations of calcium or 
magnesium can enhance its activity (Abe and Shayman, 1998). Although primarily 
functioning as a PLA2, PLA2g15 also possesses transacylase activity in acidic 
conditions (Abe et al., 1996). 
Although expressed in every tissue, the specific activity of PLA2g15 was 50 times 
greater in alveolar macrophages (Abe et al., 2004), suggesting lPLA2 to have an 
important role in these cells. Indeed, lPLA2 may be involved in surfactant 
phospholipid catabolism in alveolar macrophages. CSF2-deficient mice develop a 
progressive accumulation of the phospholipid-rich pulmonary surfactant (Dranoff et 
al., 1994), correlating with a significantly lower lPLA2 activity and expression than 
WT (Abe et al., 2004). Moreover, Pla2g15-deficient mice have increased lung 
phospholipid-rich pulmonary surfactant (Hiraoka et al., 2006). Pla2g15-deficient 
mice, backcrossed onto an apo E-null background had increased development of 
high fat diet-induced atherosclerosis, characterised by increased formation of foamy 
macrophages (or foam cells) due to defective phospholipid degradation (Taniyama 
et al., 2005, Hiraoka et al., 2006), suggesting a critical role for lPLA2 in protection 
against atherosclerosis. 
Together, these data suggest that lPLA2 has an essential role in macrophages and 
maintaining homeostasis of various organs and tissues. 
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1.4.2.5 Lipoprotein-associated PLA2s (lpPLA2s) 
Lipoprotein-associated PLA2s (lpPLA2s), also known as platelet activation factor 
(PAF) acetylhydrolases (PAF-AHs), contain two groups of PLA2s, group VII and 
group VIII. As the family name suggests, PLA2g7A is a secreted enzyme associated 
with both high- and low-density lipoproteins (HDL and LDL) in human plasma, with 
LDL-bound PLA2g7A more active than HDL-bound PLA2g7A (Stafforini et al., 1989, 
Stafforini et al., 1987). However, the family name is misleading as the remaining 
members, PLA2g7B and PLA2g8, are both intracellular proteins and not associated 
with lipoproteins. All three members catalyse the hydrolysis of PAF to produce lyso-
PAF and acetate, in a calcium-independent manner (Schaloske and Dennis, 2006, 
Dennis et al., 2011). 
PLA2g7A is implicated in the development of atherosclerosis and neonatal 
necrotising enterocolitis. PLA2g7A is predominantly secreted by macrophages, with 
expression and secretion significantly increased in macrophages in atherosclerotic 
lesions (Stafforini et al., 1990, Elstad et al., 1989), however it is unclear whether 
PLA2g7A activity is anti- or pro-atherosclerotic. Premature human infants with 
neonatal necrotising enterocolitis have decreased serum PLA2g7A levels and 
increased systemic accumulation of PAF (Caplan et al., 1990). Pla2g7a-deficient 
mice have increased incidence of neonatal necrotising enterocolitis, suggesting that 
PLA2g7A may be protective (Lu et al., 2010a). Intracellular PLA2g7B is predominantly 
expressed in epithelial cells (Kono et al., 2008) and is thought to have an antioxidant 
function, protecting the cell against oxidative stress-induced cell death (Matsuzawa 
et al., 1997). Pla2g7b-deficient mice have a delayed recovery following hepatic injury 
(Kono et al., 2008) and Pla2g7b-overexpressing mice are protected against neuronal 
injury (Umemura et al., 2007). PLA2g8 is found in the brain as a heterotrimeric protein 
complex (Ho et al., 1997). Its biological function is unclear, however it does seem to 
be implicated in brain development (Dennis et al., 2011). 
 
1.4.3 Phospholipase A2 group 1B (PLA2g1B) 
PLA2g1B was the first mammalian phospholipase to be discovered, a sPLA2 (see 
section 1.4.2.1) closely related to the PLA2 extracted from cobra venom (Dennis et 
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al., 2011), and as such is often called an ‘old’ phospholipase. Pla2g1b expression is 
detected in multiple tissues in the mouse with the highest expression detected in 
organs associated with the gastrointestinal tract. The highest expression is observed 
in the stomach, pancreas, small intestine and lung, respectively (Eerola et al., 2006). 
In most cases, the expression of Pla2g1b correlates with the PLA2g1B protein 
content detected in each organ, with the highest concentration detected in the 
stomach, pancreas, small intestine and salivary gland (Eerola et al., 2006). 
Like other sPLA2, PLA2g1B is a small enzyme (13-15 kDa), contains 7 disulphide 
bonds and requires calcium for its catalytic activity (Burke and Dennis, 2009). 
PLA2g1B is synthesised as an inactive zymogen, before cleavage of an N-terminal 
peptide is cleaved by trypsin or plasmin (Kudo and Murakami, 2002, Nakano et al., 
1994). In vitro, PLA2g1B has strict fatty acid substrate selectively, but selectivity is 
affected by the phospholipid head group (Murakami and Kudo, 1997). Specifically, 
PLA2g1B most effectively hydrolyses anionic phospholipids, such as 
phosphatidylglycerol (PG), phosphatidylethanolamine (PE) and phosphatidylserine 
(PS) over charge-neutral phosphatidylcholine (PC) (Snitko et al., 1999). The binding 
and hydrolysis of PC can be greatly increased in the presence of a detergent such 
as deoxycholate (deoxycholic acid is a bile acid) (Hanasaki et al., 1999), important 
as dietary phospholipid hydrolysis by pancreatic PLA2g1B occurs in the presence of 
bile in the small intestine. 
PLA2g1B has predominantly been studied in the context of dietary lipid digestion, 
with important roles in mediating diet-induced disease. However, expression of 
Pla2g1b in tissues outside the digestive tract suggests other biological functions. 
Indeed, further functions have been described for PLA2g1B, including immune cell 
modulation, however these are less well studied. 
 
1.4.3.1 Role of PLA2g1B in dietary lipid remodelling 
With high expression in the digestive system, the primary function of PLA2g1B is 
believed to be involved in dietary lipid remodelling to enable absorption of 
lysophospholipids. Upon feeding, PLA2g1B is released from pancreatic acinar cells 
granules into the pancreatic juice and transported to the small intestinal lumen where 
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it can mediate lipid digestion and absorption (Hui, 2012). However, Pla2g1b-deficient 
mice display normal dietary lipid absorption, suggesting that other enzymes can 
compensate for the lack of PLA2g1bB (Richmond et al., 2001). 
A genome wide association study identified a single nucleotide polymorphism in the 
human PLA2G1B gene as a risk factor for obesity (Wilson et al., 2006). Studies 
blocking PLA2g1B identified a critical role for this enzyme in diet-induced obesity. 
Specifically, PLA2g1B blockade or genetic deletion protected mice from high fat diet-
induced postprandial fat absorption and weight gain (Huggins et al., 2002, Hui et al., 
2009). Mechanistically, Pla2g2b-deficient mice were found to be resistant to obesity 
due to their ability to maintain elevated energy expenditure and core body 
temperature when subjected to a high calorie diet. PLA2g1B-mediated production 
and absorption of LPC supressed hepatic fat utilisation and downregulated energy 
expenditure (Labonte et al., 2010).  
Furthermore, Pla2g1b-deficient mice were protected from high fat diet-induced 
insulin resistance (Huggins et al., 2002). This phenotype was later described to be 
due to a reduction of PLA2g1B-mediated postprandial lysophosphatidylcholine (LPC) 
absorption during a high fat diet, which supressed insulin-stimulated glycogen 
synthesis to control blood glucose concentration (Labonte et al., 2006). This 
phenotype was also observed with the use of PLA2g1B-specific inhibitors in WT mice 
fed a high fat diet (Hui et al., 2009). Moreover, overexpression of Pla2g1b in 
pancreatic acinar cells exacerbated high fat diet-induced obesity and insulin 
resistance (Cash et al., 2011). 
PLA2g1B also induced hyperlipidemia in mice fed on a hypercaloric diet (high fat and 
high carbohydrate diet). Pla2g1b-deficient mice were protected from elevated 
plasma triglyceride and cholesterol levels induced by a hypercaloric diet, with 
protection dependent upon reduced hepatic very low-density lipoprotein (VLDL) 
production and increased triglyceride-rich lipoprotein clearance (Hollie and Hui, 
2011). Given that Pla2g1b-deficiency reduced hyperlipidemia, it is no surprise that 
Pla2g1b-deficient mice were also resistant to diet-induced atherosclerosis, when 
crossed with atherosclerosis prone Ldlr-deficient mice (Hollie et al., 2014). 
Taken together, PLA2g1B plays a major role in the induction of diet-induced diseases 
through dietary lipid remodelling and subsequent absorption. Therefore, 
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pharmacological inhibition of PLA2g1B maybe of therapeutic use to treat diet induced 
obesity and associated diseases, such as diabetes and atherosclerosis. 
 
1.4.3.2 Role of PLA2g1B in immunity 
As described above in section 1.4.3.1, much of the current research into the 
biological roles and functions of PLA2g1B has been focussed toward dietary lipid 
remodelling, and subsequent effects on diet-induced diseases, with very little focus 
on immunology. 
Other members of the sPLA2 family (see section 1.4.2.1) have been implicated in 
immune responses, infection and inflammatory disease (reviewed in (Murakami et 
al., 2016)). For example, PLA2g3 drives mast cell maturation in a paracrine manner 
(Taketomi et al., 2013), PLA2g10 is released from airway epithelial cells upon 
allergen exposure to induce leukotriene secretion by eosinophils (Henderson et al., 
2007, Lai et al., 2010) and other members contribute to antifungal and antibacterial 
defence (Balestrieri et al., 2009, Weinrauch et al., 1998). The precise mechanisms 
by which sPLA2s mediate their effects on the immune system is not clear. This, in 
part, is due to the dual functions of the protein- via catalytic activity or via binding to 
its receptor. Receptor binding can induce different responses depending on the cell 
type and the soluble M-type PLA2R can act as a sponge, sequestering excess sPLA2 
and preventing the catalytic activity. Also, sPLA2 enzymatic activity produces many 
bioactive products with direct biological activity or indirect actions via downstream 
pathways. 
PLA2g1B has various effects on immune cells in vitro. Stimulation of human 
neutrophils with PLA2g1B induced the production of the chemokine CXCL8(Jo et al., 
2004) and LTB4 (Lee et al., 2005). Interestingly, PLA2g1B does not directly induce 
extracellular arachidonic acid release, but instead acted via the sPLA2R to induce 
both activation of the MAPK-ERK signalling pathway or cPLA2 activation and 
eicosanoid production (Mandal et al., 2001, Jo et al., 2004, Lee et al., 2005). 
PLA2g1B also exerted pro-apoptotic effects on a mouse macrophage cell line, again 
via sPLA2R binding and production of TNFα (Lee et al., 2006), as well as proliferative 
and migratory effects on fibroblasts (Arita et al., 1991). It is unlikely that these effects 
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are specific to PLA2g1B, but similar effects are induced by all sPLA2 family members, 
as the sPLA2 receptor binds all other sPLA2 members. 
PLA2g1B is also implicated in mediating lung inflammation. Indeed, PLA2g1B 
induced TNFα and IL-6 production from primary human lung macrophages in a 
concentration dependent manner. Cytokine production was not dependent on the 
catalytic activity and instead relied upon the M-type sPLA2R, inducing ERK1/2 
phosphorylation (Granata et al., 2005). In addition, deletion of the sPLA2R 
exacerbated allergic lung inflammation in mice, reducing clearance of PLA2g1B 
(Tamaru et al., 2013). Increased PLA2g1B concentrations correlated with increased 
eicosanoid and TH2 cytokine concentration as well as an increased infiltration of 
eosinophils and neutrophils (Tamaru et al., 2013). This study suggests that in the 
lung, sPLA2R acts as a sponge to sequester excess PLA2g1B and limit its activity. 
This is likely to be mediated by the soluble sPLA2R, although has yet to be 
determined. 
Overall, like other sPLA2s, PLA2g1B has the potential to influence immunity by 
affecting multiple cell types. However, the role of sPLA2s enzymes, including 
PLA2g1B, in intestinal helminth infection has not been studied. 
 
1.5 Thesis aims 
Intestinal helminth infections are highly prevalent, infecting approximately a third of 
the world’s human population as well as a significant number of livestock. As a result, 
intestinal helminth infections are responsible for significant health and economic 
burdens (Bartsch et al., 2016, Fitzpatrick, 2013, Bethony et al., 2006). With a small 
number of chemotherapeutic drugs available, evidence of drug-resistant helminths 
(Kaplan and Vidyashankar, 2012) and stalling vaccine efforts, it is imperative to 
improve our understanding of antihelminth immunity to identify new therapeutic 
avenues.  
Our current understanding of antihelminth immunity places type 2 immunity at the 
forefront, with type 2 cytokines mediating various expulsion mechanisms (Grencis, 
2015, Allen and Maizels, 2011). However, the mechanism of helminth killing prior to 
expulsion remains unclear. 
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In this thesis, I aim to identify novel mechanisms of antihelminth immunity. To 
address this, we utilised the mouse model of STH, H. polygyrus. We used this 
parasite as it is a naturally occurring intestinal helminth of the mouse, in which 
C57BL/6 mice are susceptible to a 1o infection, establishing a chronic infection 
(Reynolds et al., 2012). However, following drug-cure of 1o infection, C57BL/6 mice 
are resistant to 2o challenge infection (Finkelman et al., 1997). Using this model 
system allowed us to interrogate features associated with susceptibility and 
resistance in the same genetic background. We performed both mRNA- and miRNA 
sequencing of small intestinal tissue from both susceptible and resistant mice to 
identify transcriptional changes at the site of infection. 
Using the mRNA sequencing data, we identified novel genes and pathways that we 
hypothesised to contribute to resistance to intestinal helminth infection (Chapter 3). 
Furthermore, using miRNA sequencing, we also investigated the role of miRNAs in 
regulating protective immunity to H. polygyrus. miRNA-mediated coordinated control 
of gene expression has been shown to be essential in infection and immunity, 
promoting and fine-tuning the appropriate immune response. Despite this, the role 
of miRNAs in antihelminth immunity is relatively understudied. We hypothesise that 
miRNAs are differentially expressed between susceptible and resistant mice and 
therefore regulate protective immunity to H. polygyrus (Chapter 4). 
By studying both mRNA and miRNA transcriptional changes in mice susceptible and 
resistant to H. polygyrus, we aim to uncover novel genes and pathways critically 
required for protective immunity to intestinal helminth infection. 
  





Figure 1.1 Heligmosomoides polygyrus lifecycle 
Infective L3 H. polygyrus larvae are orally ingested by the host and swallowed. The L3 
larvae then pass into the small intestine where they penetrate the intestinal mucosa and 
embed into the muscularis externa within 48 hours of infection. Here the larvae undergo 
two developmental moults (L4 then L5 stage) and re-emerge into the lumen as adult L5 
worms after 10 days. Adult worms wrap around the villi to anchor themselves, form 
mating pairs and produce eggs that are released into the environment in the host’s 
faeces. The eggs hatch in the environment and undergo two developmental moults 
becoming infective L3 larvae, thus continuing the life cycle. 
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Figure 1.2 Type 2 immune response to intestinal helminth infection 
Helminth-induced damage of epithelial cells and helminth ‘sensing’ by tuft cells induces 
the secretion of alarmins (TSLP, IL-33 & IL-25). These alarmins promote DC and ILC2 
activation as well as antigen uptake. In lymphoid tissues, DC antigen presentation to 
CD4+ T cells, in the presence of IL-4, promotes Th2 cell differentiation and migration 
back to the site of infection. Activated ILC2s and Th2 cells release the type-2 cytokines 
IL-4, IL-5 and IL-13 in the small intestine. These type-2 cytokines activate a variety of 
stromal and immune cells; goblet cell hyperplasia, increased mucus production, 
production of Relmβ, Tuft cell hyperplasia, class switching of B cells and production 
antibodies (IgA, IgE & IgG), alternate activation of macrophages, recruitment of 
eosinophils, smooth muscle hypercontractility and increased epithelial cell turnover. 
Activation of stromal cells induce the physical removal of intestinal helminths by the 
‘weep and sweep’ response. The activated and recruited immune cells form granulomas 
around embedded larvae to promote their killing at the cost of local tissue damage. 
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Figure 1.3 Canonical microRNA biogenesis and function 
Pri-miRNAs are transcribed by RNA Pol. II from the relevant gene in the nucleus. 
DiGeorge syndrome critical region gene 8 (Dgcr8) binds the pri-miRNA and recruits the 
RNase enzyme Drosha. Drosha cleaves the elongated 5’ and 3’ tails to form pre-miRNA 
with a 3’ overhang of 2nt. The pre-miRNA is then transported out of the nucleus via 
Exportin-5. In the cytoplasm, TRBP recognises and binds the pre-miRNA structure in 
complex with the RNase enzyme Dicer. Dicer cleaves the hairpin loop of the pre-miRNA 
to leave a miRNA-duplex. The miRNA duplex is recognised and bound by one of four 
Ago proteins and the complementary miRNA strand dissociates to leave a single-
stranded, mature miRNA. The miRNA-Ago complex is then loading into the RISC. The 
miRNA guides the RISC complex to the 3’ UTR of the target mRNA, complementary to 
the miRNA seed sequence. The RISC then binds to the target mRNA and induces 1) 
translational repression of the target mRNA if Ago protein 1, 3 or 4 are present in the 
RISC or 2) degradation of the target when Ago2 is present.  
  




Figure 1.4 Phospholipase A2 reaction 
PLA2 enzymes hydrolyse phospholipids at the sn-2 position to yield lysophospholipids 
and fatty acids. ‘X’ determines the phospholipid headgroup. 
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Chapter 2. Materials & Methods 
2.1 Animals 
All mice used in this study were maintained under specific pathogen-free conditions 
at both the Mill Hill Laboratory, The Francis Crick Institute (London, UK) and The 
Francis Crick Institute, 1 Midland Road (London, UK). C57BL/6, Pla2g1b–/– 
(Richmond et al., 2001), 4get (Mohrs et al., 2001), Dicerfl/fl (Murchison et al., 2005), 
R26CreERT2 (Ventura et al., 2007), R26Ryfp (Srinivas et al., 2001) Rag–/–γc–/– and 
Rag2–/– mice were bred and maintained at The Francis Crick Institute. Pla2g1b–/–
Il4gfp mice were generated by crossing Pla2g1b–/– and 4get mice at The Francis Crick 
Institute. R26CreERT2/yfpDicerfl/fl mice were generated by crossing Dicerfl/fl, R26CreERT2 
and R26yfp mice at The Francis Crick Institute. All mice used were male and between 
6-12 weeks old at the start of the experiment. Animal experiments were performed 
according to institutional guidelines and following UK Home Office regulations 
(project license 70/8809) and were approved by The Francis Crick Institute Ethical 
Review Panel. Mouse strains were genotyped by PCR analysis of tail or ear DNA 
using Transnetyx® Automated Genotyping. 
 
2.2 Intestinal helminth infections 
2.2.1 Heligmosomoides polygyrus 
The H. polygyrus lifecycle was maintained at The Francis Crick Institute. C57BL/6 
lifecycle mice were infected with 200 L3 infective H. polygyrus larvae. Faeces and 
cecal content from infected mice was harvested 14-28 days-post infection and 
spread onto damp filter paper (Whatmann) with 4-6 pieces of washed, activated 
charcoal (Sigma). The filter paper was then placed onto a 35 mm petri dish lid inside 
a 100 mm petri dish with 15 mL of MilliQ Water. The petri dishes were kept at room 
temperature, protected from light. L3 larvae were harvested from 14 days-post 
culture. 
For experiments, mice were infected with 200 L3 infective H. polygyrus larvae (oral 
gavage). Mice were drug cured (Rx) with the anthelminthic drug Pyrantel Embonate 
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(2.5 mg/dose, Pfizer) (oral gavage) on days 14 and 15. Mice were secondary (2o) 
challenge infected on day 35 or day 56, as indicated, with 200 L3 infective H. 
polygyrus larvae (oral gavage). H. polygyrus worms were counted in the wall of the 
intestine at day 5 post infection and luminal worms were counted in the small 
intestine 14 days-post 1o or 2o infection using a stereoscopic microscope (SMZ-2B, 
Nikon). 
 
2.2.2 Nippostrongylus brasiliensis 
The N. brasiliensis lifecycle was maintained by Helena Helmby at the London School 
of Hygiene & Tropical Medicine. Infective L3 larvae were kindly gifted for use at The 
Francis Crick Institute. 
For experiments, mice were infected with 350 L3 infective N. brasiliensis larvae (s.c.) 
on day 0. Luminal N. brasiliensis worms were counted in the small intestine 6, 8 and 
10 days-post infection using a stereoscopic microscope (SMZ-2B, Nikon). 
 
2.2.3 Trichuris muris 
The T. muris lifecycle, originally provided by Prof. Richard Grencis (University of 
Manchester), was maintained at The Francis Crick Institute. Rag2–/– mice were 
infected with 200 embryonated T. muris eggs. The cecum from infected mice were 
harvested from day 21-35 post infection and the adult worms removed, washed in 
PBS and incubated at 37oC for 24 hours in RPMI (Gibco), supplemented with400U/ml 
Penicillin (Gibco) and 400μg/ml Streptomycin (Gibco). Worms were then removed 
and the remaining media was harvested. The media was centrifuged and the 
supernatant discarded to leave the eggs. The eggs were washed twice in MilliQ 
water, passed through a 100 micron filter (Corning) and incubated in 150 mL in a 
tissue culture flask for 2-3 months protected from light, at room temperature to allow 
for embryonation. 
Mice were infected with 200 embryonated T. muris eggs (oral gavage) on day 0. T. 
muris worms were counted in the cecum 35 days-post infection using a stereoscopic 
microscope (SMZ-2B, Nikon). 




2.3 Tamoxifen treatment 
Mice were treated with tamoxifen (1mg i.p. plus 1mg oral gavage, Sigma) or corn oil 
(vehicle, Sigma) for 5 consecutive days. Mice were culled three days after the final 
treatment or infected with H. polygyrus and culled 14 days-post infection. 
 
2.4 Antibiotic treatment 
The antibiotics Gentamicin sulfate salt (1 mg/mL, Sigma), Metronidazole (1 mg/mL, 
Sigma), Cefloxin sodium salt (1 mg/mL, Santa Cruz Biotechnology) and Vancomycin 
hydrochloride (1 mg/mL, Sigma) were administered in the drinking water. Treatment 
started 7 days prior to 1o H. polygyrus infection (Day -7) and maintained throughout 
the duration of the experiment. 
 
2.5 Antibody treatment 
Anti-IL-4 antibody (0.5 mg/dose, BioXcell) was administered i.p. on days 13, 15, 17, 
19 and 21 after 1o H. polygyrus infection. Mice were drug cured (Rx) with the 
anthelminthic drug Pyrantel Embonate (2.5 mg/dose, Pfizer) (p.o.) on days 14 and 
15. 
 
2.6 miRNA inhibitor treatment 
In vivo miRCURY LNATM microRNA Inhibitors (Exiqon) were designed and 
manufactured for inhibiting mmu-miR-99a-5p, mmu-miR-148a-3p and mmu-miR-
155-5p. A negative control in vivo miRCURY LNATM microRNA Inhibitor (Exiqon) was 
also used.  
miRNA inhibitors were administered during 2o challenge H. polygyrus infection 
(section 2.2.1). Mice were given a 1o H. polygyrus infection on day 0 and drug cured 
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on days 14 and 15. Mice were 2o challenge infected with H. polygyrus on day 35. 
miRNA inhibitors were given prior to and during 2o challenge infection on days 33, 
35, 37 and 40 (0.125 mg per dose, s.c.). Mice were culled on day 49, 14 days-post 
2o infection. 
 
2.7 PLA2g1B treatment 
For PLA2g1B treatment, infective L3 H. polygyrus larvae were exsheathed as 
previously described (Sommerville and Bailey, 1973). 0.85% w/v NaCl (in distilled 
water) was bubbled with 40% CO2 in Nitrogen for 5 minutes, the tube was then 
sealed and incubated in a 37oC waterbath for a further 5 minutes. The pH was 
adjusted to pH2 using HCl and 5 mL was added to 30000-50000 L3 larvae before 
bubbling with 40% CO2 in Nitrogen for 30 seconds. The tube was then sealed and 
incubated in a 37oC waterbath for a further 30 minutes. Exsheathed L3 larvae were 
washed and counted before treatment with PLA2g1B. 8000 exsheathed L3 H. 
polygyrus larvae were treated with recombinant mouse PLA2g1B (Elabscience) with 
or without manoalide (200 ng/µL final concentration, Santa Cruz Biotechnology), 
manoalide alone, or heat inactivated recombinant mouse PLA2g1B in 1mL EnzChek® 
PLA2 reaction buffer (Invitrogen) at room temperature for 24 hours. Recombinant 
mouse PLA2g1B was heat inactivated by heating at 100oC for 4 hours. Following 
treatment, larvae were washed with MilliQ water prior to use in ATP assay (detailed 
below) or infection. Adult L5 H. polygyrus worms were isolated from C57BL/6 
following primary infection between days 14 and 28 using a modified Baermann 
apparatus (Johnston et al., 2015). Adult L5 H. polygyrus worms were treated with 
recombinant mouse PLA2g1B (Elabscience) or heat inactivated recombinant mouse 
PLA2g1B in EnzChek® PLA2 reaction buffer (Invitrogen) at room temperature for 24 
hours. 
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2.8 ATP assay 
The ATP of infective L3 H. polygyrus larvae, L4 H. polygyrus larvae (removed from 
intestinal wall at day 7 post infection) or adult L5 H. polygyrus worms was measured 
using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). H. polygyrus 
adult worms, two L4 larvae or 100 L3 larvae were homogenised using a motorised 
pestle in 110 µL of PBS and 110 µL of CellTiter-Glo® Reagent. The homogenate was 
incubated for 10 minutes at room temperature before centrifugation at 1000g for 3 
minutes. 200 µL of the supernatant was transferred to a 96 well opaque-walled plate 
and incubated for 10 minutes at room temperature before recording luminescence. 
An ATP standard curve was generated by using recombinant ATP (Promega) as 
detailed in the CellTiter-Glo® Luminescent Cell Viability Assay instructions. 
 
2.9 RNA extraction and analysis 
2.9.1 RNA extraction from cells and tissue samples 
Tissues were harvested and stored in RNAlater (Sigma) for 24hrs at 4oC before 
storage at -80oC. For RNA extraction, RNAlater was removed and tissue was 
homogenised in Qiazol (Qiagen) using the Precellys homogeniser (Bertin 
Instruments). Cells were lysed and stored in Qiazol (Qiagen) at -80oC. RNA was 
extracted using the RNeasy Kit (Qiagen), following the manufacturer’s instructions. 
RNA concentration was measured using a ND-1000 Spectrophotometer (NanoDrop 
Technologies) or Qubit 2.0 Fluorometer (Invitrogen). 
 
2.9.2 mRNA sequencing and analysis 
2.9.2.1 Chapter 3 mRNA sequencing and analysis 
RNA integrity was confirmed using Agilent’s 2100 Bioanalyser. Total RNA libraries 
were created using the Encore® Complete RNA-Seq Library Systems kit (NuGEN) 
or TruSeq® RNA Sample Preparation v2 kit (Illumina), following manufacturer’s 
instructions. Total RNA libraries were sequenced using the Illumina® HiSeq 2500. 
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The raw Illumina reads were analysed as follows. First, the data quality was analysed 
using FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc). Then the low 
quality bases were trimmed using Trimmomatic. The read pairs which passed the 
trimming quality filters were then aligned to mm10 (Ensembl version 75) using 
Tophat2. Counts were determined using htseq_count. Normalisation and statistical 
analysis was performed using edgeR. Differential gene analysis was calculated from 
naïve control group. Statistically significant genes with FDR < 0.05 were reported. 
 
2.9.2.2 Chapter 4 mRNA sequencing and analysis 
Biological replicate libraries were prepared using the KAPA polyA stranded mRNA 
Library Prep Kit and sequenced on Illumina HiSeq 2500 platform, generating ~30 
million 75bp single-end reads per sample. The RSEM package (version 1.2.31) (Li 
and Dewey, 2011) in conjunction with the STAR alignment algorithm (version 2.5.2a) 
(Dobin et al., 2013) was used for the mapping and subsequent gene-level counting 
of the sequenced reads with respect to Ensembl mouse GRCm.38.86 version genes. 
Normalisation of raw count data and differential expression analysis was performed 
with the DESeq2 package (version 1.10.1) (Love et al., 2014) within the R 
programming environment (version 3.2.3) (www.r-project.org/). Differentially 
expressed genes were defined as those showing statistically significant differences 
(p<0.05).  
 
2.9.3 microRNA sequencing and analysis 
RNA integrity was confirmed using Agilent’s 2100 Bioanalyser. miRNA libraries were 
created using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New 
England BioLabs), following manufacturer’s instructions. miRNA libraries were 
sequenced using the Illumina® MiSeq. The raw Illumina reads were analysed as 
follows. First, the data quality was analysed using FastQC 
(www.bioinformatics.babraham.ac.uk/projects/fastqc). Then the low quality bases 
were trimmed using Trimmomatic. The read pairs which passed the trimming quality 
filters were then aligned to mirBase (release21) using Novoalign v3.02.12 
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(http://www.novocraft.com/support/download/). Counts were determined using the 
following R script. 
aggregate_mmu_counts <- function (cfile)  
{library("plyr") 
mmu <- read.table("/Users/nnikolo/Documents/mmu.txt") 
colnames(mmu) <- c("mmu","counts") 
sample_counts <- read.table(cfile) 
colnames(sample_counts) <- c("counts", "mmu") 




write.table(sample_sum_counts, file="agg.counts", row.names = FALSE, 
col.names = FALSE, sep = "\t", quote = FALSE) 
sum(sample_sum_counts$total_counts)} 
Normalisation and statistical analysis was performed using edgeR script. Differential 
gene analysis was calculated from naïve control group. Statistically significant 
miRNAs with FDR < 0.05 were reported. 
 
2.9.4 IPA® analysis 
Analysed RNA sequencing data sets were uploaded into Ingenuity Pathway 
Analysis® (IPA®, Qiagen) where fold change filters, pathway analysis, upstream 
regulator analysis and miRNA target filter analysis algorithms were applied. 
For pathway analysis and upstream regulator analysis algorithms, uploaded 
expression data was subjected to ‘Core Analysis’. Following Core Analysis, ‘Disease 
and Bio Functions’ and ‘Upstream Analysis’ algorithms were applied and the 
predicted activation score extracted and reported.  
For miRNA target filter analysis, miRNA- and corresponding mRNA expression 
datasets were subjected to the ‘microRNA Target Filter’ analysis algorithm with a 
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minimum confidence level of Moderate (predicted). The results were filtered on 
miRNA-mRNA expression pairing, specifically ‘miRNA up, mRNA down’ and ‘miRNA 
down, miRNA up’. Resulting mRNA targets for the relevant miRNA were then 
extracted and reported. 
 
2.9.5 Ratios of ratios analysis  
Ratio of ratios plots were generated from plotting the fold change of genes in H.p. 2o 
relative to H.p. 1o (2-fold filter, p<0.05) (y axis) against the fold-change of each gene 
in both H.p. 2o and H.p. 1o, relative to naïve (2-fold filter, p<0.05) (x axis). 
 
2.9.6 mRNA Quantitative real-time polymerase chain reaction 
RNA was extracted and purified from tissue or cells as described above. Reverse 
transcription was performed with 0.1-1 µg RNA using Quantitect RT Kit (Qiagen) 
following manufacturer’s instructions to create cDNA. cDNA was used for 
quantitative real-time PCR analysis using Power SYBR® Green PCR Master Mix 
(Applied Biosystems) and quantified on the 7900HT (Applied Biosystems) or 
QuantStudio5 (Applied Biosystems). The PCR conditions were as follows: 95°C for 
15min, 40 cycles of 94°C for 30s, 55°C for 30s, 72°C for 30s followed by a melting 
step of 95°C for 15s, 60°C for 15s, 95°C for 15s. Where appropriate, relative gene 
expression was determined via normalisation to the housekeeping gene Hprt and the 
relevant control group (see Figure legends). Please see section 2.24 for primer 
sequences. 
 
2.9.7 miRNA Quantitative real-time polymerase chain reaction 
RNA was extracted and purified from tissue or cells as described above. Reverse 
transcription was performed with 0.1-1 µg RNA using miSCRIPT II RT Kit, HiSpec 
buffer, (Qiagen) following manufacturer’s instructions to create cDNA. Generated 
cDNA was used for quantitative real-time PCR analysis using Power SYBR® Green 
PCR Master Mix (Applied Biosystems) and quantified on the 7900HT (Applied 
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Biosystems) or QuantStudio5 (Applied Biosystems). The PCR conditions were as 
follows: 95°C for 15min, 40 cycles of 94°C for 30s, 55°C for 30s, 70°C for 30s 
followed by a melting step of 95°C for 15s, 60°C for 15s, 95°C for 15s. All miRNA 
and snoRNA primers were purchased from Qiagen for use with the miSCRIPT II RT 
Kit. Where appropriate, relative miRNA expression was determined via normalisation 




2.10.1 Histology staining 
Small intestinal tissue was removed and fixed in 4% formaldehyde for 24 hours then 
washed in 70% ethanol. The tissues were embedded in paraffin, and sectioned. 
Sections were stained with haematoxylin and eosin stain or Alcian blue/ periodic 
acid-Schiff stain. Stained slides were scanned with a VS120-SL slide scanner 
(Olympus, Tokyo, Japan) and images were captured with the OlyVIA image viewer 
(Olympus). 
 
2.10.2 In situ hybridisation 
Pla2g1b staining: Pla2g1b RNAscope® probes were designed by Advanced Cell 
Diagnostics and in situ hybridisation was performed with RNAscope® 2.5 Reagent 
Kit Brown (Advanced Cell Diagnostics), following the manufacturer’s instructions. 
The final Pla2g1b signal was detected chromogenically using DAB and the sections 
were counterstained with Haematoxylin Stained. Stained slides were scanned with 
a VS120-SL slide scanner (Olympus, Tokyo, Japan) and images were captured with 
the OlyVIA image viewer (Olympus). 
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2.11 Small intestine homogenate preparation 
1cm of duodenal tissue was removed and homogenised in 300 µL of cOmplete 
protease inhibitor (Roche), using the Precellys homogeniser (Bertin Instruments), 
before centrifugation. The supernatant was removed and the protein concentration 
calculated using the ND-1000 Spectrophotometer (NanoDrop Technologies). The 
small intestinal homogenate was stored at -80oC. 
 
2.12 PLA2 activity assay 
PLA2 activity was determined using EnzChek® Phospholipase A2 Assay Kit 
(Invitrogen), following manufactures instructions. 25 µL of the small intestinal 
homogenate (see section 2.11) was transferred to a ½ well 96 well plate with 25 µL 
of the substrate-liposome mix then incubated at room temperature in the dark for 10 
minutes. Fluorescence emission was measured at 515nm and reported after blank 
reduction. 
 
2.13 Preparation of single cell suspensions 
2.13.1 Isolation of cells from Spleen, mesenteric lymph nodes and thymus 
The spleen, mLNs and thymus were made into single-cell suspensions by gently 
mashing through a 40 micron filter (Thermo-Scientific), and the red blood cells were 
lysed from the spleen single cell suspension with ACK lysis buffer (Gibco). Cells were 
then resuspended in cIMDM (complete Iscove’s Modified Dulbecco’s Medium 
(cIMDM) containing 1% fetal bovine serum (FBS), 1mM EDTA, 100U/ml Penicillin 
(Gibco) and 100μg/ml Streptomycin (Gibco), 8mM L-glutamine (Gibco) and 0.05mM 
2-mercaptoethanol (Gibco)). Single cell suspensions were used for ex vivo 
restimulations and flow cytometry analysis. 
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2.13.2 Isolation of intestinal epithelial cells 
For the isolation of small intestinal epithelial cells: adipose tissue was removed from 
the small intestine before being dissected longitudinally to remove faecal contents 
and cut into 2cm segments. The epithelial layer was then dissociated by  incubating 
the intestine segments in PBS containing 10% FBS, 15 mm HEPES, 5 mm EDTA 
(Life Technologies) and 1 mm dithiothreitol (Sigma) for 30 minutes at 37 °C. The 
remaining intestinal tissue was removed using a wide mesh sieve and epithelial layer 
was retained. Cells were layered onto 20% isotonic Percoll (GE Healthcare) to 
remove debris. Cells were then resuspended in complete Iscove’s Modified 
Dulbecco’s Medium (cIMDM) containing 1% fetal bovine serum (FBS), 1mM EDTA, 
100U/ml Penicillin (Gibco) and 100μg/ml Streptomycin (Gibco), 8mM L-glutamine 
(Gibco) and 0.05mM 2-mercaptoethanol (Gibco)) and prepared for cell sorting. 
 
2.13.3 Cell counting 
Aliquots of single cell suspensions were diluted appropriately in cIMDM. Samples 
were then mixed at a 1:1 ratio in Trypan blue (Sigma). Live cells were counted using 
a cell counting haemocytometer (Hawksley) and a LED inverted light microscope 
(Leica). 
 
2.14 Fluorescence activated cell sorting (FACS) and flow 
cytometry 
Cell sorting was performed using a MoFlo XDP cell sorter (Beckman Coulter). Cell 
suspensions were stained for 25 minutes with antibodies in PBS with 1% FCS. To 
prepare for sorting, stained cells were diluted in phenol-red free IMDM (Gibco) (with 
1% FCS, 2mM EDTA (Invitrogen), 100 U/mL Penicillin and 100 µg/mL Streptomycin 
(Gibco), 8 mM L-glutamine (Gibco), and 0.05 mM 2-mercaptoethanol (Gibco)). For 
flow cytometry analysis, cells were analysed using a BD LSRFortessa™ X-20 (BD 
Biosciences) or BD LSRII (BD Biosciences) and data were analysed using FlowJo 
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software (Version 10, Treestar Inc). Cells were sometimes fixed in 2–4% 
paraformaldehyde for Flow cytometry analysis.  
For cell sorting, viability of the cells was determined using Propidium Iodide (Sigma); 
for analysis, viability of the cells was determined using the LIVE/DEAD Fixable Blue 
kit (Life Technologies). All staining was performed in the presence of FcR Blocking 
Reagent (Miltenyi Biotec).  
Intracellular cytokine staining (ICS) was performed following 6 hours of re-stimulation 
with 50ng/mL phorbol 12-myristate 13-acetate (PMA, Promega) and 1 µg/mL 
ionomycin (Sigma) and BD Golgi Stop and BD Golgi Plug (diluted 1:1000, BD 
Biosciences). Following surface stain, cells were incubated with 
Fixation/Permeabilization buffer (eBioscience) for 25 minutes followed by 25 minutes 
in Permeabilization buffer (eBioscience), and incubation with antibodies in 
Permeabilization buffer for a further 30 minutes.  
ILCs were analysed using the following strategy: Live, lymphocytes, CD45+, Lineage– 
(CD3, CD4, CD8, CD19, CD11c, CD11b, NK1.1, TCRβ, TCRγδ, Gr-1, CD49b, 
Ter119), Thy1.2+, KLRG1+, and Sca1+. 
Tregs were analysed using the following gating strategy: Live, lymphocytes, CD4+, 
TCRβ+, CD25+ and Foxp3+.  
Epithelial cells were sorted using the following gating strategy: Live, CD45– and 
EpCam+. 
 
2.15 In vitro cell culture and stimulation assays 
2.15.1 Bone marrow-derived macrophages culture and stimulation 
Bone marrow was isolated from the femur and tibia of mice and the red blood cells 
were lysed with ACK lysis buffer (Gibco). The remaining cells were then cultured in 
DMEM (Gibco) (with 20% L929 cell media (in-house preparation), 10% FCS 
(Invitrogen), 1% L-Glutamine (Gibco), 100 U/mL Penicillin and 100 µg/mL 
Streptomycin (Gibco), 10 mM HEPES (Lonza) and 0.05mM 2-mercaptoethanol 
(Gibco)) in 10mls at a density of 5x105 cells/ml at 37oC. After 7 days of culture non-
adhesive cells were removed before removing adherent BMDMs using 2.5mM EDTA 
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(Invitrogen) in PBS (Gibco) with 5% FCS (Invitrogen). Adherent BMDMS were 
washed and resuspended in DMEM (with 1% FCS (Invitrogen), 1% L-Glutamine 
(Gibco), 100 U/mL Penicillin and 100 µg/mL Streptomycin (Gibco), 10 µM HEPES 
(Lonza) and 0.05mM 2-mercaptoethanol (Gibco)). Adherent BMDMs were then 
plated at a density of 2x106 cells/ml for 24 hours. The adherent BMDMs were then 
stimulated for 24 hours with either 20ng/ml IL-4 (R&D) and 20ng/ml IL-13 (R&D) 
before RNA extraction. 
 
2.15.2 Ex vivo stimulations 
mLNs were harvested and processed into a single cell suspension (see section 
2.12.1). Cells were plated at 2x105 cells per 200µl cIMDM with 10µg/ml of H. 
polygyrus antigen extract (HEX) at 37oC. Supernatant was harvested after 4 days. 
Cytokines were detected in the supernatant using ELISAs. 
For HEX preparation, mixed sex adult L5 H. polygyrus worms were removed from 
the small intestine of infected mice and homogenised using a ground-glass 
homogeniser (Jencons H103/32/324) in 1ml of PBS, in the absence of protease 
inhibitors. The homogenate was centrifuged at 10000 g for 20 minutes. The soluble 
supernatant fraction was passed through a 0.2μm filter (Millipore) prior to protein 
concentration determination using the Pierce BCA protein assay (ThermoFisher). 
Hex was stored at -80oC until use. 
 
2.15.3 Intestinal organoid culture – in collaboration with Amina Metidji 
Mouse organoids were established and maintained at 37oC as three-dimensional 
spheroid culture in Matrigel (R&D system) from isolated crypts collected from the 
duodenum. The basic culture medium (ENR) contained advanced DMEM/F12 
supplemented with penicillin/streptomycin, 10 mM HEPES, 2mM Glutamax, B27 (all 
from Life Technologies) and 1 mM N-acetylcysteine (Sigma) supplemented with 
murine recombinant EGF (life technologies), R-spondin1-CM (Trevigen) (10% final 
volume) and Noggin-CM (kindly provided by Dr. Hans Clevers, Hubrecht Institute, 
Utrecht, The Netherlands) (20% v/v). Wnt3a-CM was used at 50% (v/v) for 7 days at 
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the beginning of the culture, then withdrawn. Organoids were stimulated with 20 
ng/mL IL-4 (R&D) and 20ng/mL IL-13 (R&D) or small intestinal homogenate (see 
section 2.11) for 48 hours. RNA was extracted and qRT-PCR performed as 
described in section 2.9.6. 
 
2.16 ELISAs and EIAs 
2.16.1 Cytokines 
IFNγ, IL-5 and IL-13 were measured using DuoSet ELISA kits, according to the 
manufacturer’s instructions (R&D). 
 
2.16.2 IgE 
Total IgE ELISA was performed by coating with Purified Rat Anti-Mouse IgE (R35-
72, BD Pharmingen) at 2 μg/mL overnight, followed by overnight incubation with 
serum and standard (Purified Mouse IgE, k isotype Standard, BD Pharmingen), and 
detection with Biotin Rat Anti-Mouse IgE at 1 μg/mL (R35-118, BD Pharmingen), 
Streptavidin HRP at 1:000 (BD Pharmingen) and ABTS One Component HRP 
Microwell Substrate (SurModics). 
 
2.16.3 IgG1 
H. polygyrus-specific IgG1 was detected by coating plates with 5 μg/mL H. polygyrus 
antigen extract (HEX) overnight, followed by overnight incubation with serially diluted 
serum and detection with Biotin Rat Anti-Mouse IgG1 (Invitrogen), Streptavidin HRP 
at 1:1000 (BD Pharmingen) and ABTS One Component HRP Microwell Substrate 
(SurModics). 
 




Cysteinyl leukotrienes and prostaglandin E2 were measured in small intestinal 
homogenate (see section 2.11) using ELISA kits, according to manufacturer’s 
instructions (Enzo), and normalised to total protein content. 
 
2.17 Serum chemistry analysis 
Whole blood was collected from mice and the serum separated after clotting. The 
serum was sent to the MRC Harwell Institute (UK) for metabolite analysis using a 
Beckman Coulter AU680 clinical chemistry analyser. 
 
2.18 Lysophosphatidylcholine Assay 
Lysophosphatidylcholine (LPC) was measured in the serum and small intestine 
homogenate (see section 2.11) using the AZWELL LPC Assay Kit, according to the 
manufacturer’s instructions (Cosmo Bio), and normalised to total protein content. 
 
2.19 Lipid extraction and analysis – in collaboration with Mariana 
Silva dos Santos and James MacRae 
Lipids were extracted from H. polygyrus L3 larvae using a method adapted from a 
previous publication (Meyer et al., 1966). Following PLA2g1B treatment ~8000 H. 
polygyrus larvae were washed three times with MilliQ water, resuspended in 2 mL 
methanol and heated in a sealed tube under nitrogen at 55oC for 20 min. After 
cooling, 4 mL chloroform was added and the sample was agitated with a magnetic 
stirrer for 3 hrs. The organic phase was removed and the residue ground (using a 
glass homogeniser) and extracted with 2 mL chloroform/methanol (2:1, v/v) for 2 hrs. 
For LC-MS, lipids were dried under nitrogen and redissolved in 100 µL 
methanol/chloroform (1:1 v/v) and diluted 1:2 with solvent A (hexane:isopropanol, 
70:30 [v: v], 0.02% [m/v] formic acid, 0.01% [m/v] ammonium  hydroxide), centrifuged 
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at 1,500 rpm for 5 min to remove trace non-lipidic materials prior to transfer to a 
glass autosampler vial (Agilent). 10 µL was injected onto a BETASIL diol column 
(5 um x 150 mm x 2.1 mm, with BETASIL diol guard column (10 mm x 2.1 mm), held 
at 20°C) in an Ultimate 3000 HPLC system coupled to a Thermo Exactive Plus 
Orbitrap MS for full scan or Q Exactive Orbitrap MS for MS/MS scan. Lipids were 
eluted at 0.15 ml/min with a binary gradient from 0% to 100% solvent 
B (isopropanol:methanol, 70:30 [v/v], 0.02% [m/v] formic acid, 0.01% 
[m/v] ammonium hydroxide): 0–10 min, 0% B; 17–22 min, 50% B; 30–35 min, 100% 
B; 40–44 min, 0% B, followed by additional 6 min 0% B post-run. MS data were 
acquired in both polarities using a full scan method. The positive and negative HESI-
II spray voltages were 4.5 and 3.5 kV, respectively; the heated capillary temperature 
was 250°C; the sheath gas pressure was 30 psi; the auxiliary gas setting was 20 psi; 
and the heated vaporizer temperature was 150°C. Both the sheath gas and the 
auxiliary gas were nitrogen. The parameters of the full mass scan were as follows: a 
resolution of 70,000, an auto gain control target under 3 × 106, a maximum isolation 
time of 200 ms, and an m/z range 200–3000. Where possible, to confirm the 
identification of significant features, samples were re-run in parallel reaction 
monitoring (PRM) mode, parameters as follows: a resolution of 17,500, an auto gain 
control target under 2 × 105, a maximum isolation time of 100 ms, an isolation window 
of m/z 0.4 and normalized collision energy were optimized for each feature 
individually. Data were acquired using Xcalibur 3.0.63 (Thermo Fisher Scientific) and 
Progenesis (Nonlinear Dynamics) was used for data alignment and peak detection. 
Data were normalized against the total ion abundance. 
Annotations were assigned to accurate masses with a maximum error of 5 ppm using 
Metlin, LipidMaps, Kegg and HMDB which were searched simultaneously using the 
CEU Mass Mediator engine (http://ceumass.eps.uspceu.es/mediator/). 
 
2.20 Scanning electron microscopy 
H. polygyrus larvae were dehydrated stepwise in ethanol (2 x 5 mins in 70, 90 and 
100% ethanol). Larvae were critical point dried from 100% Ethanol in a CPD300 
critical point drier (Leica Microsystems UK), mounted on a carbon sticky pad on a 
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stub, sputter-coated with 5 nm of platinum, and imaged in a Phenom ProX benchtop 
scanning electron microscope (Phenom-World) with a secondary electron detector. 
 
2.21 Statistical analysis 
All statistical analysis for biological data was performed using GraphPad Prism 
(v6.02). Data was analysed, where appropriate, with either an unpaired one-tailed t 
test, unpaired two-tailed t test, One-way ANOVA (Tukey’s or Dunnett’s multiple 
comparison analysis), Two-way ANOVA (Sidak’s or Dunnett’s multiple comparison 
analysis) or Mann-Whitney test. n represents the number of biological replicates. 
Please see figure legends for statistical tests used and exact value of n. Values are 
reported as the means ± SEM. * = p<0.05, ** = p<0.01, *** = p<0.001 and **** = 
p<0.0001. 
 
2.22 Data availability 
Description: RNA sequencing data comparing susceptible and resistant mice 
(Figure 3.1) (RNAseq of duodenal tissue from C57BL/6 mice both susceptible 
and resistant to Heligmosomoides polygyrus). The raw and analysed RNA 
sequencing data files have been deposited in the NCBI Gene Expression Omnibus 
database under ID code GSE102789. 
Description: LC-MS data comparing PLA2g1B-treated and control-treated H. 
polygyrus L3 larvae (Entwistle1_archive.zip). The metabolomics data have been 
deposited in the EMBL-EBI MetaboLights database under ID code MTBLS523 and 
PubMed PMID: 23109552. 
 
2.23 Flow cytometry antibodies 
Marker Clone Conjugate Manufacturer [µg/mL] 
CD3 145-2C11 APC BioLegend 1 
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CD4 RM4-5 BV605, eFluor450, eBioscience 1 
CD4 RM4-5 APC BioLegend 0.5 
CD8 53-6.7 PE-Cy7, APC BioLegend 0.5-1 
CD11b M1]70 APC BioLegend 0.2 
CD11c N418 APC BioLegend 1 
CD19 1D3 eFluor450 eBioscience 1 
CD19 6D5 APC BioLegend 0.5 
CD25 PC61 APC-Cy7 BioLegend 1 
CD25 PC61 APC eBioscience 1 
CD44 IM7 PerCPCy5.5 eBioscience 1 
CD45 30-F11 FITC eBioscience 1 
CD49b DX5 APC BioLegend 0.5 
CD62L MEL-14 APC eBioscience 1 
CD69 H1.2F3 PE BioLegend 1 
EpCam G8.8 APC eBioscience 1 
Foxp3 FJK-16S PE eBioscience 1 
Gr1 RB68C5 APC BioLegend 0.5 
IFNγ XMG1.2 PE BD Bioscience 1 
IL-4 11B11 PE eBioscience 1 
IL-5 TRFK5 APC BD Bioscience 1 
IL-13 eBio13A eFluor660 eBioscience 1 
IL-17A 17B7 PE-Cy7 eBioscience 1 
KLRG1 2F1 PerCP-eFluor710 eBioscience 1 
NK1.1 PK136 APC BioLegend 1 
Sca1 E13-161.7 PB eBioscience 2.5 
TCRγδ GL3 APC BioLegend 1 
TCRαβ H57-597 APC eBioscience 1 
TCRαβ H57-597 PerCPCy5.5 BioLegend 1 
Ter119 TER-119 APC BioLegend 1 
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Thy1.2 53-2.1 PE-Cy7 BioLegend 0.5 
 
2.24 qRT-PCR primers 
Gene Forward primer Reverse primer 
Arg1 GGAAAGCCAATGAAGAGCTG GCTTCCAACTGCCAGACTGT 
Chi3l3 CATGAGCAAGACTTGCGTGAC GGTCCAAACTTCCATCCTCCA 
Gob5 CATCGCCATAGACCACGACG TTCCAGCTCTCGGGAATCAAA 
Hprt GCCCTTGACTATAATGAGTACTTCAGG TTCAACTTGCGCTCATCTTAGG 
Pla2g1b CTCGGGCCGTGTGGCAGTTC TGCCGAGCCAGAGCACGAGT 
Retnla CCCTCCACTGTAACGAAGACTC CACACCCAGTAGCAGTCATCC 
Retnlb ATGGGTGTCACTGGATGTGCTT AGCACTGGCAGTGGCAAGTA 
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Chapter 3. Results 1: Phospholipase A2 group 1B is 
an endogenous anthelmintic, essential for immunity 
to Heligmosomoides polygyrus 
3.1 Introduction 
Intestinal helminth infections are highly prevalent in developing counties, infecting 
approximately a third of the world’s human population, causing significant host 
morbidity (Bethony et al., 2006, Hotez et al., 2008). With no current vaccine, a limited 
number of effective chemotherapeutic drugs available and the emergence drug-
resistance (Albonico et al., 2003, Taman and Azab, 2014), it is essential to further 
our understanding of mechanisms of antihelminth immunity to provide new avenues 
of therapeutic intervention. 
Our current understanding of protection against intestinal helminth infections places 
type 2 immunity at the forefront (Allen and Maizels, 2011, Reynolds et al., 2012, 
Maizels et al., 2012b). Following infection, infective helminth larvae penetrate 
through the mucosa, inducing local tissue damage, which is detected by specialised 
epithelial cells, including the recently identified tuft cell. Activated epithelial cells 
initiate type 2 immunity through the secretion of the alarmins interleukin (IL)-25, IL-
33 and TSLP (Gerbe et al., 2016, von Moltke et al., 2016, Howitt et al., 2016, Kim et 
al., 2013, Wills-Karp et al., 2012). DC activation, antigen uptake and presentation, 
alongside ILC2 activation and IL-4 secretion, promote the differentiation of naïve 
CD4+ T cells into T helper Th2 cells following helminth infection (Le Gros et al., 1990, 
Hsieh et al., 1992, Swain et al., 1990, Pelly et al., 2016). Th2 cell, and ILC2, 
production of type 2 cytokines IL-4, IL-13 and IL-5 initiate a suite of immunological 
and physiological changes to promote helminth killing and expulsion (Urban et al., 
1991a, Urban et al., 1991b, Pelly et al., 2016). These responses are IL-4Rα-
dependent and include B cell class switching and antibody production (McCoy et al., 
2008), alternate activation of macrophages (Anthony et al., 2006), goblet cell 
hyperplasia and Relmβ production (Herbert et al., 2009). Despite these advances in 
our knowledge of anti-helminth immunity, the precise mechanism(s) of helminth 
damage and killing in the tissue remain unclear. 
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In this chapter, we investigated novel mechanisms of antihelminth immunity, utilising 
the naturally occurring, strictly enteric, murine intestinal helminth H. polygyrus. Using 
H. polygyrus allows us to model both susceptibility and resistance in the same strain 
of mice, removing genetic differences, as C57BL/6 are susceptible to 1o infection 
(Reynolds et al., 2012), but after drug-clearance of the 1o infection, they are resistant 
to 2o challenge infection (Finkelman et al., 1997). To identify novel mechanisms of 
antihelminth immunity in this model, we utilised RNA sequencing of the small 
intestinal tissue, from mice both susceptible (Naïve and 1o) and resistant (1o + Rx 
(drug-cured mice) and 2o) to H. polygyrus infection, to identify transcriptional 
changes at the site of infection. 
 
3.2 Results 
3.2.1 RNA sequencing identified Pla2g1b to be upregulated in the small 
intestine of mice resistant to H. polygyrus infection 
3.2.1.1 RNA sequencing of small intestine reveals distinct gene clusters 
associated with susceptibility and resistance to H. polygyrus infection 
We infected C57BL/6 mice with H. polygyrus L3 larvae, which are naturally 
susceptible to a 1o infection (Reynolds et al., 2012). A cohort of mice was sacrificed 
at day 7 post 1o infection (H.p. 1o). The remaining mice were drug cured (Rx) of the 
1o infection on days 14 and 15, promoting resistance to subsequent secondary (2o) 
H. polygyrus challenge infection (Finkelman et al., 1997). Some mice were culled on 
days 42 and 63 after drug-cure (Rx (D42) and Rx (D63), respectively). Other mice 
were 2o challenge infected on day 35 or day 56 and sacrificed 7 days later (H.p. 2o 
(D42) and H.p. 2o (D63), respectively). At each time point, duodenal tissue was 
dissected and the RNA extracted for RNA sequencing (Figure 3.1.A). Resistance to 
2o H. polygyrus challenge infection correlated with increased immune cell infiltrate in 
the small intestine, compared to H.p. 1o (Figure 3.1.B). Following RNA sequencing 
of the duodenal tissue, we identified significantly more transcriptional activity in H.p. 
2o (D42) and H.p. 2o (D63) than H.p. 1o (relative to naïve, p<0.05) (Figure 3.1.C). 
Following application of a 2-foldchange filter, 665 genes were differentially expressed 
in H.p. 2o (D42) compared to 145 genes in H.p. 1o, with 116 common genes (relative 
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to naïve, 2-fold filter, p<0.05), again correlating with resistance to infection (Figure 
3.1.D). To further interrogate the transcriptional profile of susceptible and resistant 
mice, we utilised a ratio of ratios analysis comparing H.p. 1o and H.p. 2o (D42) 
(relative to naïve, 2-fold filter, p<0.05). With this analysis, we identified three distinct 
gene clusters (C1-C3) (Figure 3.1.E, Table 3.1-3.3). Cluster 1 (C1) identified 
common and quantitative differences between 1o and 2o infection, including several 
genes previously described in immunity to H. polygyrus, such as Arginase 1 (Arg1) 
and Relmβ (Retnlb) (Anthony et al., 2006, Herbert et al., 2009). Cluster 2 (C2) 
identified qualitative differences between susceptible and resistant mice, highlighting 
genes upregulated in 2o infection only. Cluster 3 (C3) identified qualitative differences 
downregulated in 2o infection only. Many of these genes in C2 and C3 have not 
previously been described in immunity to H. polygyrus. 
 
3.2.1.2 Transcriptomic analysis highlights potential novel regulators of 
immunity to H. polygyrus 
Utilising Ingenuity Pathway Analysis® (IPA®) software, we identified that the 
transcriptomic profile of H.p. 2o (D42) inferred a greater probability of ‘disease and 
biological functions’ pathways being activated, such as ‘Immune Cell Trafficking’ and 
‘Immunological Disease’, than in H.p. 1o (Figure 3.2.A). This was indicative of both 
the increased transcriptional activity (Figure 3.1.D) and increased speed and 
magnitude of the type 2 immune response seen in 2o H. polygyrus challenge infection 
(Pelly et al., 2017, Morimoto et al., 2004). Correlating with the different transcriptomic 
landscapes of the small intestine in H.p. 1o and H.p.2o infections, we identified 
different predicted upstream regulators, molecules predicted to be responsible for 
changes in the transcriptional landscape. For example, predicted upstream 
regulators during H.p.2o (D42) included the type 2 cytokines IL-4, IL-5 and IL-13, the 
type 2 cytokine-mediated genes Relmβ (Retnlb), tissue repair cytokine TGFβ, the 
bacterial product LPS and broad inflammatory cytokines CSF2 (GM-CSF), TNFα, IL-
6 and IL-1β (Figure 3.2.B). The type 2 immunity-associated upstream regulators 
observed in H.p.2o (D42) were not observed in H.p. 1o, but were instead replaced 
with type 1 immunity-associated molecules, including IFNγ and TNFα (Figure 3.2.B). 
These data agree with previous reports citing a slow induction of a type 2 response 
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upon 1o infection and rapid memory type 2 response in 2o H. polygyrus infection 
(Pelly et al., 2016, Pelly et al., 2017, Morimoto et al., 2004). Several upstream 
regulators were predicted to be inhibited, with Foxa2 predicted to be inhibited during 
both H.p. 1o and H.p. 2o infection (Figure 3.2.B). Overall, these analyses contribute 
to the prevailing model of resistance to H. polygyrus infection; resistance is mediated 
by quantitative differences in the type 2 immune response. 
 
3.2.1.3 Lipid metabolism pathways and Pla2g1b expression are upregulated 
in mice resistant to H. polygyrus 
To investigate differences between susceptible and resistant mice, we analysed the 
most differentially activated pathways between H.p. 1o and H.p. 2o infection. This 
pathway analysis reflected our previous observations (Figure 3.1, 3.2) of increased 
immune-activated pathways, but also identified increased activation of lipid 
metabolism pathways in H.p. 2o (Figure 3.3.A), previously described to be essential 
in alternate activation of macrophages and antihelminth immunity (Huang et al., 
2014). Interestingly, increased activation of lipid metabolism pathways were 
maintained in resistant mice, with or without 2o challenge infection, until day 63 (48 
days post drug treatment) (Figure 3.3.B). This observation correlates with long-term 
resistance to 2o challenge infection following drug-treatment (Urban et al., 1991b). 
Within Cluster 2 (C2), unique genes expressed in H.p. 2o infection (Figure 3.1.E, 
Table 3.2), we identified elevated expression of Pla2g1b, which encodes the enzyme 
involved in lipid metabolism, phospholipase A2 group 1B. Pla2g1b expression was 
not upregulated in H.p. 1o compared to naïve, but was significantly upregulated 
following drug treatment, with or without 2o challenge infection, correlating with 
increased activation of lipid metabolism pathways and resistance to H. polygyrus 
(Figure 3.3.C). PLA2 enzymatic activity was also significantly increased in the small 
intestine of resistant mice (Figure 3.3.D). Despite Pla2g1b being the most abundant 
PLA2 isoform expressed in H.p. 2o, other isoforms of PLA2 enzymes were 
differentially expressed in the small intestine upon infection with H. polygyrus, most 
likely contributing to the overall PLA2 activity in the small intestine (Figure 3.3.E). 
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3.2.2 Pla2g1b-deficiency does not alter the immune compartment 
Before testing the role of PLA2g1B in resistance to H. polygyrus infection, we first 
determined whether Pla2g1b–/– mice had any intrinsic immune cell defect prior to 
infection. T cell development to CD4+CD8+ stage was unaffected in Pla2g1b–/– mice 
(Figure 3.4.A). T cell maturation to single positive T cells and egress into peripheral 
organs was also unaffected by Pla2g1b-deficiency with similar frequencies of naïve- 
and activated CD4+CD8– or CD4–CD8+ T cells in Pla2g1b–/– mice (Figure 3.4.B-E). 
Foxp3+ Tregs, B cells and ILC2s in the mLNs were also unaffected in Pla2g1b–/– mice 
(Figure 3.4.F-H). 
 
3.2.3 Pla2g1b is essential for resistance against small intestinal helminths 
To formally test the role of PLA2g1B in immunity to H. polygyrus, we subjected 
Pla2g1b–/– mice to 2o H. polygyrus challenge infection. Unlike WT mice, Pla2g1b–/– 
mice failed to expel 2o challenge infection, instead establishing a patent infection 
(Figure 3.5.A-B). We then set to determine whether PLA2g1B was required for 
immunity against other small and large intestinal helminths. Pla2g1b–/– mice had a 
delayed expulsion of the mouse adapted, small intestine-dwelling parasite N. 
brasiliensis, with intestinal worms persisting 8 days-post infection (Figure 3.5.C). 
However, PLA2g1B was not required for expulsion of the large intestine-dwelling 
whipworm T. muris, with Pla2g1b–/– mice expelling all luminal worms 35 days-post 
infection (Figure 3.5.D). 
 
3.2.4 Type 2 immunity is intact in Pla2g1b-deficient mice following H. 
polygyrus infection 
3.2.4.1 Pla2g1b-deficiency does not alter CD4+ T cell response to 2o H. 
polygyrus infection 
Following the observation that PLA2g1B was essential for immunity to H. polygyrus, 
and that type 2 immune responses are required for expulsion, we set out to determine 
whether Pla2g1b-deficiency was required for type 2 memory response. Specifically, 
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Th2 cell differentiation and type 2 cytokine production essential in orchestrating 
protective immunity to H. polygyrus (Urban et al., 1995, Urban et al., 1991b, Urban 
et al., 1991a). To monitor differentiation and commitment to the Th2 lineage in 
Pla2g1b–/– mice, we inter crossed Pla2g1b–/– mice with Il4gfp reporter mice (Mohrs et 
al., 2001). We also analysed cellular IL-4 protein production by intracellular cytokine 
staining (ICS). No significant difference in frequency or number of Il4gfp-expressing T 
cells in the mLN or spleen 7 days-post 2o H. polygyrus infection was observed 
between WT or Pla2g1b–/– mice (Figure 3.6.A-B). Neither was there any significant 
difference in number or frequency of IL-4+CD44hiCD4+ T cells between genotypes 
(Figure 3.6.C). Interestingly, we identified a greater number of IL-4+CD44hiCD4+ T 
cells in the Pla2g1b–/– mice (Figure 3.6.D), despite previously identifying no 
significant difference in the frequency or number of Il4gfp-expressing T cells. This 
discrepancy between the ICS and Il4gfp reporter data maybe due to the potential 
differences in comparing protein production and transcriptional activity. The increase 
in number of IL-4+CD44hiCD4+ T cells in the Pla2g1b–/– mice is perhaps due to the 
perturbation of resistance in Pla2g1b–/– mice (Figure 3.5.A-B), therefore promoting 
an increased Th2 response in an attempt to clear the infection. Pla2g1b-deficency 
did not alter the frequency of Th1 or Th17 cells following infection, with a similar 
frequency of IFNγ+- and IL-17A+CD44hiCD4+ T cells in Pla2g1b–/– mice (Figure 
3.6.C). However, we saw an increased number of IFNγ+CD44hiCD4+ T cells following 
2o H. polygyrus infection in Pla2g1b–/– mice (Figure 3.6.D).This may be due to the 
PMA and ionomycin restimulation required to identify cytokine production by ICS as 
H. polygyrus antigen stimulation induced no significant difference in IFNγ production 
(Figure 3.6.E). PMA and ionomycin restimulation is fundamentally different to 
antigen-specific stimulation; PMA and ionomycin will activate all cells, including T 
cells in an antigen independent manner, whereas antigen-specific stimulation will 
only activate antigen-specific T cells. Therefore, the increased number of IFNγ-
producing T cells are not likely to be H. polygyrus dependent, and are an artefact of 
unspecific PMA and ionomycin stimulation. H. polygyrus antigen-specific Th2 recall 
responses were also intact in Pla2g1b–/– mice, with similar amounts of IL-13 and IL-
5 produced (Figure 3.6.E). Treg cells, which can be induced by H. polygyrus 
secretory products (Grainger et al., 2010) and are capable of suppressing Th2 cell-
mediated inflammation (Wilson et al., 2005), were also unaffected by Pla2g1b-
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deficiency (Figure 3.6.F-G). Taken together, these data indicate that there were no 
qualitative and only minor quantitative differences in T cell responses and T cell-
derived cytokines following 2o H. polygyrus infection. 
 
3.2.4.2 Pla2g1b is not required for appropriate antibody response to H. 
polygyrus 
B cell class switching and antibody production is essential for protective immunity to 
H. polygyrus infection (Liu et al., 2010, McCoy et al., 2008). Pla2g1b-deficiency did 
not affect total CD19+ B cell frequencies at steady state (Figure 3.4.G) and similarly 
IgE or H. polygyrus-specific IgG1 production was not altered upon 2o H. polygyrus 
infection in Pla2g1b–/– mice (Figure 3.7.A-C). These data illustrate that PLA2g1B is 
not required for peripheral B cell frequencies or function. 
 
3.2.4.3 Pla2g1b-deficiency does not alter alternative activation of 
macrophages 
Stimulation through the IL-4Rα, a subunit of the IL-4 receptor used by both IL-4 and 
IL-13, promotes alternative activation of macrophages (Goerdt and Orfanos, 1999). 
In 2o H. polygyrus infection, aaMϕs are important essential for protective immunity to 
H. polygyrus (Anthony et al., 2006). Arginase 1 (Arg1), Relmα (Retnla) and Ym1 
(Chi3l3), gene markers of alternative activation of macrophages (Rodriguez-Sosa et 
al., 2002, Dasgupta et al., 2011, Raes et al., 2002), were intact in the small intestine 
of Pla2g1b–/– mice upon 2o infection (Figure 3.8.A). Similarly, macrophage intrinsic 
Pla2g1b was confirmed to not be required for alternative activation of macrophages 
in vitro, with IL-4 and IL-13 stimulation of BMDMs inducing expression of Arginase 1 
(Arg1), Relmα (Retnla) and Chitiase-like 3 (Chi3l3) in both WT and Pla2g1b-deficient 
macrophages (Figure 3.8.B). These data collectively demonstrate that aaMϕs were 
intact in Pla2g1b–/– mice. 
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3.2.4.4 ILC2 populations are unaffected in Pla2g1b–/– mice following H. 
polygyrus infection 
Previous reports have illustrated that ILC2s expand in number following H. polygyrus 
infection and are important in supporting early Th2 differentiation (Pelly et al., 2016). 
We therefore set out to identify whether Pla2g1b deficiency affected the ILC2 
population. As was demonstrated in naïve Pla2g1b–/– mice (Figure 3.4.H), the ILC2 
population was also unaffected in the mLN following 2o H. polygyrus infection (Figure 
3.9). 
Taken together, type 2 immune responses appeared to be fully intact in Pla2g1b-
deificent mice. Despite this, mice lacking Pla2g1b failed to expel a 2o H. polygyrus 
challenge infection. We next set out to determine the function of PLA2g1B in H. 
polygyrus infection, beyond type 2 immune responses. 
 
3.2.5 Pla2g1b-deficient mice display normal lipid metabolism and generation 
of bioactive lipids 
PLA2 enzymes function by hydrolysing phospholipids into fatty acids and 
lysophospholipids, with many of these products often biologically active with 
important downstream roles (Six and Dennis, 2000). PLA2g1B has primarily been 
described as a dietary phospholipase, secreted from the pancreas, responsible for 
digesting dietary fats to allow for their absorption (Richmond and Hui, 2000). 
However, at steady state, Pla2g1b–/– mice were shown to have no defect in dietary 
fat digestion and absorption, with defects only seen upon administration of a high fat 
diet (Richmond et al., 2001, Labonte et al., 2010, Labonte et al., 2006). To determine 
whether PLA2g1B-mediated dietary phospholipid digestion was altered in Pla2g1b–/– 
mice upon 2o H. polygyrus infection, we measured serum metabolites from WT and 
Pla2g1b–/– mice. No significant difference in serum lipid metabolites, triglycerides, 
glycerol, free fatty acids or LPC in naïve or infected mice were observed between 
WT and Pla2g1b–/– mice (Figure 3.10.A-B), suggesting that there was no defect in 
lipid digestion and absorption. There was a significant decrease in LPC concentration 
in the small intestinal homogenate of naïve Pla2g1b–/– mice, which was unchanged 
upon 2o infection (Figure 3.10.B). However, in WT mice, the increased LPC 
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concentration was reduced to the same concentration as the Pla2g1b–/– mice upon 
2o H. polygyrus infection (Figure 3.10.B). The difference in small intestinal LPC in 
naïve mice did not translate to differences in serum LPC concentration.  
sPLA2 enzymes, including PLA2g1B, are also capable of activating intracellular 
cPLA2 via binding the sPLA2R (Fonteh et al., 1998, Fonteh et al., 2000), hydrolysing 
phospholipids in the cell membrane to release arachidonic acid, initiating the 
eicosanoid production pathway (Funk, 2001). Eicosanoids are both induced and 
important in immunity to intestinal helminth infection (Douch et al., 1996, Machado 
et al., 2005). However, no defect in the production of eicosanoids, specifically in 
cysteinyl leukotriene or prostaglandin synthesis, was observed in small intestinal 
homogenate from 2o H. polygyrus infected Pla2g1b–/– mice (Figure 3.10.C).  
Overall, these data illustrate that Pla2g1b-deficiency does not affect dietary lipid 
digestion and absorption or eicosanoid production in H. polygyrus infection. 
 
3.2.6 No gross transcriptomic differences were identified in Pla2g1b-deficient 
mice at baseline or upon 2o H. polygyrus infection 
In an attempt to identify the mechanism by which PLA2g1B mediates resistance to 
H. polygyrus infection, we harvested duodenal tissue from naïve and 2o H. polygyrus 
infected (7 days-post infection) WT and Pla2g1b–/– mice. Following RNA extraction 
and RNA sequencing, we could not identify any differences in the transcriptional 
landscape between genotypes in naïve mice, with the exception of Pla2g1b (Figure 
3.11.A). In 2o infected mice, we saw decreased expression of both Pla2g1b and 
Lars2 in Pla2g1b–/– mice, however the downregulation of Lars2 did not reach 
statistical significance (FDR = 0.058, relative to WT H.p. 2o) (Figure 3.11.A). 
Pathway analysis confirmed the similarity of the two genotypes upon 2o H. polygyrus 
infection, with predicted activation of immune and inflammatory pathways evident 
(Figure 3.11.B). We also saw no defect in the predicted activation of lipid metabolism 
pathways in Pla2g1b–/– mice upon 2o infection (Figure 3.11.C), supporting the 
conclusions drawn from the data presented above in 3.2.5 (Figure 3.10). RNA 
sequencing data identified similar levels of goblet cell and mucus-associated genes, 
which correlate with expulsion (Hashimoto et al., 2009, Hasnain et al., 2010, Inagaki-
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Ohara et al., 2011). Similarly, AB-PAS staining intestinal tissue appeared 
comparable between WT and Pla2g1b–/– mice (Figure 3.11.D-E). The increased 
expression of the goblet cell-derived antihelminth molecule Relmβ (Retnlb), which 
inhibits adult H. polygyrus feeding in vivo (Herbert et al., 2009), was also unaffected 
in Pla2g1b-deficient mice (Figure 3.11.D). All other PLA2 enzymes expressed in the 
small intestine were not altered by the absence of Pla2g1b (Figure 3.11.F). These 
data provide one explanation why lipid metabolism pathways (Figure 3.11.C), lipid 
metabolite uptake and eicosanoid production were unaffected in Pla2g1b–/– mice 
(Figure 3.10). Overall, these data illustrate that Pla2g1b-deficiency does not affect 
the transcriptional response to 2o H. polygyrus infection, suggesting that PLA2g1B is 
not acting like a ‘cytokine’ or second messenger in antihelminth immune responses. 
 
3.2.7 PLA2g1B has direct anthelmintic properties which act in synergy with 
the immune system to trap and kill H. polygyrus 
3.2.7.1 PLA2g1B treatment compromises H. polygyrus establishment in vivo 
Previous reports have demonstrated essential roles of sPLA2 enzymes in defence 
against fungal infections (Balestrieri et al., 2009) and in providing bactericidal activity 
through bacterial membrane degradation (Weinrauch et al., 1998, Degousee et al., 
2002, Koduri et al., 2002). We therefore asked whether PLA2g1B had a direct effect 
on H. polygyrus, promoting resistance to infection. 
To test this, we treated exsheathed L3 H. polygyrus larvae (to recapitulate the status 
of the larvae after passing through the stomach (Sommerville, 1957, Sommerville 
and Bailey, 1973)) with recombinant mouse PLA2g1B for 24 hours in vitro, before 
infecting naïve WT mice. Following infection with the PLA2g1B-treated larvae, we 
saw no defect in the ability of the larvae to migrate to the small intestine and embed 
into the intestinal wall (Figure 3.12.A), suggesting PLA2g1b treatment does not 
perturb infectivity of L3 H. polygyrus larvae. However, we identified a dose-
dependent reduction of luminal L5 adult H. polygyrus worms 14 days-post infection, 
with a significant reduction seen with both 1 and 10 ng/µL PLA2g1B-treated larvae. 
(Figure 3.12.B). PLA2g1B-mediated protection was abrogated when PLA2g1B was 
heat inactivated or treated with the PLA2 inhibitor manoalide (Figure 3.12.B-C), 
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illustrating that the catalytic activity of PLA2g1B was essential in mediating its 
anthelmintic effect. The significant reduction in adult worms did not translate into 
reduced H. polygyrus egg production, with a non-significant decline seen after 10 
ng/µL PLA2g1B treatment (Figure 3.12.D). These data collectively suggest that in 
vitro PLA2g1B treatment of infective L3 H. polygyrus larvae has direct anthelmintic 
effects; perturbing larval development and/or rendering the larvae more susceptible 
to killing in the wall of the small intestine  
 
3.2.7.2 PLA2g1B treatment does not compromise the fitness of H. polygyrus 
in vitro or ex vivo  
To further investigate PLA2g1B effects on H. polygyrus, we treated L3 larvae, 
sheathed or exsheathed, and L5 adult worms in vitro with PLA2g1B for 24 hours, 
before measuring ATP concentration in the worms, an assay previously used to 
determine helminth fitness (Ishiwata and Watanabe, 2007, Herbert et al., 2009) 
(Figure 3.13.A). Following PLA2g1B treatment, no significant difference was seen in 
ATP concentration of sheathed or exsheathed L3 larvae (Figure 3.13.B). Similarly, 
no significant difference in L5 adult worm fitness was identified following PLA2g1B 
treatment (Figure 3.13.C). We then asked whether in vitro PLA2g1B treatment 
compromised the fitness of H. polygyrus in vivo. To test this, we treated exsheathed 
L3 larvae in vitro and infected WT mice. We then isolated H. polygyrus at either the 
L4 or L5 stage of development and analysed their fitness ex vivo, determined by ATP 
concentration (Figure 3.13.D). Isolation of L4 or L5 adult H. polygyrus, 7 or 14 days-
post infection respectively, revealed a decrease in ATP concentration following 
PLA2g1B treatment, although not significant in either developmental stage (Figure 
3.13.E-F). Overall, the in vitro data suggest that PLA2g1B does not compromise H. 
polygyrus fitness alone, but requires another factor, such as environment-induced 
moulting or other antihelminth immune pressures, found in vivo, to impact fitness and 
development. 
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3.2.7.3 PLA2g1B and the immune compartment act in synergy to provide 
protect against intestinal helminth infection 
Following the observation that PLA2g1B did not have a significant impact on worm 
ATP levels (section 3.2.7.2, above) and that the protective effect of PLA2g1B-treated 
L3 larvae (Figure 3.12) did not recapitulate the full clearance of worms observed 
during 2o H. polygyrus infection in WT mice (Figure 3.5.A), we hypothesised that for 
complete elimination of H. polygyrus, a combined PLA2g1B-mediated effect on 
larvae alongside immune-mediated physiological responses would be required. To 
test this and test whether direct PLA2g1B treatment could rescue immunity in 
Pla2g1b–/– mice, we 1o infected and drug-cured WT and Pla2g1b–/– mice to elicit 
robust type 2 immune responses (as reported in section 3.2.4) and performed 2o 
challenge infection with vehicle- or PLA2g1B-treated L3 larvae (Figure 3.14.A). As 
expected, WT mice killed the majority of both vehicle- and PLA2g1B treated H. 
polygyrus larvae and Pla2g1b–/– mice failed to clear vehicle-treated larvae (Figure 
3.5.A). However, full H. polygyrus killing and clearance was fully rescued in Pla2g1b–
/– mice when the challenge bolus of L3 larvae were treated with PLA2g1B (Figure 
3.14.B).  
To further test the requirement for the cooperation of a functional immune 
compartment and direct PLA2g1B effects, we infected Rag–/–γc–/– mice with 
PLA2g1B-treated larvae (Figure 3.14.A). Following 1o infection, WT mice that were 
infected with PLA2g1B-treated larvae had a reduced worm burden 14 days-post 
infection, as expected (Figure 3.12, Figure 3.14.C). However, Rag–/–γc–/– mice 1o 
infected with PLA2g1B-treated larvae were unable to kill and expel H .polygyrus, with 
no significant difference observed from vehicle-treated H. polygyrus larvae (Figure 
3.14.C). PLA2g1b-treatment of L3 larvae was also unable to rescue H. polygyrus 
killing and clearance in Rag–/–γc–/– mice following 2o infection (Figure 3.14.D).  
Overall, these data presented demonstrate that direct PLA2g1B-mediated 
anthelmintic effect acts in synergy with a functional immune compartment, most likely 
the type 2 immune response, to induce full killing and resistance to H. polygyrus. 
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3.2.8 PLA2g1B-treatment induces changes in L3 larval lipids 
3.2.8.1 PLA2g1B induces no overt structural changes to L3 H. polygyrus 
larvae 
We hypothesised that PLA2g1B may mediate its direct anthelmintic actions on H. 
polygyrus by inducing physical damage and/or structural changes to L3 larvae, 
perturbing normal development in vivo. To test this, we performed scanning electron 
microscopy on vehicle and PLA2g1B-treated exsheathed L3 H. polygyrus larvae. No 
gross physical changes were observed following PLA2g1B treatment of L3 larvae, 
with the anterior, midriff and posterior structure appearing fully intact (Figure 3.15).  
 
3.2.8.2 PLA2g1B-treatment induces a lower abundance of phospholipids in L3 
larvae. 
PLA2 enzymes hydrolyse phospholipids (Kudo and Murakami, 2002). We therefore 
asked whether PLA2g1B altered the phospholipid composition of L3 H. polygyrus 
larvae. To test this, we extracted lipids from vehicle- or PLA2g1B-treated L3 larvae 
and analysed the lipid composition using LC-MS/MS. Of the 1165 apolar features 
detected, 112 were significantly different between the chromatograms of vehicle- and 
PLA2g1B-treated larvae, identifying significantly lower phospholipid abundance in 
PLA2g1B-treated larvae (Figure 3.16.A). Of the 112 significant apolar features, 6 
were identified as phosphatidylethanolamines (PEs) by comparing their precursor 
ion and MS/MS fragments with the LipidBlast library (Figure 3.16.B-E), with each 
being lower in PLA2g1B-treated larvae (Figure 3.17.A).  
PEs consist of a phosphoethanolamine head group attached to a glycerol backbone, 
itself attached to two fatty acid moieties via phosphoether and ester bonds, 
respectively (van Meer et al., 2008). As a result, PE MS spectra display traits of fatty 
acid-containing molecules; clusters that have inter-cluster mass shifts of 28 Da 
(CH2CH2) and intra-cluster mass shifts of 2 Da, indicative of difference in double 
bond number (i.e. fatty acid saturation) (Figure 3.16.B). From this, we identified and 
annotated the ions of PE species using positive-ion MS/MS and negative-ion 
fragmentation, quantified in Figure 3.17.A. For example, we show the identification 
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of PE 36:3 (18:1, 18:2), which is reduced in abundance in PLA2g1B-treated larvae 
(Figure 3.16.C, Figure 3.17.A). Positive ion MS/MS of PE 36:3 (18:1, 18:2) was 
used to confirm assignment of the peak as PE, where neutral loss of 141 Da indicates 
a phosphoethanolamine head group, fragmentation indicated on structural diagram 
(Figure 3.16.D). Negative ion fragmentation of the ion PE 36:3 (18:1, 18:2) identified 
both fatty moieties as 18:1 and 18:2, fragmentation indicated on structural diagram 
(Figure 3.16.E). However, both the arrangement of the fatty acid moieties at the 
glycerol backbone (i.e. sn-1 or sn-2) and the position of the double bonds could not 
be inferred from this analysis. 
A further 3 features could be putatively annotated as PEs by using other identified 
PEs as a reference; comparing peak retention time, inter-cluster mass shifts of 28 
Da (CH2CH2) and intra-cluster mass shifts of 2 Da. However, MS/MS could not be 
performed due to low abundance, preventing confirmation of PE identity. These three 
putatively annotated PEs were, again, lower in abundance in PLA2g1B-treated larvae 
(Figure 3.17.B). The remaining significantly different apolar features were unable to 
be identified, possessing lipidic features that could not be annotated, even putatively, 
by comparison to common libraries (Figure 3.17.C). These unidentifiable apolar 
features were seen to both increase and decrease in abundance following PLA2g1B 
treatment (Figure 3.17.C).  
Overall these data suggest that PLA2g1B is cleaving phospholipids present in H. 
polygyrus L3 larvae. Whether this compromises larval development or promotes host 
resistance to invading larvae is still to be determined.  
 
3.2.9 Intestinal Pla2g1b upregulation requires drug-clearance of primary H. 
polygyrus infection 
Our initial RNA sequencing data demonstrated that Pla2g1b expression was 
upregulated in the small intestine of drug-treated resistant mice, with or without 2o 
challenge infection, up to 49 days-post drug treatment (Figure 3.3.C). We therefore 
investigated the kinetics of Pla2g1b upregulation in more detail within our 2o 
challenge infection model. As Pla2g1b is abundantly expressed in the pancreas 
(Eerola et al., 2006), we initially tested whether pancreatic Pla2g1b expression was 
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altered in our infection model. No change in Pla2g1b expression in the pancreas 
throughout our model was observed (Figure 3.18.A). However, we confirmed 
upregulation of Pla2g1b in the duodenal tissue of resistant mice, with significant 
upregulation seen at day 28, 14 days-post drug-treatment (Figure 3.18.B). 
Upregulation of Pla2g1b was not seen during the course of a 1o infection (Figure 
3.18.C), or with drug-treatment alone in the absence of a 1o infection (Figure 3.18.D). 
Upregulation of Pla2g1b required drug-clearance of a 1o infection (Figure 3.18.D). 
These data indicate that Pla2g1b expression is elevated in the small intestine 
concomitantly with the acquisition of resistance to H. polygyrus. We next set out to 
determine both the source of Pla2g1b expression in the small intestine. 
 
3.2.10 Pla2g1b expression is restricted to epithelial cells in the small intestine 
of resistant mice. 
The family of sPLA2 enzymes share a high degree of homology, making it challenging 
to raise specific antibodies against PLA2g1B. This problem, coupled with the fact 
that PLA2g1B is a secreted protein, make it technically very challenging to perform 
immunohistochemistry to identify the source of PLA2g1B in the small intestine. We 
therefore utilised in situ hybridisation technology to identify the cellular source of 
Pla2g1b expression in small intestinal tissue of resistant mice. In situ hybridisation 
identified that Pla2g1b expression was restricted to the epithelial layer of resistant 
mice (Figure 3.19.A-B), and not present in the granuloma surrounding the encysted 
larvae, 7 days-post 2o infection (Figure 3.19.C). To confirm Pla2g1b expression was 
expressed in the intestinal epithelial cells of resistant mice we utilised FACS to isolate 
epithelial cells from infected mice. However, due to technical difficulties in obtaining 
viable cells when sorting from the intestine during 2o challenge infection, we sorted 
cells from the intestine of resistant mice at day 28, 14 days after drug-cure, when 
Pla2g1b expression was significantly increased (Figure 3.18.B). CD45–EpCam+ 
epithelial cells sorted from resistant mice had significantly increased Pla2g1b 
expression, compared to naïve mice, whereas there was no change in 
CD45+EpCam– sorted cells (Figure 3.19.D). The FACS data corroborates the in situ 
hybridisation data, confirming that Pla2g1b expression was increased in resistant 
mice and expressed in the epithelial cells of the small intestine. 




3.2.11 Regulation of Pla2g1b 
3.2.11.1 Pla2g1b expression is regulated by the microbiota and Rag- and 
common gamma chain-dependent immune cells in vivo 
IL-4 is necessary and sufficient for resistance to H. polygyrus (Urban et al., 1991b). 
We therefore asked whether IL-4 was required, directly or indirectly, for induction of 
Pla2g1b expression in resistant mice. To test this, we treated mice with anti-IL-4 
antibody (αIL-4) or an isotype control before, during and after drug-clearance of 1o 
infection and then analysed Pla2g1b expression in the duodenal tissue at day 28, 14 
days after drug-cure. Interestingly, αIL-4 treatment had no effect on intestinal 
Pla2g1b expression in resistant mice (Figure 3.20.A), suggesting that Pla2g1b is not 
regulated in an IL-4 or type-2 immune dependent manner. To test whether Rag-
dependent adaptive immune cells or common gamma chain-dependent innate 
immune cells were required for Pla2g1b expression in resistant mice, we infected 
and drug-cured Rag–/–γc–/– mice and measured Pla2g1b expression in the small 
intestine by qRT-PCR. Pla2g1b upregulation was abrogated in Rag–/–γc–/– resistant 
mice (Figure 3.20.B), suggesting that adaptive or innate immune cells or γc-
dependent signalling is required to induce Pla2g1b expression in intestinal epithelial 
cells of resistant mice.  
To identify additional type-2 independent mechanisms of Pla2g1b upregulation, we 
asked whether the host microbiota contributed to Pla2g1b regulation. Intestinal 
helminth infection has previously been described to induce changes in the 
composition of the intestinal microbiota (Rausch et al., 2013, Reynolds et al., 2014b, 
Zaiss et al., 2015, Giacomin et al., 2016, Kannan et al., 2017), however further 
changes following drug-cure induced resistance have not been studied. To test 
whether the intestinal microbiota was required for the upregulation of Pla2g1b, we 
treated mice with a cocktail of antibiotics prior to (day -7) and all throughout 1o 
infection and drug-cure until harvest at day 28. Antibiotic-treated mice completely 
failed to upregulate Pla2g1b (Figure 3.20.C), indicating that intestinal microbiota are 
essential for elevated Pla2g1b expression in resistant mice. Following on from this 
observation, we next tested if antibiotic treatment would perturb resistance, 
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preventing clearance of 2o H. polygyrus challenge infection and, if so, could PLA2g1B 
treatment of the infective L3 larvae restore immunity. Indeed, we identified that 
antibiotic treatment, prior to (day -7) and all throughout 1o infection, drug-cure and 2o 
infection, prevented expulsion of 2o challenge infection (Figure 3.20.D). 
Furthermore, the number of luminal worms in the antibiotic-treated mice was 
comparable to that of a 1o infection (infective dose 64 adult worms, data not shown). 
However, PLA2g1B treatment of the L3 infective larvae did not rescue killing and 
clearance of 2o H. polygyrus infection in antibiotic-treated mice (Figure 3.20.D). 
Taken together, these data indicate that upregulation of Pla2g1b expression in the 
epithelial cells of resistant mice requires both the microbiota and Rag- and/or 
common gamma chain-dependent immune cells or signalling. In addition, antibiotic 
treatment abrogates protective immunity to H. polygyrus which cannot be rescued 
by PLA2g1B treatment of the L3 larvae prior to infection. 
 
3.2.11.2  Pla2g1b expression does not correlate with goblet and tuft cell marker 
expression 
With Pla2g1b expression restricted to and upregulated in intestinal epithelial cells of 
resistant mice (Figure 3.19), we utilised the intestinal organoids culture system to 
determine how Pla2g1b expression was regulated. Intestinal organoid culture is an 
in vitro culture system of intestinal epithelial stem cells which differentiate into all 
epithelial cell types and self-organise in crypt-villus structures in the absence of a 
non-epithelial cellular niche (Sato et al., 2009). Upon stimulation with IL-4 and IL-13, 
we identified a significant downregulation of Pla2g1b expression and upregulation of 
the goblet cell markers Relmβ (Retnlb) and Gob5 (Figure 3.21.A). These data 
suggest that Pla2g1b is negatively regulated by IL-4Rα signalling in the in vitro 
intestinal organoid system, contrasting to the in vivo data where blocking IL-4 had no 
effect on Pla2g1b expression. However, the organoid data could also be interpreted 
that Pla2g1b expression is not located in the epithelial cell subtypes induced by IL-
4Rα signalling, both tuft and goblet cells (Gerbe et al., 2016). The small intestine 
RNA sequencing data set (see section 3.2.1) demonstrates that tuft cell gene 
markers, Dclk1, Trpm5, Pou2f3 and Siglec5 (Gerbe et al., 2016, von Moltke et al., 
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2016, Howitt et al., 2016), do not correlate with Pla2g1b expression (Figure 3.3.C, 
Figure 3.21.B).  
In an attempt to identify factors which induce Pla2g1b expression in the intestinal 
organoid culture system, we treated organoids with small intestinal homogenate from 
resistant mice following 2o infection. Intestinal homogenate from resistant mice was 
able to drive Pla2g1b expression in intestinal organoids, although not reaching 
statistical significance (p=0.088) (Figure 3.21.A). This data suggests that the 
factor(s) to drive Pla2g1b expression are present in resistant mouse intestine or 
lumen, however further experiments are required to conclusively demonstrate this; 
perhaps by titrating or fractionating the duodenal homogenate from resistant mice. 
Further investigation of intestinal epithelial cell subtypes maybe required to 
determine the precise source of Pla2g1b expression. Moreover, identification of the 
critical factor in the small intestinal homogenate would provide greater understanding 
of how Pla2g1b is expressed in intestinal epithelial cells. 
 
3.3 Discussion 
Intestinal helminths have evolved with their hosts over thousands of years (Cox, 
2002) and, as a result, are highly effective in establishing chronic infections. Although 
host mortality is rare, host morbidity is common. Human soil transmitted helminths 
are highly prevalent in developing countries (Bethony et al., 2006, Hotez et al., 2008). 
With the failing of vaccine efforts, limited numbers of chemotherapeutic drugs and 
the emergence of drug-resistant helminths (Albonico et al., 2003, Taman and Azab, 
2014) there is a need for a better understanding of antihelminth immunity and 
generation of new therapeutics. 
To address this issue, we set out to provide a global analysis of the small intestinal 
transcriptome during H. polygyrus 1o and 2o infection. H. polygyrus, as a model of 
human helminthiasis, allowed us to compare susceptibility and acquired resistance, 
in the same genetic background of mice, to identify critical regulators of immunity. 
From this analysis, we identified that Pla2g1b expression was upregulated in 
resistant mice, with or without 2o infection. Furthermore, PLA2g1B had direct 
anthelmintic effects and was essential for resistance to H. polygyrus. The remainder 
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of this chapter discusses our findings in in the context of antihelminth immunity, 
highlighting implications, shortfalls and further questions. 
 
3.3.1 RNA sequencing as a tool to identify mechanisms of antihelminth 
immunity 
RNA sequencing of duodenal tissue from C57BL/6 mice identified many genes 
previously implicated in resistance to H. polygyrus infection, including Arginase 1 
(Arg1) (Anthony et al., 2006) and Relmβ (Retnlb) (Herbert et al., 2009). Interestingly, 
these genes were among those we identified that were quantitatively different 
between 1o (susceptible) and 2o (resistant) mice, detailed in Cluster 1 (Figure 3.1.E, 
Table 3.1). This pattern of expression was mimicked in the pathways analysis, where 
‘diseases and biological function pathways’ were predicted to be activated in both 1o 
and 2o infection but to a greater magnitude in 2o infection (Figure 3.2.A). These 
observations support the prevailing notion of resistance to H. polygyrus; trapping and 
killing of invading larvae is promoted by a memory type 2 immune response, inducing 
a faster and stronger immune response upon infection (Morimoto et al., 2004, Pelly 
et al., 2016, Pelly et al., 2017).  
Accompanying these quantitative differences, we also identified qualitative 
differences between susceptible and resistant mice, with gene signatures only 
present in resistant mice. The number of unique, differentially expressed genes was 
4.5 times greater in H.p. 2o than in H.p. 1o (relative to naïve, 2-fold filter, p<0.05) 
(Figure 3.1.D). These H.p. 2o-unique genes were separated into two distinct clusters, 
based upon upregulation (Cluster 2, Table 3.2) or down-regulation (Cluster 3, Table 
3.3, Figure 3.1.E). The majority of these genes had not previously been described 
in resistance to intestinal helminth infection. We also identified a significant increase 
in predicted activation of lipid metabolism pathways during 2o infection (Figure 3.3.A-
B), leading us to investigate Pla2g1b during resistance to intestinal helminth 
infection. 
The design of our RNA sequencing experiment incorporated additional groups, 
enabling the capacity for more detailed analysis of susceptible and resistant mice. 
These additional groups included resistant mice that were not 2o challenge infected 
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after drug clearance of a 1o infection (Rx (D42)). Additionally, we also incorporated 
groups which were left a longer period of time after drug clearance of 1o infection 
before receiving 2o infection (H.p. 2o (D63)) or not (Rx (D63)) (Figure 3.1.A). The 
incorporation of H.p. 2o (D63) allowed us to confirm that genes identified in H.p.2o 
(D42) were also present during 2o challenge infection at a later time, suggesting that 
that they are essential for long term resistance to H. polygyrus infection. The addition 
of groups Rx (D42) and Rx (D63) gave us the ability to identify any changes in the 
transcriptome of the small intestine after resolution of a 1o infection, that were 
maintained over a long time period (Figure 3.2.C). These time points also reduced 
the likelihood of identifying acute tissue repair genes and instead suggested a ‘new 
baseline’, promoting resistance to subsequent 2o challenge infection. As a result, we 
identified that Pla2g1b expression in the small intestine was upregulated following 
drug-mediated clearance of 1o infection and maintained for up to 49 days, with or 
without 2o infection (Figure 3.3.C) and correlated with resistance. 
Although not performed here, it would be of great interest to study the intestinal 
transcriptome of groups Rx (D42) and Rx (D63), relative to naïve mice. This would 
enable description of the new transcriptional baseline of resistant mice and 
potentially identify other genes, previously undescribed in antihelminth immunity, 
essential for protection against 2o H. polygyrus challenge infection. This is an area 
that is particularly understudied in antihelminth immunity, with the majority of 
research focussed on the immune response during infection. This research would be 
extremely informative and potentially aid effective antihelminth vaccine efforts. 
 
3.3.2 Anthelmintic properties of PLA2g1B 
3.3.2.1  A new role for an ‘old’ sPLA2 
PLA2g1B was one of the first sPLA2 enzymes discovered and studied in mammals, 
originally purified from the pancreas (Murakami et al., 2014). PLA2g1B was originally 
described as a digestive sPLA2, secreted from the pancreas into the intestinal lumen 
following a high fat meal, responsible for cleaving dietary and biliary phospholipids 
(Murakami et al., 2014, Murakami et al., 2015, Williams et al., 1989, Richmond et al., 
2001). Perturbation of PLA2g1B activity protects from diet-induced obesity, 
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hyperglycaemia, insulin resistance, hepatic steatosis and atherosclerosis due to 
reduced intestinal absorption of lipids (Labonte et al., 2006, Hui et al., 2009, Labonte 
et al., 2010, Hollie and Hui, 2011, Hollie et al., 2014, Hui, 2016).  
Here we demonstrate an essential role for PLA2g1b in resistance to intestinal 
helminth infection (Figure 3.5), which appears to be independent of dietary lipid 
absorption and generation of bioactive lipid mediators (Figure 3.10). Interestingly, 
we did identify a significant decrease in LPC concentration in the small intestinal 
homogenate of WT mice upon 2o H. polygyrus infection, compared to naïve tissue. 
This decrease was absent in Pla2g1b–/– mice, which maintained a significantly lower 
LPC concentration in both naïve and 2o infected tissue (Figure 3.10.B). These data 
suggest that LPC may be metabolised locally following H. polygyrus infection in WT 
mice, a process that is absent in Pla2g1b–/– mice. Whether intestinal PLA2g1B-
derived LPC is essential for mediating resistance to 2o challenge infection, however, 
is unclear. However, it is unlikely any PLA2g1B-induced dietary lipids contribute to 
intestinal immunity, including LPC, as critical antihelminth immune components are 
intact in naïve and infected mice (See section 3.2.2 and 3.2.4), although we cannot 
rule out any other direct or indirect effects of dietary lipids in antihelminth immunity. 
Instead we show that PLA2g1B had direct anthelmintic effects on H. polygyrus L3 
larvae, reducing global phospholipid abundance and specifically reducing PE 
species (Figure 3.16, Figure 3.17). Although both human and murine PLA2g1B have 
direct antibacterial properties in vitro, albeit significantly less potent than other sPLA2 
family enzymes (Koduri et al., 2002), this is the first time PLA2g1B has been shown 
to be protective against an infective pathogen in vivo. Despite other PLA2 enzymes 
implicated in protective immunity to intestinal helminths, particularly cPLA2 enzymes 
in the generation of LTs and other downstream mediators (Brown et al., 2008, 
Patnode et al., 2014, Rogerio and Anibal, 2012, Espinoza et al., 2002), their role has 
never been shown to be essential. Furthermore, no other sPLA2 enzyme has been 
shown to have direct action on intestinal helminths.  
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3.3.2.2 Role of phospholipids in intestinal helminths 
Using LC-MS/MS, we were able to identify that PLA2g1B treatment reduced the 
global phospholipid abundance of L3 H. polygyrus larvae (Figure 3.16). Specifically, 
we were able to and putatively identify and confirm the identity of PEs, which were 
reduced following PLA2g1B treatment (Figure 3.16 and Figure 3.17). Unfortunately, 
we were not able to identify other lipidic compounds due to low abundance, however 
we confirmed that these compound are likely to be lipids due to their apolar features. 
Further optimisation of the lipid extraction method and increasing our starting 
material may be required to gain a greater resolution in our data analysis. 
Phospholipids are an essential component in all cell membranes, composed of two 
hydrophobic fatty acids tails and a hydrophilic phosphate head group connected by 
a glycerol molecule (van Meer et al., 2008). The phosphate groups contain different 
molecules, such as choline or serine, thus providing the phospholipids with different 
properties. Helminth parasites possess phospholipids in their membranes, 
containing known and unknown phospholipid species, differing between helminths 
(Retra et al., 2015, Van Hellemond et al., 2006, Satouchi et al., 1993, Beames and 
Fisher, 1964, Beames, 1964). 
PE is a highly abundant phospholipid, present in membranes of mammals, bacteria, 
yeast and intestinal nematodes (Beames, 1964), and is required for an array of 
cellular functions, acting both as a signalling molecule and a precursor for signalling 
molecules (Vance and Tasseva, 2013). Roles for PE have been described in 
membrane curvature, cellular stress, mitochondrial morphology as well as brain and 
liver function (Vance and Tasseva, 2013).  
The role of PE, and other phospholipid species, are not well described in intestinal 
helminths. However, in the free-living nematode, C. elegans, low levels of PE in the 
brain lead to endoplasmic reticulum stress and neurodegeneration, indicating that 
PE is essential for brain function (Wang et al., 2014). 
Further work is required to understand the role of phospholipids in intestinal 
helminths, with work so far providing a description of phospholipid content and 
diversity in intestinal helminths. Until genetically modifiable intestinal helminth tools 
are available, this line of research will be particularly challenging. The use of 
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synthetic, and possibly more potent, phospholipases may be of use to test the 
requirement of phospholipids in H. polygyrus viability. Additionally, the use of C. 
elegans as a model organism may also provide clues to the functions of 
phospholipids in infective helminths. 
 
3.3.2.3 Endogenous anthelmintic molecules 
Despite a good understanding of the protective type 2 immune response to intestinal 
helminth infection (Allen and Maizels, 2011, Reynolds et al., 2012, Maizels et al., 
2012b), we do not yet know the precise mechanism how invading helminths are 
killed. Host-derived endogenous antihelminth molecules have been described, 
including Relmβ and Arginase. These add to the arsenal of other endogenous 
antimicrobial proteins, such as cathelicidins, defensins, histatins, lysozyme and 
lactoferrin (Zelechowska et al., 2016).  
Relmβ is the only molecule previously described to have direct effects on intestinal 
helminths, essential for immunity to lumen-dwelling small intestinal helminths. 
Herbert and colleagues elegantly demonstrate that Relmβ impairs adult H. polygyrus 
feeding on host tissue in vivo (Herbert et al., 2009). Arginase production from aaMϕ 
is essential for the trapping of H. polygyrus larvae in the intestinal wall, impairing 
larval health and preventing emergence of adult worms into the lumen (Anthony et 
al., 2006). The authors did not treat intestinal larvae with recombinant Arginase in 
vitro to determine whether Arginase has direct anthelmintic properties, although they 
suggest it is not due to Arginase- or aaMϕ-dependent collagen deposition trapping 
of the larvae, as collagen was only detected 12 days-post 2o H. polygyrus infection 
(Anthony et al., 2006).  
Endogenous anthelmintics have been suggested to be present in the small intestine 
of sheep resistant to intestinal helminth infection. Douch and colleagues 
demonstrated that compounds present in the gastrointestinal mucus of nematode 
resistant sheep had antihelminth activity (Douch et al., 1996). Sheep were repeatedly 
infected and drug-treated with Trichostrongylus colubriformis or Haemonchus 
contortus L3 larvae. Small intestinal sections were then ligatured to form sacs that 
were then incubated with exsheathed L3 larvae for 1 hour. The L3 larvae that were 
Chapter 3 Results 1 
117 
 
incubated in resistant sheep small intestinal tissue were significantly less motile than 
those incubated in uninfected sheep small intestine (Douch et al., 1996). The authors 
suggested the antihelminth activity of the resistant small intestine mucosa was due 
to LTs and other ‘anti-parasitic’ substances, however these were not formally tested 
in this study. Others have suggested that LTs have a role in antihelminth immunity, 
however direct effects on intestinal helminths have not been confirmed (Moqbel et 
al., 1990, Machado et al., 2005). If LTs are essential for killing of H. polygyrus, they 
may act in concert with PLA2g1B as cLTs were intact in Pla2g1b–/– mice, which failed 
to expel H. polygyrus (Figure 3.10.C). Extrapolation of our findings indicates that the 
anti-parasitic molecules described by Douch and colleagues are unlikely to be LTs, 
Relmβ or Arginase but maybe PLA2g1B. It would be interesting to determine whether 
PLA2g1B is responsible resistance in sheep. For example, is Pla2g1b expression 
and PLA2 activity elevated in resistant sheep intestinal tissue? Are exsheathed L3 T. 
colubriformis and H. contortus larvae sensitive to PLA2g1B in vitro, with respect to 
larval motility and migration (Rabel et al., 1994) as well as their infectivity in naïve 
sheep. It would also be of interest to adapt the larval migration inhibitory assay (Rabel 
et al., 1994) and other anthelmintic screens (Hu et al., 2013), for use with PLA2g1B-
treated H. polygyrus larvae. This could shed light on how PLA2g1B affects the 
function of H. polygyrus. 
 
3.3.2.4 Cooperation between PLA2g1B and type 2 effector mechanisms is 
required for functional anti-helminth immunity 
Type 2 effector mechanisms are essential in mediating resistance to intestinal 
helminth infections. In the context of H. polygyrus infection, IL-4Rα signalling is 
essential for resistance (Urban et al., 1991b), promoting alternative activation of 
macrophages (Anthony et al., 2006), B cell class switching and IgG1 production 
(Katona et al., 1991, Urban et al., 1991a, McCoy et al., 2008) and goblet cell 
hyperplasia and Relmβ production (Herbert et al., 2009). Here we demonstrate that 
PLA2g1B is essential for resistance to H. polygyrus and N. brasiliensis, with Pla2g1b–
/– mice unable to clear a 2o H. polygyrus challenge infection despite a sizable type 2 
immune response (section 3.2.3 and 3.2.4). Furthermore, we demonstrated that 
Pla2g1b expression was distinct from IL-4 in vivo (Figure 3.20.A), suggesting that it 
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may not be regulated by IL-4Rα signalling. Resistance to H. polygyrus infection 
requires the cooperation of type 2 immune responses and the direct anthelmintic 
effect of PLA2g1B, with mice deficient in either one failing to eliminate 2o challenge 
infection (Figure 3.14). Moreover, we show that PLA2g1B is able to reduce worm 
burden during a 1o infection (Figure 3.12), overcoming the necessity of a memory 
type 2 response. 
 
3.3.2.5 Does pancreas-derived PLA2g1B play a role? 
We identified Pla2g1b to be expressed in the small intestine, specifically in epithelial 
cells, and upregulated in resistant mice (section 3.2.1, 3.2.9 and 3.2.10). However, 
Pla2g1b is expressed in a variety of tissues in C57BL/6 mice, with expression highest 
in the glandular stomach, pancreas and small intestine respectively (Eerola et al., 
2006). With the majority of research on PLA2g1B focussing on its role in dietary and 
biliary lipid digestion following secretion from the pancreas, we observed that 
pancreas-specific Pla2g1b expression levels were unchanged during the H. 
polygyrus 2o challenge infection model (Figure 3.18.A). These data suggests that 
the protective effects of PLA2g1B are likely to be dependent upon de novo small 
intestine-derived Pla2g1b expression in resistant mice, we cannot however exclude 
a role for pancreatic PLA2g1B.  
To test this, we would require a mouse where Pla2g1b is flanked by two lox-p sites 
and a pancreas –specific Cre-recombinase driver. Using the pancreas wide Cre-
recombinase Pdx1Cre would not be appropriate as it also induces recombination in 
the duodenum (Magnuson and Osipovich, 2013). Specific deletion of Pla2g1b in 
pancreatic acinar cells using the inducible Cre-recombinase driver Cela1Cre-ER would 
be more appropriate as Pla2g1b expression is restricted to acinar cells in the 
pancreas (Richmond and Hui, 2000), induces close to 100% activity in acini after 
tamoxifen treatment (Ji et al., 2008) and does not affect the small intestine 
(Magnuson and Osipovich, 2013). In addition, to demonstrate that small intestine 
epithelial cell-derived Pla2g1b is essential for resistance to H. polygyrus, restricting 
Pla2g1b deficiency to intestinal epithelial cells using the villinCre would not be 
appropriate as this Cre-recombinase driver also marks acinar cells (Magnuson and 
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Osipovich, 2013). It would therefore be of benefit to identify the epithelial sub-type 
that expresses Pla2g1b and subsequently use a Cre-recombinase driver specific to 
that sub-type. 
In addition to a genetic approach to restrict pancreatic PLA2g1B, bile duct ligation 
would prevent pancreas-derived PLA2g1B from entering the small intestine. Bile duct 
ligation in rodents is commonly used to study obstructive cholestatic injury, inducing 
a strong fibrotic response after 21 days (Tag et al., 2015). This model would allow 
bile duct ligation prior to 2o challenge infection with H. polygyrus and analysis of 
luminal worm burden 14 days-post infection. There is a possibility that the fibrotic 
response would affect antihelminth immunity, therefore potentially confounding the 
results.  
Regardless, if physiological expression of pancreatic Pla2g1b contributes to 
resistance to H. polygyrus, it would be of interest to see if super-physiological levels 
of pancreatic PLA2g1B can induce resistance upon 1o infection of H. polygyrus. To 
test this, we could utilise the mouse which over expresses human PLA2G1B in 
pancreatic acinar cells (Cash et al., 2011), and determine luminal H. polygyrus load 
in the small intestine following 1o infection. 
 
3.3.3 Regulation of Pla2g1b expression 
3.3.3.1  Microbiota in resistant mice 
We identified that upregulation of small intestinal Pla2g1b in vivo was abrogated with 
antibiotic treatment (Figure3.20), indicating that changes in the intestinal microbiota 
is required for Pla2g1b upregulation. Intestinal helminth infection has previously been 
shown to induce changes in the intestinal microbiota (Rausch et al., 2013, Reynolds 
et al., 2014b, Zaiss et al., 2015, Giacomin et al., 2016, Kannan et al., 2017), however 
changes in the microbiota following drug-clearance of infection has not been 
investigated. Following our findings, it would be of great interest to determine the 
changes in the small intestinal microbiota both susceptible and resistant mice, with 
and without 2o infection. To test this, we could use the model used for our tissue RNA 
sequencing (Figure 3.1), but instead harvest both faecal and duodenal samples for 
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16S rRNA sequencing to determine both the presence and abundance of bacterial 
species. 
Following our observation that small intestinal Pla2g1b in vivo was abrogated with 
antibiotic treatment (Figure 3.20), and with PLA2g1B essential for resistance to H. 
polygyrus (Figure 3.5), we demonstrated that antibiotic treatment abrogated 
resistance and prevented clearance of 2o H. polygyrus challenge infection. However, 
PLA2g1B treatment of the L3 larvae in vitro, prior to 2o infection, failed to rescue 
protective immunity. This experiment must be repeated to confirm these findings. 
However, this preliminary data suggests that the abrogation of resistance following 
antibiotic treatment was not only due to a failure to upregulate Pla2g1b expression. 
We previously demonstrated that for functional killing a clearance of H. polygyrus 
required a functional immune system and direct PLA2g1B anthelmintic effects 
(Figure 3.14), therefore we can speculate that the antibiotic treatment may have also 
abrogated the type 2 immune response. Antibiotic treatment can alter both type 2 
immune responses and barrier function in the intestine (Stefka et al., 2014). Future 
studies should address the effect of antibiotic treatment on the immune response 
following H. polygyrus infection in this model. This would establish if antibiotic 
treatment abrogated protection to H. polygyrus due to the failure to both upregulate 
Pla2g1b and mount an effective immune response, or alternatively induce another 
critical unknown antihelminth mechanism. 
In addition to using antibiotic treatment, we could also perform faecal transplant 
experiments to determine the role of the microbiota in resistant to intestinal helminth 
infection. Specifically, transferring the faecal content from resistant mice to naïve 
recipient mice may be sufficient to induce Pla2g1b expression and confer resistance. 
Whether there are differences in the microbiota of individual’s resistant to intestinal 
helminth infection and whether resistance could be induced in susceptible individuals 
by altering the intestinal microbiota is currently unclear and warrants further study. 
 
3.3.3.2 Requirement of immune cells for Pla2g1b expression 
As well as the upregulation of Pla2g1b expression in resistant mice being dependent 
upon the microbiota, we also identified that Rag–/–γc–/– mice also failed to upregulate 
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Pla2g1b after clearance of a 1o H. polygyrus infection (Figure 3.20). This indicates 
a requirement for Rag-dependent adaptive and/or common gamma chain-dependent 
innate immune cells or signalling in the upregulation of Pla2g1b in small intestine 
epithelial cells. Further experiments are required to identify the specific cell type(s) 
that are required for Pla2g1b upregulation. Initially testing Rag–/– and γc–/– mice to 
identify the critical compartment for Pla2g1b upregulation in resistant mice, followed 
by specific innate or adaptive cell knockout mice could provide greater resolution and 
identification of the critical cell type required for Pla2g1b upregulation.  
Our data show that both the microbiota and a functional immune system are required 
for Pla2g1b upregulation in epithelial cells of resistant mice. From this we can 
formulate two hypotheses in how the microbiota and immune cells act together to 
induce Pla2g1b expression. 
1. A change in composition of the microbiota maintains or induces a population 
of immune cells, which in turn, provides a signal to the intestinal epithelial 
cells to increase Pla2g1b expression.  
2. The lack of a functional immune compartment in Rag–/–γc–/– mice perturbs 
the change in microbiota composition, required to provide a signal to the 
intestinal epithelial cells, which in turn, upregulates Pla2g1b expression.  
Previous studies have demonstrated that both specific strains of bacteria and 
bacteria-derived products present in the intestinal tract are essential for the 
development and maintenance of immune cell populations (Atarashi et al., 2011, 
Ivanov et al., 2009, Gaboriau-Routhiau et al., 2009, Furusawa et al., 2013). In 
addition, the intestinal microbiota, both bacteria and protozoa, have been shown to 
have direct effects on intestinal epithelial cells, shaping gene expression and 
structure (Howitt et al., 2016, Davison et al., 2017, Quevrain et al., 2016). 
Furthermore, Rag1-deficient mice have been shown to have dysbiosis of intestinal 
microbiota (Smith et al., 2014). Taken together, this body of literature supports both 
hypotheses above.  
Analysis and comparison of the small intestinal microbiota composition, by 16S 
sequencing, between mice after drug-clearance of 1o H. polygyrus infection and 
during 1o infection would allow the identification of specific bacterial strains 
associated with resistance. An increase or decrease in specific bacterial species may 
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promote Pla2g1b expression in resistant mice. In order to determine which 
hypothesis above is correct, comparison of the resistance-induced changes (drug-
clearance of 1o H. polygyrus infection) in the small intestinal microbiota between WT 
and immune-deficient mice, such as Rag–/–γc–/– mice, would be required. If the same 
changes in microbiota were seen, hypothesis 1 is likely to be correct as Pla2g1b is 
not upregulated in Rag–/–γc–/– mice, despite the same changes in microbiota 
composition occurring. However, if there were differences in the changes in bacterial 
species, hypothesis 2 is likely to be correct as the lack of a functional immune system 
would have prevented changes in the microbiota which are required for Pla2g1b 
upregulation. Additionally, measurement of Pla2g1b expression in the small intestine 
following faecal transfer from WT drug-cured mice, or transfer of the bacterial species 
or product critical for Pla2g1b upregulation, into both naïve WT and Rag–/–γc–/– mice 
would differentiate between hypothesis 1 and 2 above. If faecal transfer of from WT 
drug-cured mice to Rag–/–γc–/– mice induced Pla2g1b expression in the small 
intestine, hypothesis 2 is likely to be correct. If faecal transfer does not induce 
Pla2g1b expression in the small intestine of Rag–/–γc–/– mice, hypothesis 1 is likely to 
be correct. 
 
3.3.3.3 Type 2 immunity and PLA2g1B paradox: IL-4Rα signalling 
IL-4Rα is essential for resistance to H. polygyrus infection (Urban et al., 1995, Urban 
et al., 1991b), inducing Th2 differentiation (Urban et al., 1991a, Urban et al., 1991b) 
and downstream type 2 effector mechanisms (Katona et al., 1991, McCoy et al., 
2008, Herbert et al., 2009, Anthony et al., 2006). However, we show that Pla2g1b 
expression, which is essential for resistance to H. polygyrus (Figure 3.5), is 
unaltered in resistant mice following IL-4 blockade in vivo (Figure 3.20.A). These 
data indicate that Pla2g1b expression is not regulated by IL-4. From our in vivo 
experiments, we cannot determine if IL-4Rα signalling regulates Pla2g1b expression 
as IL-13, which is equally or more important in mediating type 2 effector responses 
(Zhu et al., 1999, Li et al., 1999, Finkelman et al., 1999), is capable of inducing IL-
4Rα signalling (Mueller et al., 2002). For this we would have to block both IL-4 and 
IL-13 simultaneously or, cross the Il4rafl/fl (Jenkins et al., 2013) and VillinCre mice to 
restrict Il4ra-deficency to intestinal epithelial cells. 
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Interestingly, when we investigated the role of IL-4Rα signalling in vitro using 
intestinal epithelial organoid cultures, we identified that following IL-4 and IL-13 
stimulation Pla2g1b expression was decreased (Figure 3.21.A). This suggests that 
Pla2g1b is negatively regulated by IL-4Rα signalling, contrasting to the in vivo data 
where blocking IL-4 had no effect on Pla2g1b expression. However, there may be 
technical limitations which confound the in vitro organoid data. The intestinal 
organoids were stimulated for 48 hours prior to RNA extraction and gene expression 
analysis. We know this time period allows for the differentiation and hyperplasia of 
both goblet and tuft cells (Gerbe et al., 2016). With Pla2g1b unlikely to be restricted 
to tuft or goblet cells (Figure 3.21.B), the decrease in Pla2g1b expression seen in 
intestinal organoids upon IL-4 and IL-13 stimulation is likely to be due to a lower 
abundance of the sub-type of Pla2g1b expressing epithelial cells due to the 
increased abundance and outgrowth of both tuft and goblet cells. To overcome this, 
we can reduce the stimulation duration of IL-4 and IL-13, analysing gene expression 
before the expansion of tuft and goblet cells. Alternatively, we could promote the 
differentiation of the intestinal organoids to different epithelial sub-types (Basak et 
al., 2017) and compare Pla2g1b expression or stimulate each subtype with IL-4 and 
IL-13, as well as other cytokines, and analyse Pla2g1b expression.  
 
3.3.3.4 Pla2g1b expression in resistant strains 
With PLA2g1B essential for resistance to H. polygyrus (Figure 3.5) and different 
strains of mice known to have differing levels of susceptibility to H. polygyrus 
infection (Reynolds et al., 2012), it would be interesting to identify if Pla2g1b 
expression correlated with resistance to H. polygyrus infection in different laboratory 
mouse strains. Other genetic factors, such as major histocompatibility complex H-2 
loci (Behnke and Wahid, 1991) and IL-9 (Behnke et al., 2003), have been associated 
with resistance to H. polygyrus, however Pla2g1b has not been directly associated 
with genetic resistance. Intriguingly, C57BL/6 mice have a genetic mutation in 
Pla2g2a, another sPLA2, which prevents the production of functional PLA2g2A, unlike 
the more resistant BALB/c strain. PLA2g2A is expressed in the intestine of BALB/c 
mice (Eerola et al., 2006) and is implicated in antimicrobial defence (Okita et al., 
2015, Harwig et al., 1995, Murakami et al., 2014). With all sPLA2 enzymes catalysing 
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the same reaction, but with differing substrate specificities (Nevalainen et al., 2008, 
Koduri et al., 2002), would other sPLA2 promote resistance to H. polygyrus infection 
or are sPLA2 anthelmintic properties restricted to Pla2g1b? And could C57BL/6 mice 
be more susceptible to 1o H. polygyrus infection due to a lack of functional PLA2g2A? 
It is unlikely that other sPLA2 enzymes, expressed in the small intestine, are required 
for resistance to H. polygyrus infection as their expression is not differentially 
expressed 2o H. polygyrus infection (Figure 3.3.E), nor is their expression altered in 
Pla2g1b–/–  mice upon 2o H. polygyrus infection (Figure 3.11.F), although PLA2g2A 
cannot be ruled out. To test the role of PLA2g1B and PLA2g2A in immunity to H. 
polygyrus we would have to backcross the Pla2g1b–/– mice to a BALB/c background 
and compare the luminal worm burden to Pla2g2a–/– mice upon 2o H. polygyrus 
infection.  
 
3.3.4 Implications for therapeutics 
With Pla2g1b shown to be essential in mice for immunity to small intestine-dwelling 
helminths (Figure 3.5), the question arises as to whether the same gene is essential 
from resistance to small intestine-dwelling helminth infection in humans and 
livestock. 
Initially, it would be interesting to test whether human PLA2g1B has any impact on 
human intestinal nematodes, similar to our H. polygyrus L3 in vitro treatment system 
(Figure 3.14.A). In addition, utilisation of the in vitro assays developed to screen 
anthelmintic compounds against L3 larvae of various helminth species could identify 
if PLA2g1B had a role in antihelminth immunity in other mammals, discussed 
previously in section 3.3.2.2. 
Several immunological parameters correlate with human resistance to intestinal 
helminth infection, such as IgE or IL-5 (van den Biggelaar et al., 2002, Ndhlovu et 
al., 1996, Hagan et al., 1991). It would be of interest to analyse PLA2G1B expression 
in small intestinal biopsies from individuals and identify if there is any correlation with 
resistance to intestinal helminth infection. 
Importantly, identifying the precise mechanism of PLA2g1B’s effect on intestinal 
helminths and the role of parasite-phospholipids in helminth infection and health is 
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critical, as discussed in section 3.3.2.3. Identifying these mechanisms could lead to 
the design of synthetic helminth-specific molecules, leading to the generation of new 
anthelmintics. Whether this would culminate in another prophylactic treatment or 
whether this could provide long lasting immunity is unclear. 
To provide long lasting immunity to helminth infections vaccines are necessary but, 
despite progression in mouse models (Hewitson et al., 2011), generation of human 
vaccines have stalled. With our finding that protective type 2 immune effector 
mechanisms require PLA2g1B-mediated anthelmintic effects (Figure 3.14), 
promoting PLA2G1B expression may boost vaccine-induced protection to intestinal 
helminth infection. As mentioned, for this to be implemented, the mechanism of 
Pla2g1b regulation in epithelial cells would need to be precisely determined 
(discussed in section 3.3.3) and used to create a therapeutic which can artificially 
boost and maintain its expression.   
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Figure 3.1 RNA sequencing of intestinal tissue reveals distinct gene clusters 
associated with resistance to H. polygyrus 
(A) C57BL/6 mice were orally infected with 200 L3 H. polygyrus larvae on day 0. A cohort 
of mice was sacrificed 7 days-post 1o H. polygyrus infection (H.p. 1o). Remaining mice 
were drug treated (Rx) on days 14 and 15. Two cohorts of mice were then harvest on 
day 42 or Day 63 (Rx (D42) and Rx (D63), respectively). Another two cohorts of mice 
were then 2o challenge infected with H. polygyrus on day 35 or day 56 and harvested 7 
days-post 2o infection (H.p. 2o (D42) and H.p. 2o (D63), respectively). RNA was harvested 
from the duodenum at each time point, n=8. (B) H&E staining of the small intestine from 
H.p. 1o and H.p. 2o (D42). (C) The number of genes significantly differentially expressed 
in H.p. 1o, Rx (D42), Rx (D63), H.p.2o (D42) and H.p.2o (D63) (up- and downregulated, 
relative to naïve, p<0.05).  (D) Common and differentially expressed genes in H.p. 1o 
and H.p. 2o (D42) (relative to naïve, 2-fold filter, p<0.05). (E) Ratio of ratios analysis of 
differentially expressed genes in H.p. 1o and H.p. 2o (D42) (relative to naive, 2-fold filter, 
p<0.05) identified distinct gene clusters (C1-3). See also Table 3.1, Table 3.2 and Table 
3.3 for genes in C1-3.  




Figure 3.2 Pathway analysis of susceptible and resistant mice 
(A) Top 20 pathways predicted to be activated in H.p. 2o (D42) and H.p. 1o (relative to 
naïve, 2-fold filter, p<0.05). (B) Top 10 predicated activated and inhibited upstream 
regulators of H.p. 1o and H.p. 2o (D42) transcriptomes (relative to naïve, 2-fold filter, 
p<0.05). 
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Figure 3.3 RNA sequencing and pathway analysis identified Pla2g1b and lipid 
metabolism pathways to be upregulated in resistant mice 
(A) Top 10 pathways predicted to be activated more highly in and H.p. 2o (D42) than H.p. 
1o (relative to naïve, 2-fold filter, p<0.05). (B) Lipid metabolism pathway predicted 
activation score (relative to naïve, 2-fold filter, p<0.05). (C) Pla2g1b expression in small 
intestine from RNA sequencing data, confirmed by qPCR. (D) PLA2 activity in the small 
intestine of naïve, H.p. 1o and H.p. 2o mice. (E) Phospholipase A2 isoform expression in 
the small intestine from RNA sequencing. Data represented as mean ± SEM, n=6-8. ns 
= not significant, *** = p<0.001, **** = p<0.0001 determined using a one-way ANOVA 
with Dunnett’s or Tukey’s multiple comparison analysis. 
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Figure 3.4 Pla2g1b–/– mice do not display any immune defects at baseline 
Immune cell frequency was assessed in naïve mice by flow cytometry. (A) CD4+CD8+ T 
cells. (B) Naïve CD8+ T cells. (C) Activated CD8+ T cells. (D) Naïve CD4+ cells. (E) 
Activated CD4+ cells. (F) Foxp3+ Regulatory T cells. (G) B cell frequency (H) Total 
number of ILC2s in the mLN. Data represented as mean ± SEM, n=5-6. All data is 
representative of at least two independent experiments. ns = not significant, determined 
using an unpaired two-tailed t test. 
  




Figure 3.5 Pla2g1b is essential for resistance to small intestinal helminths 
(A) Luminal H. polygyrus worms in the small intestine 14 days-post 2o infection. (B) 
Faecal egg burden 14 days-post 2o H. polygyrus infection, no eggs were seen in 
Pla2g1b+/+ mice. (C) Luminal N. brasiliensis worms in the small intestine 6, 8 and 10 
days-post infection. (D) Luminal T. muris worms in the cecum and large intestine 35 
days-post infection. Rag–/– mice were used as an additional control to confirm the 
infectious dose administered. Data represented as mean ± SEM, n=5-6. All data is 
representative of at least two independent experiments. ns = not significant, * = p<0.05, 
**** = p< 0.0001, determined using an unpaired two-tailed t test.  
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Figure 3.6 T cell response is intact in Pla2g1b–/– mice following 2o H. polygyrus 
infection 
Frequency (A) and total number (B) of Il4gfp+CD44hi CD4+ cells in the mesenteric lymph 
node (mLN) and the spleen 7 days-post 2o infection. Frequency (C) and total number (D) 
of cytokine producing T cells in the mLN 7 days-post 2o infection. (E) ex vivo H. polygyrus 
antigen-specific cytokine production from the mLN 7 days-post 2o infection. Frequency 
(F) and total number (G) of Foxp3+ regulatory T cells in the mLN and spleen 7 days-post 
2o infection. Data represented as mean ± SEM, n=5-6, representative of at least two 
independent experiments, ns = not significant, * = p<0.05, *** = p< 0.001 determined 
using an unpaired two-tailed t test. 
  




Figure 3.7 Antibody responses are intact in Pla2g1b–/– following 2o H. polygyrus 
infection 
(A) H. polygyrus-specific IgG1 in the serum from mice 7 days-post 2o H. polygyrus 
infection (B) IgE in the serum from mice 7 days-post 2o H. polygyrus infection, quantified 
in (C). Data represented as mean ± SEM, n=5-6. All data is representative of at least two 
independent experiments. ns = not significant, determined using a two-way ANOVA with 
Sidak’s multiple comparison analysis or an unpaired two-tailed t test. 
  




Figure 3.8 Pla2g1b-deficiency does not perturb alternate activation of 
macrophages 
(A) Alternately activated macrophage marker gene expression in the small intestine of 
mice 7 days-post 2o H. polygyrus infection. (B) Bone marrow-derived macrophages were 
stimulated with IL-4 and IL-13 for 24 hours and Arg1, Retnla and Chi3l3 gene expression 
was analysed. Data represented as mean ± SEM, n=5-6. All data is representative of at 
least two independent experiments. ns = not significant, determined using an unpaired 
two-tailed t test. 
  




Figure 3.9 Pla2g1b-deficency does not alter the ILC2 population following 2o H. 
polygyrus infection 
(A) Total numbers of ILC2 cells in the mLN 7 days-post 2o H. polygyrus infection. Data 
represented as mean ± SEM, n=5, representative of at least two independent 
experiments. ns = not significant, determined using an unpaired two-tailed t test. 
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Figure 3.10 Lipid metabolism and bioactive lipid synthesis is intact in Pla2g1b-
deficient mice 
(A) Lipid metabolites in the serum of naïve and 7 days-post 2o H. polygyrus infected 
mice. (B) Lysophosphatidylcholine (LPC) concentration in the serum and small intestinal 
homogenate of naïve and 7 days-post 2o H. polygyrus infected mice. (C) Cysteinyl 
leukotrienes (LTs) and Prostaglandin E2 (PGE2) concentration in the small intestine of 
naïve and 7 days post 2o H. polygyrus infected mice. Data represented as mean ± SEM, 
n=4-6. All data is representative of at least two independent experiments. ns = not 
significant, determined using a two-way ANOVA with Sidak’s multiple comparison 
analysis. 
  




Chapter 3 Results 1 
142 
 
Figure 3.11 RNA sequencing of the small intestine reveals no significant 
differences in Pla2g1b–/– mice 
(A) RNA sequencing-generated transcriptional landscape of the small intestine of naïve 
and 7 days-post 2o infection WT (Pla2g1b+/+) and Pla2g1b–/– mice. (B) Top 10 predicated 
pathways 7 days-post 2o H. polygyrus infection of WT (Pla2g1b+/+) and Pla2g1b–/– mice 
(relative to naïve, 2-fold filter, p<0.05). (C) Lipid metabolism pathway predicted activation 
score in WT (Pla2g1b+/+) and Pla2g1b–/– mice 7 days-post 2o H. polygyrus infection 
(relative to naïve, 2-fold filter, p<0.05). (D) Goblet cell-associated gene expression in the 
small intestine of naïve and 7 days-post 2o H. polygyrus infected WT and Pla2g1b–/– 
mice. (E) Mucus staining (Alcian blue-periodic acid Schiff) of the small intestine from 
mice 7 days-post 2o H. polygyrus infection. (F) Phospholipase A2 isoform expression in 
the small intestine 7 days-post 2o H. polygyrus infection of WT (Pla2g1b+/+) and Pla2g1b–
/– mice. Data represented as mean ± SEM, n=5-6, ns = not significant, * = p<0.05, 
determined in RNA sequencing analysis (see methods). 
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Figure 3.12 PLA2g1B has direct anthelmintic properties which prevent 
establishment of H. polygyrus 
(A) Number of H. polygyrus larvae embedded in the small intestinal wall 5 days-post 
infection following 24-hour in vitro treatment of L3 larvae with PLA2g1B, n=5. (B) Luminal 
H. polygyrus worms in the small intestine 14 days-post 1o infection following 24-hour in 
vitro treatment of L3 larvae with PLA2g1B, n=10 (data pooled from two independent 
experiments). (C) Luminal H. polygyrus worms in the small intestine 14 days-post 1o 
infection following 24-hour in vitro treatment of L3 larvae with PLA2g1B ± Manoalide (200 
ng/µL), n=5. (D) Faecal egg count 14 days-post 1o infection following 24-hour in vitro 
treatment of L3 larvae with PLA2g1B, n=10 (data pooled from two independent 
experiments). All data is representative of at least two independent experiments. ns = 
not significant, * = p<0.05, ** = p<0.01, *** = p<0.001 determined using a one-way 
ANOVA with Tukey’s or Dunnett’s multiple comparison analysis.   




Chapter 3 Results 1 
146 
 
Figure 3.13 PLA2g1B treatment does not compromise the fitness of H. polygyrus 
(A) Protocol of in vitro PLA2g1B treatment of H. polygyrus L3 larvae and L5 adult worms 
for 24-hours, followed by ATP concentration analysis. (B) ATP concentration of L3 H. 
polygyrus larvae following 24-hour PLA2g1B treatment. n=3. (C) ATP concentration of 
adult L5 H. polygyrus following 24-hour PLA2g1B treatment. (D) Protocol of ex vivo ATP 
analysis of L4 and L5 adult H. polygyrus. L3 larvae were treated in vitro with 10 ng/µL 
PLA2g1B for 24-hours before infection of C57BL/6 mice. Mice were then harvested at 7- 
and 14 days-post infection to harvest L4 and L5 H. polygyrus respectively and ATP 
concentration was then analysed. (E) ATP concentration of L4 H. polygyrus isolated from 
the small intestine 7 days-post infection following 24-hour treatment with PLA2g1B, n=40 
(data pooled from three independent experiments). (F) ATP concentration of L5 adult H. 
polygyrus isolated from the small intestine 14 days-post infection following 24-hour 
treatment with PLA2g1B, n=12. All data is representative of at least two independent 
experiments. ns = not significant, determined using a one-way ANOVA with Dunnett’s 
multiple comparison analysis or unpaired two-tailed t test. 
   




Figure 3.14 PLA2g1B acts in synergy with type 2 immunity to induce protection 
against H. polygyrus infection 
(A) Mice were orally infected with 200 L3 H. polygyrus (H.p.) larvae on day 0 and were 
drug treated (Rx) on days 14 and 15. Mice were then reinfected with PLA2g1B-treated 
L3 H. p larvae on day 35 and harvested 14 days-post infection (2o). Another cohort of 
Pla2g1b–/–  or WT mice were orally infected with 200 L3 H. polygyrus (H.p.) larvae on 
day 0 and harvested 14 days-post infection (1o). (B) Luminal H. polygyrus worms in the 
small intestine 14 days-post 1o or 2o infection following 24-hour treatment with PLA2g1B. 
(C) Luminal H. polygyrus worms in the small intestine 14 days-post 1o infection following 
24-hour treatment with PLA2g1B. (D) Luminal H. polygyrus worms in the small intestine 
14 days post 2o infection following 24-hour treatment with PLA2g1B. Data represented 
as mean ± SEM, n=4-5. All data is representative of at least two independent 
experiments, ns = not significant, ** = p<0.01, **** = p< 0.0001 determined using a two-
way ANOVA with Sidak’s multiple comparison analysis.  




Figure 3.15 Scanning electron microscopy reveals no overt structural changes in 
PLA2g1B-treated L3 H. polygyrus larvae 
(A) Scanning electron microscopy of vehicle- or PLA2g1B-treated exsheathed L3 H. 
polygyrus larvae. 
  




Figure 3.16 LC-MS/MS identifies that PLA2g1B treatment decreases 
phosphatidylethanolamine (PE) abundance in L3 H. polygyrus larvae 
(A) Relevant section of the base peak chromatogram of control and PLA2g1B-treated 
larvae showing elution of PE phospholipids in negative ion mode. (B) Example spectrum 
from the section of the chromatogram shown in (A) at the approximate retention time of 
PE species, 23.23-23.40 minutes. PEs consist of a phosphoethanolamine head group 
attached to a glycerol backbone, itself attached to two fatty acid moieties via 
phosphoether and ester bonds, respectively. As a result, PE MS spectra display traits of 
fatty acid-containing molecules (clusters that have inter-cluster mass shifts of 28 Da 
(CH2CH2) and intra-cluster mass shifts of 2 Da (indicative of difference in double bond 
number (fatty acid saturation)). The six identified and three putatively identified PEs are 
shown in Figure 3.17.A-B. (C) Extracted ion chromatogram of the ion corresponding to 
PE 36:3 (18:1, 18:2) in negative ion mode (m/z 740.5226). (D) Positive-ion MS/MS was 
used to confirm assignment of the peak as PE, where neutral loss of 141 Da indicates 
phopshoethanolamine head group. Here, we show the fragmentation of the ion 
corresponding to PE 36:3 (18:1, 18:2) in positive ion mode (m/z 742.5362). (E) Negative 
ion fragmentation of the ion corresponding to PE 36:3 (18:1, 18:2) (m/z 740.5226). By 
identifying both fatty moieties, the individual molecular species were recognized (in this 
instance, 18:1 and 18:2). Both, the arrangement of the fatty acid moieties at the glycerol 
backbone (i.e. sn-1 or sn-2) and the position of the double bonds could not be inferred. 
LC-MS/MS experiments were performed and analysed by Mariana Silva dos Santos and 
James MacRae. 
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Figure 3.17 PLA2g1B treatment induces changes in L3 H. polygyrus larval lipid 
abundance 
Relative abundances of phosphatidylethanolamine (PE) and other unidentified lipids 
extracted from PLA2g1B-treated (10 ng/µL) and control-treated (0 ng/µL) larvae. (A) 
Identified PEs. Features were regarded as ‘identified’ by comparison of their precursor 
ion and MS/MS fragments with the LipidBlast library, as outlined in Figure 3.16. The 
arrangement of fatty acid moieties on the glycerol backbone (i.e. whether in the sn-1 or 
sn-2 position) and the position of double bonds could not be inferred. PE 38:3 and PE 
38:4 were detected as a mixture of different fatty acid moieties. (B) Putatively identified 
PEs. The features could be ‘annotated’ as PEs by comparison of peak retention time and 
inter-cluster mass shifts of 28 Da (CH2CH2) and intra-cluster mass shifts of 2 Da 
(indicative of difference in double bond number (fatty acid saturation)) with other, 
identified PEs. MS/MS could not be performed due to low abundance. (C) Unidentified 
lipid compounds. Apolar features that could not be identified, even putatively, by 
comparison to common libraries. Data is shown as normalized intensities expressed in 
arbitrary units, n=3 Error bars indicate minimum and maximum values. TIC: Total ion 
current. RT: Retention time. LC-MS/MS experiments were performed and analysed by 
Mariana Silva dos Santos and James MacRae. 
  




Figure 3.18 Pla2g1b expression is induced after drug-clearance of 1o H. polygyrus 
infection 
Kinetics of Pla2g1b expression in the pancreas (A) and small intestine (B) during H. 
polygyrus 2o infection model. (C) Kinetics of Pla2g1b expression in the small intestine 
during H. polygyrus 1o infection. (D) Pla2g1b expression at day 28 (14 days post Rx) in 
the small intestine. H.p. 1o = 1o H. polygyrus infection, H.p. 2o = 2o H. polygyrus infection, 
Rx = drug treatment, Veh = vehicle. Data represented as mean ± SEM, n=5-6. All data 
is representative of at least two independent experiments. * = p<0.05, ** = p<0.01, 
determined using a one-way ANOVA with Dunnett’s multiple comparison analysis or 
unpaired two-tailed t test. 
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Figure 3.19 Pla2g1b expression is restricted to epithelial cells in the small intestine 
of resistant mice 
(A) Pla2g1b detection by RNAScope® ISH in the small intestine of naïve and 7 days-post 
2o H. polygyrus (H.p. 2o) infected mice. (B) Pla2g1b detection by RNAScope® ISH in 
epithelial cells of the small intestine 7 days-post 2o H. polygyrus infection (H.p. 2o). (C) 
Pla2g1b detection by RNAScope® ISH in the granuloma surrounding H. polygyrus (H.p.) 
within the small intestine 7 days-post 2o H. polygyrus infection. (D) Pla2g1b expression 
in fluorescence activated cell sorted (FACS) CD45–EpCam+ and CD45+EpCam– cells 
from the intestinal epithelium from naïve and resistant (day 28) mice, n=6. Data 
represented as mean ± SEM, ns = not significant, * = p<0.05 determined using a Mann-
Whitney test. 
  




Figure 3.20 Intestinal Pla2g1b is regulated by the microbiota and Rag- and 
common gamma-chain-dependent cells in resistant mice 
(A) Pla2g1b expression at day 28 (14 days-post Rx, 1o-Rx) in the small intestine following 
anti-IL-4 (αIL-4) or Isotype (Iso) treatment, n=9-10 (data pooled from two independent 
experiments). (B) Pla2g1b expression at day 28 (14 days-post Rx, 1o-Rx) in the small 
intestine, n=7-10 (data pooled from two independent experiments) (C) Pla2g1b 
expression at day 28 (14 days post Rx, 1o-Rx) in the small intestine following antibiotic 
treatment, n=9-10 (data pooled from two independent experiments). (D) Luminal H. 
polygyrus worms in the small intestine 14 days-post 2o infection following antibiotic 
treatment and 24-hour larvae treatment with PLA2g1B, infective dose = 64 adult worms 
(determined by 1o infection), n=5, data representative of one experiment. All data 
represented as mean ± SEM, * = p<0.05, ** = p<0.01, determined using a one-way 
ANOVA with Tukey’s multiple comparison analysis or Mann-Whitney test.  
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Figure 3.21 Pla2g1b expression is negatively regulated by IL-4Rα signalling in 
intestinal organoids 
(A) Pla2g1b, Retnlb and Gob5 expression in intestinal organoid cultures following 
stimulation with IL-4 & IL-13 and small intestinal (S.I.) homogenate from mice 7 days-
post 2o H. polygyrus infection (H.p. 2o). (B) Tuft cell-specific gene expression data in 
small intestine from RNA sequencing data from Figure 3.1. Data represented as mean 
± SEM, n=. All data is representative of at least three independent experiments. * = 
p<0.05, *** = p<0.001, **** = p< 0.0001 determined using an unpaired t-test or by RNA 
sequencing analysis. 
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Cluster 1: Genes 
H.p. 2o vs H.p. 1o 
Fold change 
H.p. 1o Fold change 
(rel. to naïve) 
H.p. 2o Fold change 
(rel. to naïve) 
Chi3l3/Chi3l4 31.6 126.6 3995.5 
Gsdmc 17.3 67.5 1165.4 
Spp1 12.7 5.0 63.8 
Rnase2 12.1 373.8 4535.5 
Retnlb 7.9 66.0 519.6 
Ccl8 7.8 11.6 90.7 
Pla2g4c 7.8 49.4 384.1 
Retnla 7.5 73.3 547.0 
Arg1 5.5 24.0 131.8 
Timp1 5.2 11.4 60.0 
Olr1 5.1 5.5 28.1 
Ccl24 4.3 14.5 62.9 
Irg1 3.6 18.0 5.0 
Ccl7 3.6 8.4 30.4 
F7 3.3 25.1 83.2 
Cpxm1 3.2 5.2 16.5 
Ccl2 2.6 8.5 21.7 
Hp 2.5 12.5 30.8 




Table 3.1 Cluster 1 gene list 
Genes in cluster 1 as determined in Figure 3.1.D (Filtered on >5 fold in H.p. 1o (relative 




2.4 5.1 12.5 
F13a1 2.3 5.5 12.5 
Trem2 2.2 8.2 18.3 
Cbr2 2.2 10.5 23.1 
Serpina3 2.1 8.4 17.4 
C3 2.0 5.2 10.4 
Saa3 2.0 9.8 19.2 
2310042E22Rik 
(Includes Others) 
1.7 11.8 20.4 
Scd2 1.3 5.7 4.3 
Sell 1.1 8.7 9.1 
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Cluster 2: Genes 
H.p. 2o vs H.p. 1o 
Fold change 
H.p. 1o Fold change 
(rel. to naïve) 
H.p. 2o Fold change 
(rel. to naïve) 
1810009j06Rik/ 
Gm2663 
162.1 1.0 162.1 
Mcpt1 74.3 1.0 74.3 
Mcpt2 59.7 1.0 59.7 
Reg1b 45.7 1.0 45.7 
Reg3d 33.9 1.0 33.9 
Cpa3 32.8 1.0 32.8 
Spta1 28.7 1.0 28.7 
Mir-675 26.3 1.0 26.3 
Fetub 22.7 1.0 22.7 
Rab44 19.1 1.0 19.1 
Ppy 17.5 1.0 17.5 
Slc7a2 17.0 1.0 17.0 
Ranbp3l 16.9 1.0 16.9 
Pah 16.5 1.0 16.5 
Cuzd1 16.2 1.0 16.2 
Itih4 15.6 1.0 15.6 
Prss3 14.7 1.0 14.7 
Sprr2g 12.9 1.0 12.9 
Amy2a 12.7 1.0 12.7 
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Prss2 12.6 1.0 12.6 
Paqr9 12.4 1.0 12.4 
Try4/Try5 12.4 1.0 12.4 
Dcdc2 12.2 1.0 12.2 
Gc 11.9 1.0 11.9 
Tmed11 11.4 1.0 11.4 
Ggh 11.2 1.0 11.2 
Sycn 11.1 1.0 11.1 
Cel 11.1 1.0 11.1 
Serpini2 10.9 1.0 10.9 
Amy1a (Includes 
Others) 
10.8 1.0 10.8 
Ccl2 10.6 1.0 10.6 
Klk3 10.6 1.0 10.6 
Gp2 10.1 1.0 10.1 
Cela3a 9.9 1.0 9.9 
Ptf1a 9.8 1.0 9.8 
Sostdc1 9.8 1.0 9.8 
Ctrb2 9.7 1.0 9.7 
Cpa1 9.7 1.0 9.7 
Tmed6 9.6 1.0 9.6 
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Cckar 9.6 1.0 9.6 
Gm5409/Try10 9.6 1.0 9.6 
Cldn10 9.1 1.0 9.1 
Aass 8.7 1.0 8.7 
Rnase1 8.6 1.0 8.6 
Ptger3 8.2 1.0 8.2 
Slc38a3 8.2 1.0 8.2 
Pnliprp2 8.0 1.0 8.0 
Cbs 7.9 1.0 7.9 
Retnlb 7.9 1.0 7.9 
Amy2b 7.8 1.0 7.8 
Alox15 7.8 1.0 7.8 
Clps 7.8 1.0 7.8 
Loc100862462 7.7 1.0 7.7 
Siglec5 7.7 1.0 7.7 
Gatm 7.6 1.0 7.6 
Erp27 7.6 1.0 7.6 
Angpt1 7.5 1.0 7.5 
Slc34a2 7.5 1.0 7.5 
Tnip3 7.5 1.0 7.5 
Muc6 7.5 1.0 7.5 
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Cpb1 7.4 1.0 7.4 
C8orf47 7.4 1.0 7.4 
Casp9 7.3 1.0 7.3 
Sh2d6 7.3 1.0 7.3 
Pla2g1b 7.3 1.0 7.3 
Lrrc7 7.2 1.0 7.2 
Hapln4 7.1 1.0 7.1 
Igk 7.1 1.0 7.1 
Chst2 7.1 1.0 7.1 
Nupr1 6.8 1.0 6.8 
Rgs22 6.8 1.0 6.8 
Vtn 6.7 1.0 6.7 
Pnliprp1 6.7 1.0 6.7 
Aqp12a/Aqp12b 6.6 1.0 6.6 
Gabra4 6.6 1.0 6.6 
Iapp 6.6 1.0 6.6 
Lrrn1 6.5 1.0 6.5 
Ighg2c 6.4 1.0 6.4 
Arhgdig 6.3 1.0 6.3 
Hamp/Hamp2 6.3 1.0 6.3 
Igf1 6.3 1.0 6.3 
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Tmem108 6.3 1.0 6.3 
Tff2 6.3 1.0 6.3 
Wfdc18 6.3 1.0 6.3 
Ang2 (Includes 
Others) 
6.2 1.0 6.2 
Treml2 6.2 1.0 6.2 
Ly6g6f 6.1 1.0 6.1 
Clu 6.1 1.0 6.1 
Ctsv 6.1 1.0 6.1 
Sh2d7 6.1 1.0 6.1 
Cela3b 6.1 1.0 6.1 
Cilp 5.9 1.0 5.9 
Alox5ap 5.9 1.0 5.9 
Nphs1 5.9 1.0 5.9 
Gnmt 5.9 1.0 5.9 
Dhrs9 5.9 1.0 5.9 
Lcat 5.9 1.0 5.9 
Fut2 5.9 1.0 5.9 
Prss1 5.9 1.0 5.9 
Aldh1l2 5.8 1.0 5.8 
Gprc5c 5.7 1.0 5.7 
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Fkbp11 5.7 1.0 5.7 
Muc1 5.7 1.0 5.7 
Rny1 5.7 1.0 5.7 
Hck 5.7 1.0 5.7 
Tfpi2 5.6 1.0 5.6 
G6pc 5.6 1.0 5.6 
Igh-VS107 5.6 1.0 5.6 
Pdcd1lg2 5.6 1.0 5.6 
Cpa2 5.5 1.0 5.5 
Hpn 5.5 1.0 5.5 
Clec7a 5.5 1.0 5.5 
Gal 5.4 1.0 5.4 
Rbpjl 5.3 1.0 5.3 
Nfil3 5.3 1.0 5.3 
Srgn 5.2 1.0 5.2 
Cldn8 5.2 1.0 5.2 
Fam221a 5.2 1.0 5.2 
Hsbp1l1 5.2 1.0 5.2 
Cela1 5.1 1.0 5.1 
Me1 5.1 1.0 5.1 
Ca4 5.1 1.0 5.1 
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Tspan6 5.1 1.0 5.1 
Fn1 5.1 1.0 5.1 
Slc38a5 5.1 1.0 5.1 
Glipr2 5.0 1.0 5.0 
 
Table 3.2 Cluster 2 gene list 
Genes in cluster 2 as determined in Figure 3.1.E (Filtered on >5 fold in H.p. 2o (relative 
to naïve), p<0.05). 
  




Table 3.3 Cluster 3 gene list 
Genes in cluster 3 as determined in Figure 3.1.E (Filtered on <-5 fold in H.p. 2o (relative 
to naïve), p<0.05). 
Cluster 3: Genes 
H.p. 2o vs H.p. 1o 
Fold change 
H.p. 1o Fold change 
(rel. to naïve) 
H.p. 2o Fold change 
(rel. to naïve) 
Gm11194 -33.2 1.0 -33.2 
Slc13a2 -20.6 1.0 -20.6 
Dbp -11.1 1.0 -11.1 
Cyp2a12/ 
Cyp2a22 
-7.6 1.0 -7.6 
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Chapter 4. Results 2: The role of microRNAs in 
antihelminth immunity 
4.1 Introduction 
microRNAs (miRNAs) are small, non-protein coding RNA molecules of 
approximately 21 nt in length, which negatively regulate mRNA translation. miRNAs 
can act by either translational inhibition or mRNA degradation (Ambros, 2003), thus 
providing finite control over gene expression. As a result, miRNAs have been 
implicated in a plethora of biological settings, from development to immunity.  
In the nucleus, miRNAs are transcribed from their respective gene by RNA 
polymerase II to produce primary miRNA (pri-miRNA) molecules (Lee et al., 2004, 
Lee et al., 2002). The pri-miRNA molecule is then recognised by the RNA binding 
protein Dgcr8, recruiting the RNase Drosha to allow the pri-miRNA molecule to be 
processed to form a precursor miRNA (pre-miRNA) molecule (Lee et al., 2003, Han 
et al., 2004, Denli et al., 2004, Gregory et al., 2004, Landthaler et al., 2004). Exportin-
5 facilitates the transport of the pre-miRNA out of the nucleus and into the cytoplasm 
(Yi et al., 2003). In the cytoplasm the pre-miRNA is processed into mature, functional 
miRNA molecules by the RNase Dicer (Hutvagner et al., 2001, Ketting et al., 2001, 
Knight and Bass, 2001). The free mature miRNA molecule is then recognised and 
bound by an Argonaute (Ago) protein to form a miRNA-Ago complex (Chendrimada 
et al., 2005). This complex is then incorporated into the RNA-induced silencing 
complex (RISC), where the miRNA guides the RISC to its complementary mRNA 
target(s) for gene silencing, preventing mRNA translation into protein (Maniataki and 
Mourelatos, 2005, MacRae et al., 2005, Gregory et al., 2005, Martinez et al., 2002). 
Animal models of intestinal helminth infections support the notion that type 2 
poalrised immune responses are essential for protective immunity (Reynolds et al., 
2012, Maizels et al., 2012b, Allen and Maizels, 2011). miRNAs have been 
investigated in a variety of immunological processes and are essential in the 
resolution of many infectious diseases. Despite this, the identification and role of 
miRNAs in immunity to intestinal helminth infections is relatively unstudied.  
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In this Chapter, we set out to identify and test the role of miRNAs in intestinal helminth 
infection. Specifically asking how local miRNA expression changes following 
helminth infection and identifying miRNAs that are essential for antihelminth 
immunity. To answer these questions, we utilised the naturally occurring, strictly 
enteric, murine intestinal helminth H. polygyrus as it enabled us to model 
susceptibility and resistance in C57BL/6 mice using the 2o challenge infection model 
(Finkelman et al., 1997), as described above. We employed genetic tools to induce 
global miRNA downregulation in vivo, broadly investigating the role of miRNAs in 
immunity to intestinal helminth infection. We also took a more precise approach, 
utilising small sequencing of small intestinal tissue from mice both susceptible and 
resistant to H. polygyrus, as described in Chapter 3, to identify miRNAs implicated 
in immunity to intestinal helminths. Coupling both our miRNA and mRNA sequencing 
datasets, we were able to elucidate candidate miRNAs and putative mRNA targets, 
essential for resistance to H. polygyrus. 
 
4.2 Results 
4.2.1 Global downregulation of miRNA species does not induce resistance to 
H. polygyrus 
Previous studies have demonstrated the importance of a memory type 2 immune 
response in mediating resistance to 2o H. polygyrus challenge infection (Katona et 
al., 1991, Urban et al., 1991a, Urban et al., 1991b). A mixed type 2 and potent 
regulatory immune response is mounted upon 1o infection, allowing a chronic 
infection to establish (Reynolds et al., 2012). However, the type 2 immune response 
initiated upon 2o infection occurs more quickly and at a greater magnitude (Pelly et 
al., 2017, Morimoto et al., 2004), also supported by our mRNA sequencing data 
(Figure 3.1 and Figure 3.2).  
In light of this, we hypothesised that miRNAs provide another level of regulation, 
inhibiting mRNA translation and therefore protein production, restraining protective 
type 2 immune responses during a 1o H. polygyrus infection. We also hypothesised 
that downregulation of miRNAs would release this regulatory ‘brake’ on the immune 
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system, permitting a robust effector response to develop during a 2o H. polygyrus 
infection.  
To test this hypothesis, we generated an inducible system in mice where we could 
eliminate mature miRNA production in vivo during a 1o H. polygyrus infection, in an 
attempt to induce resistance. Constitutive Dicer-deficient mice are embryonically 
lethal (Bernstein et al., 2003). We therefore crossed the Dicerfl/fl mice with the mice 
containing the ubiquitous inducible Cre-recombinase driver R26CreERT2. Following 
tamoxifen treatment, the R26CreERT2Dicerfl/fl mouse will delete Dicer, the enzyme 
required for mature miRNA production (Hutvagner et al., 2001, Ketting et al., 2001, 
Knight and Bass, 2001). 
 
4.2.1.1 Inducible Dicer deletion reduced mature miRNAs in the small intestine 
To confirm that the mouse functioned as expected, we confirmed that tamoxifen 
treatment in vivo would remove Dicer expression and reduce mature miRNA 
expression. We crossed the R26CreERT2Dicerfl/fl mice with the R26yfpDicerfl/fl mice to 
produce the R26CreERT2/yfpDicerfl/fl mice. This provided two functions: firstly, it allowed 
us to track Cre-recombinase activity. Secondly, it kept the R26CreERT2 allele 
heterozygous as homozygosity for this allele can induce Cre-recombinase toxicity 
upon tamoxifen administration (personal communication with E. Scheighoffer, The 
Francis Crick Institute). R26CreERT2/yfpDicerfl/fl mice were treated with either tamoxifen 
or vehicle only for 5 consecutive days (days 0, 1, 2, 3 and 4) and we harvested the 
small intestinal RNA at day 7 (Figure 4.1.A). Tamoxifen treatment led to a 50% 
reduction in Dicer mRNA expression (Figure 4.1.B) and a 50-60% reduction in 
mature miRNA expression (Figure 4.1.C). Despite imperfect deletion, we then 
investigated the effect of this miRNA reduction on immunity to H. polygyrus infection. 
 
4.2.1.2  Reduced Dicer expression does not impact resistance to H. polygyrus 
To test whether the 50-60% reduction of mature miRNA expression had any impact 
on immunity to H. polygyrus, we administered tamoxifen for 5 consecutive days (days 
-5, -4, -3, -2 and -1) prior to infection with H. polygyrus. We harvested the small 
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intestinal tissue 14 days-post infection to confirm Dicer deletion and determine worm 
burden (Figure 4.2.A). We again identified a 50% decrease in Dicer expression 14 
days-post infection (15 days-post final tamoxifen treatment) (Figure 4.2B), similar to 
that previously seen 3 days-post final tamoxifen treatment (Figure 4.1B), indicating 
that Dicer competent cells had not repopulated over the course of infection. Despite 
the 50% decrease in Dicer expression there was no significant change in luminal H. 
polygyrus adult worms or eggs secreted in the faeces (Figure 4.2.C-D), suggesting 
that 50% downregulation in mature miRNAs did not permit resistance to 1o H. 
polygyrus infection.  
For technical reasons, we could not test our hypothesis with these genetic tools. 
From the data generated, with 50-60% reduction of Dicer and miRNAs, we rejected 
our hypothesis outlined in 4.2.1, that miRNAs restrain protective responses to 1o H. 
polygyrus infection and that downregulation of all mature miRNAs restrict resistance 
to 1o H. polygyrus infection. These studies suggest that the regulation of host 
immunity to H. polygyrus infection is likely more complex than global down- or global 
upregulation of miRNA species. As a result, to further understand the roles of specific 
miRNA species mediating immunity to intestinal helminth infection we performed 
miRNA sequencing of the small intestinal tissue of mice susceptible and resistant to 
H. polygyrus, in the same model utilised in Chapter 3, to identify miRNAs implicated 
in immunity to H. polygyrus. 
 
4.2.2 Intestinal miRNA expression in mice resistant to H. polygyrus 
4.2.2.1 miRNA sequencing identifies 24 candidate miRNAs implicated in 
resistance to H. polygyrus infection 
We infected a large cohort of C57BL/6 mice with H. polygyrus L3 larvae. A group of 
mice were sacrificed at day 7 post 1o infection (H.p. 1o). The remaining mice were 
drug cured (Rx) of the 1o infection on days 14 and 15. Some mice were culled on 
days 42 and 63 after drug-cure (Rx (D42) and Rx (D63), respectively). Other mice 
were 2o challenge infected on day 35 or day 56 and sacrificed 7 days later (H.p. 2o 
(D42) and H.p. 2o (D63), respectively). At each time point, duodenal tissue was 
dissected and the RNA extracted for mRNA and miRNA sequencing (Figure 4.3.A). 
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This was the same experiment previously described in Chapter 3, however we took 
a portion of the RNA for miRNA sequencing. This enabled us to have mRNA and 
miRNA transcriptomes for each animal in each group.  
Of note, the depth of the miRNA sequencing performed in these experiments was 
sub-optimal. Ideally, a sequencing depth of 12 million reads per sample is optimal, 
allowing detection approximately 80% of all expressed miRNAs (Sun et al., 2014). 
We only achieved 1-3 million reads per sample and therefore lowly expressed 
miRNA species may not have been detected. In addition, only 4 biological replicates 
were used for the miRNA sequencing, unlike the 8 replicates used for mRNA 
sequencing. This was due to technical difficulties in creating the miRNA sequencing 
libraries. As a result, any candidate miRNAs identified with miRNA sequencing had 
to be validated by qRT-PCR using the full 8 biological replicates. 
Following miRNA sequencing of the duodenal tissue we only identified 5 miRNA 
species significantly differentially expressed in H.p. 1o (relative to naïve, p<0.05). 
This number was increased after drug-cure to 16 and 19 differentially expressed 
miRNAs (relative to naïve, p<0.05), Rx (D42) and Rx (D63) respectively. However, 
the highest number of differentially expressed miRNAs was seen after 2o infection, 
with 35 and 67 miRNAs significantly differentially expressed (relative to naïve, 
p<0.05), H.p. 2o (D42) and H.p. 2o (D63) respectively (Figure 4.3.B). 
To identify miRNAs that may influence resistance to H. polygyrus, we compared the 
miRNA transcriptome of H.p. 1o, H.p. 2o (D42) and H.p. 2o (D63) (each relative to 
naïve, p<0.05) (Figure 4.3.C). This comparison identified 22 miRNAs that were 
qualitatively different between susceptible and resistant mice, not expressed in H.p. 
1o but were expressed in both early H.p. 2o (D42) and later H.p. 2o (D63). We also 
identified 2 miRNAs that were commonly expressed in H.p. 1o, H.p. 2o (D42) and 
H.p. 2o (D63) (relative to naïve, p<0.05), but were quantitatively different in resistant 
mice, with increased expression in both H.p. 2o (D42) and H.p. 2o (D63) (Figure 
4.3.D). Utilising both early and late time points of H.p.2o infection increased our 
confidence that these miRNAs may influence resistance to infection.  
Overall, miRNA sequencing identified 24 candidate miRNAs differentially expressed 
in resistant mice, compared to susceptible and naïve mice.  
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4.2.2.2 qRT-PCR validation identifies miR-99a-5p, miR-148a-3p and miR-155-
5p to be upregulated in mice resistant to H. polygyrus. 
miRNA sequencing identified 24 candidate miRNAs implicated in resistance to H. 
polygyrus infection. These 24 candidate miRNAs were then validated by qRT-PCR 
in the full 8 biological replicates. The criteria for candidate miRNA selection was as 
follows; miRNA expression must be statistically significant (p<0.05) in both H.p. 2o 
(D42) and H.p. 2o (D63), when compared to naïve. Using these criteria three 
candidate miRNAs, miR-99a-5p, miR-148a-3p and miR-155-5p, were validated and 
taken forward for further analysis (Figure 4.4.A). For all three candidate miRNAs, 
qRT-PCR validation closely resembled miRNA sequencing expression, confirming 
two different expression dynamics. Both miR-99a-5p and miR-148a-3p expression 
was unaltered between naïve and H.p. 1o but were significantly upregulated following 
drug treatment and remained elevated with or without 2o challenge infection (Figure 
4.4.A). In contrast, miR-155-5p expression was only induced upon 2o challenge 
infection (Figure 4.4.A). 
Of the remaining miRNAs. 6 were significantly differentially expressed in either H.p. 
2o (D42) or H.p. 2o (D63) (p<0.05), compared to naïve mice, and therefore not taken 
forward for further analysis (Figure 4.4.B). One other miRNA, miR-326-3p, was 
significantly differentially expressed in both H.p. 2o (D42) and H.p. 2o (D63) (p<0.05, 
compared to naïve), but the qPCR and RNA sequencing expression profile differed 
drastically. For this reason, miR-326-3p was not taken forward for further analysis 
(Figure 4.4.C). The remaining miRNAs were not significantly differentially expressed 
in either H.p. 2o (D42) or H.p. 2o (D63) (p<0.05, compared to naïve).  
Of the three candidate miRNAs, only miR-155 has been shown to be essential for 
immunity to H. polygyrus, with resistance to 2o H. polygyrus abrogated in miR-155–/– 
mice (Okoye et al., 2014). miR-99a-5p and miR-148a-3p have not been implicated 
in antihelminth immunity or, more broadly, type 2 immunity. We therefore took these 
three candidate miRNAs forward, analysing their putative mRNA targets and testing 
their roles in immunity to H. polygyrus. 
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4.2.3 Complementary mRNA sequencing and analysis identifies candidate 
miRNA putative mRNA targets 
Using the mRNA sequencing dataset (Figure 3.1), complementary to the miRNA 
dataset (Figure 4.1), we performed in silico ‘expression paired analysis’ using IPA® 
software to identify putative mRNA targets that were inversely regulated to the three 
candidate miRNAs. 
From both H.p. 2o (D42) and H.p. 2o (D63), we identified mRNAs that were 
significantly differentially expressed (relative to naïve, p<0.05) and predicted to be 
direct targets of either miR-99a-5p, miR-148a-3p or miR-155-5p in silico and followed 
the paired expression profile (i.e. mRNA expression increased if miRNA is decreased 
or, in our case, mRNA expression decreased if miRNA is increased) (Figure 4.5.A). 
Assuming that the mechanisms of immunity are similar between early H.p. 2o (D42) 
and late H.p. 2o (D63), we filtered the list of putative mRNA gene targets to those 
that were common to both H.p. 2o (D42) and H.p. 2o (D63), and passed a 1.5-fold 
change filter (Figure 4.5.B). We identified distinct regulatory nodes for each 
candidate miRNA, with very few common mRNA targets shared between the three 
candidate miRNAs. Unfortunately, the number of mRNA targets for each miRNA was 
too small to adequately perform pathway analysis functions, therefore preventing the 
identification of miRNA-regulated pathways that contribute to immunity against H. 
polygyrus. 
 
4.2.4 Candidate miRNA inhibition in vivo 
4.2.4.1 Pharmacological inhibition of miR-99a-5p, miR-148a-3p and miR-155-
5p does not perturb resistance to H. polygyrus infection 
To test whether elevated miR-99a-5p, miR-148a-3p or miR-155-5p were required for 
resistance to H. polygyrus, we used pharmacological miRNA inhibitors during 2o 
challenge infection (Figure 4.6.A). The locked nucleic acid (LNA) miRNA inhibitors 
act by competitively binding to the target miRNA. Inhibitors were used for two main 
reasons. Firstly, to our knowledge, miR-99a-5p and miR-148a-3p knockout mice 
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have not been generated. Secondly, therapeutic and transient inhibition of miRNAs 
would avoid the impact of miRNA inhibition on any developmental processes. 
As all three miRNAs were significantly upregulated 7 days-post 2o challenge infection 
(Figure 4.4), we treated mice with miRNA inhibitors before (day 33), during (day 35) 
and after (day 37 and 40) 2o H. polygyrus infection (Figure 4.6.A). At day 49 (14 
days after 2o H. polygyrus infection) we tested the effect of the miRNA inhibitors on 
miRNA expression, parasitology and immunity. We identified that all of the individual 
miRNA inhibitors, miR-99a-5pΔ, miR-148a-3pΔ and miR-155-5pΔ, significantly 
reduced the expression of their respective miRNA targets in the small intestine 
(relative to vehicle treatment) (Figure 4.6.B). We also confirmed that the control 
inhibitor had no significant effect on any candidate miRNA expression (Figure 4.6.B).  
Control inhibitor-treated mice maintained resistance to H. polygyrus infection, with a 
significant reduction in luminal worm numbers and eggs secreted in the host faeces 
14 days-post 2o infection compared to 1o infection (Figure 4.6.C and Figure 4.7.D). 
However, individual miRNA inhibition also had no significant effect on resistance to 
H. polygyrus with luminal worm numbers and secreted eggs not significantly different 
to mice receiving the control inhibitor, despite a small trend in increased luminal 
worms following miR-148a-3p or miR-155-5p inhibition (Figure 4.6.C and Figure 
4.7.D). 
 
4.2.4.2 Pharmacological inhibition of miR-99a-5p, miR-148a-3p and miR-155-
5p does not perturb type 2 immune responses following 2o H. 
polygyrus infection 
Pharmacological inhibition of miR-99a-5p, miR-148a-3p or miR-155-5p did not 
abrogate resistance to H. polygyrus. However, we determined whether miRNA 
inhibition had any impact on immune responses following 2o challenge infection. Th2 
cell differentiation and type 2 cytokine production is essential in mediating resistance 
to H. polygyrus (Urban et al., 1995, Urban et al., 1991a, Urban et al., 1991b). The 
frequency of IL-4-, IL-13- and IL-5-producing CD44hiCD4+ cells had significantly 
increased in the mLN 14 days-post 2o infection in the control inhibitor-treated mice, 
compared to naïve (Figure 4.7.A). Following miRNA inhibitor treatment, a similar 
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increased frequency of type 2 cytokine-producing CD4+CD44hi cells was observed. 
No aberrant production of IFNγ or IL-17A was identified (Figure 4.7.A). In the spleen, 
the frequency of IL-4-, IL-13-, IL-5- and IFNγ-producing CD44hiCD4+ cells was 
significantly increased 14 days-post 2o infection in the control inhibitor-treated mice, 
compared to naïve, and unchanged following miR-99a-5pΔ or miR-155-5pΔ (Figure 
4.7.B). However, we observed a small, but significant decrease in the frequency of 
IL-4 and IL-5 producing CD44hiCD4+ cells following miR-148a-3pΔ, when compared 
to control inhibitor-treated mice (Figure 4.7.B). Despite the decrease in IL-4 and IL-
5 producing T cells following miR-148a-3pΔ, this had no impact on resistance to H. 
polygyrus 2o infection (Figure 4.6.C). 
The type 2 effector immune response, mediated by the Th2 cytokines IL-4 and IL-
13, was also intact, with production of H. polygyrus-specific IgG1 unaltered following 
inhibition of either miR-99a-5p, miR-148a-3p or miR-155-5p (Figure 4.8.A). 
Similarly, the induction of Arg1, Relmβ (Retnlb) and Gob5 was also unaltered 
following inhibition of either miR-99a-5p, miR-148a-3p or miR-155-5p (Figure 4.8.B-
C). 
Taken together, these data demonstrate that the inhibition of miR-99a-5p, miR-148a-
3p or miR-155-5p did not alter the antihelminth type 2 immunity. 
 
4.2.5 Concurrent candidate miRNA inhibition in vivo 
4.2.5.1 Simultaneous inhibition of miR-99a-5p, miR-148a-3p and miR-155-5p 
abrogates resistance to H. polygyrus 
Individual pharmacological inhibition of miR-99a-5p, miR-148a-3p or miR-155-5p 
had very little effect on immune responses and no impact on immunity to H. polygyrus 
(Figure 4.6, 4.7 and 4.8). Given that all three miRNAs were simultaneously elevated 
during resistance (Figure 4.4.A), we hypothesised that all three miRNAs may act in 
concert and that concurrent inhibition of all three miRNAs would abrogate expulsion 
following a 2o challenge infection. 
We therefore treated mice with PBS, control inhibitor or all three miRNA inhibitors 
combined before (day 33), during (day 35) and after (day 37 and 40) 2o H. polygyrus 
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infection (Figure 4.6.A). Control inhibitor treatment had no effect on the expression 
of miR-99a-5p, miR-148a-3p or miR-155-5p expression in the small intestine, 
whereas the triple miRNA inhibitor treatment (miRNA3Δ) significantly reduced the 
expression of all three miRNAs (Figure 4.9.A).  
As demonstrated previously, control inhibitor treated mice were resistant to 2o H. 
polygyrus infection, with no significant difference seen when compared to vehicle 
control treated mice (Figure 4.9.B-C). However, miRNA3Δ abrogated resistance to 
2o H. polygyrus infection, with mice harbouring significantly more luminal worms than 
control inhibitor treated mice, comparable to that of a 1o infection (Figure 4.9.B). 
 
4.2.5.2 Simultaneous inhibition of miR-99a-5p, miR-148a-3p and miR-155-5p 
induces an inappropriate T cell response 
ICS analysis of activated CD4+ T cells in the mLN revealed no perturbation in the 
frequency of type 2 cytokine-producing T cells (IL-4, IL-13 or IL-5) and no aberrant 
induction of IFNγ- or IL-17A-producing T cells following miRNA3Δ, when compared to 
control inhibitor treatment (Figure 4.10.A). However, ICS analysis in the spleen 
identified a significant reduction of type 2 cytokine-producing CD44hiCD4+ T cells and 
an increase in IFNγ- and IL-17A-producing CD44hiCD4+ T cells following miRNA3Δ 
(Figure 4.10.B). Th2 cells and type 2 cytokine production is essential for resistance 
to H. polygyrus (Urban et al., 1991a, Urban et al., 1991b) and aberrant Th1 cell 
differentiation and cytokine production has previously been demonstrated to 
abrogate protective immunity and promote chronicity in H. polygyrus and other 
intestinal helminth infections (Coomes et al., 2015, Bancroft et al., 1994, Perrigoue 
et al., 2009). To quantitate the H. polygyrus-specific cytokine production by T cells 
we stimulated the mLN cells, isolated following 2o challenge infection, with H. 
polygyrus antigen ex vivo. We identified an increased production of the Th1 cytokine 
IFNγ following miRNA3Δ treatment, although not reaching statistical significance, 
when compared to control inhibitor treatment (Figure 4.11.A). The production of the 
Th2 cytokine IL-13 was intact following H. polygyrus antigen stimulation ex vivo 
(Figure 4.11.A). The antigen specific ex vivo stimulation data (Figure 4.11.A) is in 
discrepancy with the results generated from ICS in the mLN (Figure 4.10.A), but in 
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agreement with the ICS data from the spleen (Figure 4.10.B). In the mLN, this may 
be due the differences between the stimulation, the antigen independent PMA and 
ionomycin stimulation of all cells or the antigen-specific stimulation of T cells. 
Furthermore, the ICS data informs of the frequency of cytokine-producing T cells and 
does not absolutely quantitate the cytokine produced, unlike the absolute cytokine 
detection by ELISA following antigen-specific stimulation ex vivo.  
Overall, the T cell cytokine production data is inconclusive, but suggested that a 
comparable Th2 response was induced following 2o H. polygyrus infection of triple 
miRNA inhibitor treated mice, however an aberrant Th1/Th17 response may have 
also been induced. 
 
4.2.5.3 Antihelminth effector molecules are intact following simultaneous 
inhibition of miR-99a-5p, miR-148a-3p and miR-155-5p 
We next set out to investigate if previously described essential mechanisms of 
antihelminth were intact in miRNA-inhibited mice during 2o H. polygyrus. Type 2 
antihelminth immune mechanisms were unaffected by miRNA3Δ. Specifically, H. 
polygyrus-specific IgG1 production was unaffected by miRNA3Δ (Figure 4.11.A) 
(McCoy et al., 2008). Intestinal expression of Arg1, a marker of aaMϕs and essential 
for immunity (Anthony et al., 2006), was also not significantly altered by miRNA3Δ, 
despite a trend to be increased compared to control inhibitor treatment (Figure 
4.11.B). Similarly, the antihelminth molecule Relmβ (Retnlb), essential for immunity 
(Herbert et al., 2009), and Ccl24, a key chemokine in initiating protective immunity 
(Kannan et al., 2017), were also unaffected by miRNA3Δ (Figure 4.11.C-D). 
Interestingly, expression of the endogenous anthelmintic PLA2g1B (Pla2g1b), 
identified in Chapter 3, was decreased following miRNA3Δ, although not reaching 
statistical significance (Figure 4.11.E). Furthermore, the mucus response to 2o 
challenge infection was also perturbed by miRNA3Δ, with the mucin genes Muc1 and 
Muc16 significantly decreased when compared to control inhibitor treated mice 
(Figure 4.11.F-G). 
Overall, critical antihelminth effector molecule gene expression was intact following 
miRNA3Δ. However, the mucus response was significantly altered following miRNA3Δ 
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in 2o challenge infected mice. Whether a defective Muc1 and Muc16 response can 
perturb resistance to H. polygyrus is currently unclear, unlike Muc5ac which is 
required for expulsion of T. muris (Hasnain et al., 2011, Hasnain et al., 2010). 
 
4.2.5.4 Increased antimicrobial signalling signature following simultaneous 
inhibition of miR-99a-5p, miR-148a-3p and miR-155-5p 
With no obvious perturbation in type 2 immunity or critical downstream mediators 
following miRNA3Δ, we performed RNA sequencing of the small intestinal tissue 14 
days-post 2o infection to identify the transcriptional impact of miRNA3Δ. We compared 
the intestinal transcriptome of mice following miRNA3Δ to both control inhibitor treated 
mice and to vehicle treated mice, 14 days post 2o H. polygyrus infection This allowed 
us to confidently identify the transcriptional signature induced by concurrent inhibition 
of miR-99a-5p, miR-148a-3p and miR-155-5p and control for the impact of 
exogenous control miRNA inhibitor and vehicle treatment. 
243 genes were identified to be significantly differentially expressed following 
miRNA3Δ when compared to both the control inhibitor and vehicle treatment (p<0.05). 
We then analysed these 243 significantly differentially expressed genes using IPA® 
software. Upstream regulator analysis identified 13 molecules/factors which were 
predicted to be significantly activated following miRNA3Δ, relative to control inhibitor 
treatment. The majority of these factors are involved in the innate immune response 
to microbial pathogens, such as LPS, TNFα, TLR4, TICAM1, MyD88, CSF2 and IL-
1β (Figure 4.12.A). Transcriptional changes responsible for the predicated activation 
of these upstream regulators are displayed in Figure 4.12.B (p<0.05, 1.5 fold change 
filter, relative to control inhibitor treatment). From this array of genes, we identified 
three critical antimicrobial genes, Irg1 (also known as Acod1, Interferon response 
gene 1), Tnfa and Lyz2 (lysozyme 2), all of which were upregulated following 
miRNA3Δ, relative to control inhibitor and vehicle treatment (Figure 4.12.C-E). 
Overall, these data suggest that miRNAs miR-99a-5p, miR-148a-3p and miR-155-
5p inhibit antimicrobial signalling pathways following 2o H. polygyrus challenge 
infection. Furthermore, inhibition of these miRNAs during 2o challenge infection 
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resulted in increased antimicrobial signalling, which has previously been associated 
with susceptibility to H. polygyrus (Reynolds et al., 2014a). 
 
4.3 Discussion 
miRNAs are a non-protein coding regulatory RNA species, transcribed from specific 
genes and function by regulating mRNA translation into protein (Ambros, 2003). This 
post-transcriptional fine-tuning function of gene expression has been implicated in a 
variety of biological settings, including immune responses. Never the less, the role 
of miRNAs in regulating immunity to intestinal helminth infection has not been well 
studied. 
Intestinal helminth infections are highly prevalent in the developing world (Bethony 
et al., 2006, Hotez et al., 2008), with chronic infection associated with host morbidity 
(2016). Stalling vaccine efforts (Hotez et al., 2016) and the emergence of drug-
resistant helminths (Albonico et al., 2003, Taman and Azab, 2014) calls for a greater 
understanding of antihelminth immunity to provide new therapeutic avenues. 
In this chapter, we investigated the role of miRNAs in protective immunity to the 
intestinal helminth H. polygyrus. This model allowed us to compare susceptibility and 
resistance in the same host strain. We determined that a 50% global depletion of the 
miRNA processing enzyme Dicer, and subsequent depletion of mature miRNAs, did 
not influence resistance in C57BL/6 mice following a 1o H. polygyrus infection. 
miRNA sequencing of the small intestine identified miRNAs that were differentially 
expressed in both susceptible and resistant mice following H. polygyrus infection. 
Specifically, we identified three miRNAs, miR-99a-5p, miR-148a-3p and miR-155-
5p, that were uniquely upregulated in resistant mice. Individual pharmacological 
inhibition of each of these three miRNAs did not perturb resistance to 2o H. polygyrus 
infection. However, combined inhibition of miR-99a-5p, miR-148a-3p and miR-155-
5p abrogated resistance to 2o H. polygyrus infection, likely through multiple 
mechanisms including dysregulated type 1 immune responses, antimicrobial 
responses and mucin gene expression 
The remainder of this chapter discusses our methods and findings in the context of 
antihelminth immunity, highlighting implications, shortfalls and further questions. 
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4.3.1 The ‘sledgehammer approach’: Attempted global Dicer and miRNA 
knockdown ineffective 
We hypothesised that miRNAs restrain protective responses to 1o H. polygyrus 
infection, permitting chronicity. Furthermore, we hypothesised that a global 
downregulation of miRNAs released a ‘brake’ on the immune system, permitting 
immune-mediated clearance of a 2o H. polygyrus infection. We tested this hypothesis 
by deleting Dicer, the miRNA processing enzyme, to downregulate miRNA 
expression prior to 1o H. polygyrus infection. We only achieved a 50% decrease in 
Dicer expression and a 50-60% reduction in miRNA expression (Figure 4.1). If we 
could achieve greater than 50-60% reduction in miRNA expression, we may be able 
to test our hypothesis. However, the genetic system we had used was imperfect and 
did not allow us to adequately test our hypothesis (Figure 4.2).  
Reducing Dicer, and subsequent miRNA, expression by a maximum of 50% in the 
small intestine was a technical limitation of the mouse we generated, 
R26CreERT2/yfpDicerfl/fl. Despite increased tamoxifen treatments, we were unable to 
reduce Dicer expression more than 50% (data not shown). Penetrance of tamoxifen 
and induction of Cre-recombinase may have been suboptimal in specific cells and/or 
tissues. It would be of interest to isolate different cell types from the small intestine 
following tamoxifen treatment to determine if Dicer expression was differentially 
reduced in different cell types, suggesting tamoxifen-induced Cre-recombinase 
activity was increased in those cells.  
Furthermore, if the 50% reduction in Dicer expression was ubiquitous across all cells 
and tissues, the subsequent reduction of all functional miRNAs may mask the role of 
an essential miRNA, in a specific cell type, critical for antihelminth immunity. We 
therefore pursued a miRNA sequencing approach to identify specific miRNA species 
implicated in resistance to intestinal helminth infection. 
miRNA sequencing of WT mice following 1o and 2o H. polygyrus infection confirmed 
differential expression of miRNAs in susceptible and resistant mice (Figure 4.3). 
However, a similar number of miRNAs were upregulated as downregulated in 
following 2o H. polygyrus infection, suggesting that miRNAs are not generally 
regulated, but are much more complex, suggesting that our initial hypothesis was 
incorrect. 
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4.3.2 miRNA sequencing 
4.3.2.1 Issues, caveats and lessons learnt 
Optimisation of miRNA sequencing used in this thesis posed a significant technical 
challenge. One particular area which required significant optimisation was the size 
separation of the small RNA library, to specifically enrich the sample for miRNAs. 
Automated methods were unsuccessful, resulting in a reduced miRNA read 
percentage. We overcame this by manually size selecting the miRNA fraction of the 
small RNA library using gel electrophoresis and manual extraction under UV 
illumination. This resulted in a significant increase in miRNA read percentage in 4 
biological replicates for each group. To validate candidate miRNAs, any candidate 
miRNA identified from the miRNA sequencing was validated by qRT-PCR using the 
full 8 biological replicates. 
An important limitation of our miRNA sequencing was the depth of sequencing. The 
number of reads produced was sub-optimum. A previous study demonstrated that 
sequencing depth of 12 million reads per sample allowed for the detection of 
approximately 80% of all expressed miRNAs, with lower depth significantly reducing 
the detection of miRNAs (Sun et al., 2014). In our data set we only achieved 1-3 
million reads per sample and therefore were unlikely to detect lowly expressed 
miRNAs. As a result, our miRNA transcriptome analysis was likely to be incomplete, 
missing out on the differential expression of lowly expressed miRNAs. 
Whole tissue miRNA sequencing also presented challenges when attempting to 
elucidate potential mechanisms of the differentially expressed miRNAs. The miRNA 
expression profile is likely to be different depending on cell type, with different 
miRNAs expressed in different cell types and specific miRNAs being more or less 
abundant in different cell types. Furthermore, the targets of a specific miRNAs can 
differ from cell type to cell type. Therefore, the action of the same miRNA may be 
different, for example, in a T cell to its action in a macrophage or epithelial cell. 
Consequently, despite miRNA sequencing of whole tissue giving us a broad view of 
the miRNA expression profile of the small intestine, we lacked resolution to identify 
in which cell type(s) the expression of the candidate miRNAs were critical. As a 
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result, elucidating a precise mechanism was challenging and further investigation is 
required in this area to both identify the cell type and the putative mRNA targets. 
Overall, the miRNA sequencing performed in this Chapter was technically 
challenging and contained several potential limitations. However, early identification 
of these caveats enabled us to account for these as best as possible, particularly in 
the validation of candidate miRNA expression. We were therefore confident in our 
identification of the three candidate miRNAs, miR-99a-5p, miR-148a-3p and miR-
155-5p, being differentially expressed in resistant mice. We also appreciate that, due 
to suboptimal sequencing depth, we may have missed miRNA species differentially 
expressed in our H. polygyrus infection model. 
 
4.3.2.2 Intestinal miRNA profile changes following helminth infection 
Despite the limitations of our miRNA sequencing data set, we were able to identify 
differentially expressed miRNAs in our model of susceptibility and resistance to H. 
polygyrus (Figure 4.3). Specifically, we identified 5 miRNAs that were differentially 
expressed 7 days-post 1o infection (H.p. 1o), with significantly more miRNAs 
differentially expressed 7 days-post 2o infection (H.p. 2o) (35 and 67 miRNAs on day 
42 (H.p. 2o (D42)) and 63 (H.p. 2o (D63)) respectively (relative to naïve, p<0.05)). 
Interestingly, following drug-cure of 1o infection and without 2o infection (Rx (D42) 
and Rx (D63)), miRNAs were significantly differentially expressed in the small 
intestine and maintained until 49 days-post drug-treatment. The number of 
differentially expressed miRNAs in resistant mice, without 2o infection, was less than 
that seen in resistant mice upon infection (16 and 19 miRNAs on day 42 (Rx (D42)) 
and 63 (Rx (D63)) respectively (relative to naïve, p<0.05)), suggesting that a suite of 
miRNAs was differentially expressed upon 2o infection. Although not analysed in 
depth here, it would be interesting to study the miRNAs that are differentially 
expressed in the groups Rx (D42) and Rx (D63). This ‘new baseline’ of miRNA 
expression may confer protection against subsequent challenge infections.  
Of the 5 miRNAs that were differentially expressed in H.p. 1o (relative to naïve, 
p<0.05), it would be of interest to identify if their differential expression was required 
for susceptibility to H. polygyrus expression. Specifically, would pharmacological 
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manipulation of these miRNAs influence resistance to 1o H. polygyrus infection? If 
this was indeed the case, understanding the mRNA targets of these miRNAs may 
uncover biological pathways that promote resistance to infection. Furthermore, do 
intestinal helminths induce changes in host miRNAs to promote chronic infection? 
Indeed, intestinal helminths have been demonstrated to produce immunomodulatory 
proteins and miRNAs which act on the host to promote susceptibility to infection 
(Maizels et al., 2012a, Grainger et al., 2010, Buck et al., 2014). However, whether 
these products alter host miRNA expression is unclear. 
 
4.3.3 Individual miRNA inhibition 
4.3.3.1 Why was individual miRNA inhibition ineffective? 
Following the observation that miRNAs miR-99a-5p, miR-148a-3p and miR-155-5p 
were upregulated in mice resistant to H. polygyrus (Figure 4.4), we tested whether 
these miRNAs were functionally important for protective immunity to H. polygyrus 
infection. Despite significant inhibition of the miRNAs, using pharmacological 
inhibition of each miRNA individually during 2o challenge infection did not impact 
resistance. We therefore concluded that miR-99a-5p, miR-148a-3p and miR-155-5p 
were not essential for resistance to H. polygyrus. However, a previous study 
illustrated that genetic deletion of miR-155 abrogated immunity to 2o H. polygyrus 
infection (Okoye et al., 2014), suggesting miR-155 is essential for resistance to H. 
polygyrus. In light of this discrepancy, it would be of interest to create both miR-99a-
5p–/– and miR-148a-3p–/– mice and assess whether genetic deletion of these miRNAs 
will also abrogate immunity to H. polygyrus infection. The importance in 
understanding the differences between transient pharmacological inhibition and 
germline genetic deletion studies is discussed below in section 4.3.3.2. 
One potential explanation of why the miRNA inhibitors did not abrogate resistance 
to H. polygyrus is that they did not effectively inhibit miRNA expression and function 
in all target tissues and cells. This is however unlikely. The miRNA inhibitors used in 
these experiments function by competitively binding to their target miRNA, 
preventing the miRNA binding to mRNA. Therefore, the miRNA inhibitors function by 
blocking miRNA binding, rather than by directly downregulating miRNA expression. 
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We determined that the miRNA inhibitors decreased the target miRNA expression 
by at least 85%, with the remaining miRNAs likely not functional due to binding by 
the miRNA inhibitors, although this has not been demonstrated. To confirm the 
efficacy of the miRNA inhibitors, the expression of the mRNA targets must be 
compared to both control inhibitor treatment and the miRNA knockout mouse. 
A second explanation of why the miRNA inhibitors did not abrogate resistance to H. 
polygyrus is that the timing of inhibition within the infection model was not optimal. 
This is especially imperative for both miR-99a-5p and miR-148a-3p as they were 
both upregulated in resistant mice, without 2o infection (Figure 4.4). Perhaps, the 
critical functions of both miR-99a-5p and miR-148a-3p in mediating resistance are 
immediately after drug-treatment and not during 2o challenge infection. If this were 
to be the case the transient knockdown of these two miRNAs during 2o infection 
would not abrogate resistance. Therefore, treating the mice during drug treatment 
and throughout 2o infection maybe more appropriate. 
Another possible explanation as to why the individual inhibition of the miRNAs did 
not abrogate resistance to H. polygyrus is that miR-99a-5p, miR-148a-3p and miR-
155-5p cross-regulate the same pathway(s) and perturbation of an individual miRNA 
is not enough to abrogate these pathways. Instead, all three candidate miRNAs 
would need to be concurrently inhibited to release the pathway(s) from miRNA-
regulation and abrogate resistance to H. polygyrus. This is discussed further in 
section 4.3.4. 
 
4.3.3.2 Pharmacological inhibitors versus knockout mice: lessons for 
potential therapeutics 
In section 4.2.4, we determined that individual inhibition of the three candidate 
miRNAs, miR-99a-5p, miR-148a-3p and miR-155-5p, did not perturb protective 
immunity to 2o H. polygyrus infection, despite significantly reducing miRNA 
expression by at least 85%. Conversely, a previous study demonstrated that miR-
155–/– mice failed to expel a 2o H. polygyrus challenge infection (Okoye et al., 2014). 
The discrepancy between the results of these two independent studies may highlight 
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the differences between pharmacological inhibition and genetic deletion models. A 
head-to-head comparison would be required to confirm this discrepancy. 
The key difference between genetic deletion and pharmacological inhibition is the 
constitutive nature of the deletion in the knockout mouse versus the temporal 
downregulation following inhibitor administration. In light of this, both the timing and 
complete removal of the miRNA is likely to be important, as discussed above in 
section 4.3.3.1. This is of great importance when considering the translation of 
results from genetic deletion studies for potential use in the clinic. Pharmacological 
inhibitor treatment may not reproduce the effects seen following genetic deletion and 
it is therefore essential to validate findings using models of genetic deletion with 
pharmacological inhibition. Investigating the differences observed using these two 
approaches may further improve our understanding of the biology in question, 
specifically in the thresholds of gene/protein expression, protein activity versus 
scaffold function and the design of pharmacological agents. 
In the context of miRNAs, these findings highlight a fundamental importance of 
validating results identified using miRNA-knockout mice with pharmacological 
inhibitors. Many conclusions have been drawn using specific miRNA-knockout mice 
in the context of in vivo disease modelling. Whether pharmacological inhibition of 
these specific miRNAs would replicate the phenotype observed in knockout mice 
remains undetermined in the majority of cases.  
 
4.3.4 The power of three: Concurrent miRNA inhibition abrogated protective 
immunity 
Despite individual inhibition of the three candidate miRNAs, miR-99a-5p, miR-148a-
3p and miR-155-5p, being ineffective in perturbing protection against H. polygyrus, 
we identified that simultaneous inhibition of the three candidate miRNAs prevented 
expulsion of a 2o H. polygyrus challenge infection (Figure 4.9). However, further 
studies are required to confirm this finding and identify potential mechanisms. 
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4.3.4.1 Do miRNAs miR-99a-5p, miR-148a-3p and miR-155-5p cooperate to 
regulate intestinal immune homeostasis? 
Analysis of the T cell response following combined miRNA inhibition revealed a 
reduced frequency of type 2 cytokine-producing T cells and an increased frequency 
of type 1 and type 17 T cells in the spleen. However, this was not observed in the 
local draining mLNs (see section 4.2.5.2). It would be of interest to further analyse 
the T cell response 5-7 days-post infection, rather than at day 14, to determine if 
miRNA inhibition perturbed Th2 immunity at the peak of the memory response. 
Moreover, analysing T cell cytokine production in the small intestine during 2o 
infection would also allow us to determine if the T cell response was intact at the site 
of infection. However, this is a limitation of the infection model as the recovery of live 
cells from the intestine following 2o H. polygyrus infection is impossible. 
Analysis of the small intestine determined that the expression of critical antihelminth 
effector molecules Arginase 1 and Relmβ were intact following triple miRNA inhibition 
(Anthony et al., 2006, Herbert et al., 2009). Furthermore, the gene expression of 
Ccl24, a chemokine demonstrated to be important in promoting resistance to H. 
polygyrus (Kannan et al., 2017), was also intact. Interestingly, the expression of the 
endogenous anthelmintic PLA2g1B was seen to be decreased as a result of triple 
miRNA inhibition, although not reaching statistical significance. In Chapter 3, we 
demonstrated that intestinal Pla2g1b expression was dependent upon the microbiota 
and functional immune cells. Whether IEC Pla2g1b expression is directly or indirectly 
regulated by miR-99a-5p, miR-148a-3p and/or miR-155-5p is unclear, although 
Pla2g1b is not a predicted mRNA target of miR-99a-5p, miR-148a-3p or miR-155-
5p. We also observed that concurrent inhibition of these three miRNAs prevented 
the upregulation of the cell surface mucin genes Muc1 and Muc16. The gel-forming 
mucins Muc2 and Muc5ac are essential for the expulsion of T. muris (Hasnain et al., 
2011, Hasnain et al., 2010), whereas intestinal Muc1 expression correlated with 
expulsion of N. brasiliensis (Turner et al., 2013). Muc1 has previously been 
demonstrated to be a critical intestinal barrier function, enhancing protection against 
bacteria and bacterial toxins (McAuley et al., 2007). Both Muc 1 and Muc16 have 
also been implicated in mucosal homeostasis, with both mucins demonstrated to 
supress TLR signalling in epithelial cells perhaps through the formation of a physical 
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barrier preventing epithelial cell contact with TLR agonists (Menon et al., 2015). The 
roles of Muc1 or Muc16 have not been addressed in antihelminth immunity. Perhaps 
these two mucins act to disrupt the intestinal niche of H. polygyrus, forming part of 
the ‘weep and sweep’ response. Alternatively, the upregulation of these two cell 
surface mucins could provide protection against the translocation of the intestinal 
microbiota into the intestinal tissue, following damage elicited from intestinal helminth 
infection, reduce antimicrobial signalling and promote protective immunity to H. 
polygyrus (Reynolds et al., 2014a). This hypothesis is outlined in Figure 4.13.A. 
Transcriptional analysis of the small intestine suggested that the concurrent inhibition 
of miR-99a-5p, miR-148a-3p and miR-155-5p led to increased antimicrobial 
signalling, increasing the expression of antimicrobial response genes, including Irg1, 
Tnfα and Lyz2, and a predicted increase in activation of antimicrobial molecules, 
such as LPS, TLR4, MyD88 and TNFα (see section 4.2.5.4). MyD88 is an essential 
molecule in the signal transduction of IL-1 and TLR signalling pathways (Medzhitov 
et al., 1998, Adachi et al., 1998). MyD88 signalling has previously been 
demonstrated to inhibit protective immunity to H. polygyrus infection (Reynolds et al., 
2014a), suggesting that microbial detection and antimicrobial responses promote 
susceptibility. Therefore, the abrogation of protective immunity and worm expulsion, 
induced by simultaneous inhibition of miR-99a-5p, miR-148a-3p and miR-155-5p 
following 2o H. polygyrus challenge infection, maybe due to increased MyD88-
mediated antimicrobial signalling. An increased antimicrobial response may also be 
responsible for the increased Th1 and Th17 cytokine response identified in the 
spleen, with both Th cell subsets important in the resolution of bacterial and fungal 
infections (Luckheeram et al., 2012). We therefore hypothesise that miR-99a-5p, 
miR-148a-3p and miR-155-5p inhibit TLR-MyD88-mediated antimicrobial signalling, 
which allows for protective immunity and expulsion of 2o H. polygyrus infection 
(Figure 4.13.B). Whether these miRNAs directly or directly regulate antimicrobial 
signalling pathways and target gene expression remains unclear in our model. 
Previous studies have demonstrated that miR-99a-5p, miR-148a-3p and miR-155-
5p can directly modulate MyD88-NF-ϰB signalling pathways and response genes 
(see section 4.3.4.2 below). 
In conclusion of these data, we hypothesise that in resistant mice, the upregulation 
of miRNAs miR-99a-5p, miR-148a-3p and miR-155-5p either function to maintain 
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barrier function and contribute to antimicrobial responses (Figure 4.13.A), indirectly 
explaining the elevated anti-microbial responses seen upon miRNA inhibition, or 
directly inhibit excessive antimicrobial signalling (Figure 4.13.B) allowing protective 
immunity to be unimpeded. Future work is required to confirm, test and validate these 
initial findings and hypotheses of how these miRNAs contribute to resistance to 
intestinal helminth infection 
 
4.3.4.2 Regulation of antimicrobial signalling by miR-99a-5p, miR-148a-3p and 
miR-155-5p and impact on immunity to intestinal helminth infection. 
The activation of TLRs and subsequent antimicrobial responses can be regulated by 
miR-99a-5p, miR-148a-3p and miR-155-5p. Specifically, miR-148a directly targets 
DNA methyltransferase (DNMT)1 causing the hypomethylation and upregulation of 
SOCS1 which in turn directly inhibits TLR3 and TLR4 signalling in DCs (Liu et al., 
2016). miR-99a overexpression attenuates LPS-induced apoptosis and miR-99a 
inhibition potentiated LPS-induced apoptosis activity in cardiomyocytes (Jing et al., 
2017). In contrast to miR-99a and miR-148a, miR-155 has been demonstrated to 
positively regulate LPS-induced TLR4 signalling, with miR-155 expression 
upregulated following LPS stimulation of macrophages and required for sustaining 
LPS-induced TNFα responses (Cheng et al., 2012, Mantuano et al., 2016, Li et al., 
2013). Interestingly, several helminth products can to bind to TLRs, such as double-
stranded RNA and the lipid lysophosphatidylserine from Schistosoma mansoni, 
which binds to TLR3 and TLR2, respectively (Aksoy et al., 2005, van der Kleij et al., 
2002). Similarly, the ES product ES-62 from the filarial nematode 
Acanthocheilonema viteae stimulates TLR4 (Goodridge et al., 2005, Goodridge et 
al., 2004). H. polygyrus infection is also likely to result in host TLR signalling not only 
via ES products, but through exposure to the microbiota following physical disruption 
of the epithelial barrier upon infection. We can therefore postulate that these 
microbial signals are likely to impair the hosts ability to induce a protective type 2 
immune response upon infection. Indeed, Myd88-deficient mice have an increased 
protective immune response to 1o H. polygyrus infection (Reynolds et al., 2014a).  
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The NF-ϰB signalling cascade is one component of the MyD88-mediated 
antimicrobial signalling pathway which initiates the transcription of a variety of 
antimicrobial and inflammatory response genes (Medzhitov et al., 1998, Adachi et 
al., 1998). miRNAs miR-99a-5p, miR-148a-3p and miR-155-5p can regulate NF-ϰB 
signalling molecules and target genes. Specifically, miR-99a can inhibit LPS-induced 
NF-ϰB translocation to the nucleus and target gene transcription, such as TNFα, IL-
1β and IL-6 in endothelial cells (Bao et al., 2016). Furthermore, both miR-148a and 
miR-155 also directly target RelA, an essential component of NF-ϰB signalling, thus 
inhibiting NF-ϰB signal transduction (Bao and Lin, 2014). In addition, miR-148a-3p 
also directly targets IϰB kinase (IKK)-β, the catalytic subunit responsible for NF-ϰB 
activation (Ghosh and Karin, 2002), also preventing NF-ϰB translocation to the 
nucleus and target gene transcription (Patel et al., 2015). The role of NF-ϰB 
signalling has been investigated in immunity to intestinal helminth infection. Both NF-
ϰB1- and NF-ϰB2-deficient mice failed to expel T. muris infection, with both strains 
inducing an inappropriate Th1 response (Artis et al., 2002). A later study 
demonstrated that IKK-β expression in IECs was required for expulsion of T. muris, 
specifically in inducing TSLP expression and subsequent initiation of Th2 cell-
dependent-immunity (Zaph et al., 2007). Whether NF-ϰB signalling is required for 
immunity to H. polygyrus remains unclear.  
We hypothesised that the upregulation of miRNAs miR-99a-5p, miR-148a-3p and 
miR-155-5p in resistant mice regulates antimicrobial immunity or signalling, indirectly 
influencing protective immunity to H. polygyrus. We can test whether the miRNA-
regulation of antimicrobial signalling is required for protective immunity to H. 
polygyrus. To do this we could treat Myd88-deficient mice with combined 
administration of miR-99a-5p, miR-148a-3p and miR-155-5p inhibitors in an attempt 
to rescue protective immunity. If these miRNA inhibitor-treated mice expel a 2o H. 
polygyrus infection we can conclude that the upregulation of miRNAs miR-99a-5p, 
miR-148a-3p and miR-155-5p in resistant mice is essential for immunity to H. 
polygyrus through the regulation of antimicrobial signalling. 
Taken together, these data support our hypothesis and indicate that miR-99a-5p, 
miR-148a-3p and miR-155-5p may cooperate to inhibit various aspects of 
antimicrobial responses, directly or indirectly, allowing for unimpeded protective 
immunity and expulsion of 2o H. polygyrus challenge infection. Furthermore, the co-
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regulation of a specific pathway by these three independent miRNAs may explain 
why inhibition of one single miRNA was ineffective in perturbing immunity to H. 
polygyrus; as the three miRNAs may have some level of redundancy in effectively 
suppressing these antimicrobial pathways. 
 
4.3.5 The importance of miRNAs in antihelminth immunity 
Overall, the experiments presented in this Chapter demonstrate that miRNAs are 
differentially regulated following intestinal helminth infection, with distinct miRNA 
profiles in mice with acquired resistance to H. polygyrus compared to susceptible 
mice. Furthermore, we identified three miRNAs, miR-99a-5p, miR-148a-3p and miR-
155-5p, that were upregulated in resistant mice during 2o H. polygyrus infection and 
were essential for resistance to 2o H. polygyrus infection. Taken together, these data 
illustrate an essential role of miRNAs in regulating functional antihelminth immunity 
and highlight an understudied area of research in immunity to intestinal helminth 
infections. 
Further research is required to elucidate the proposed coordinated mechanisms of 
miR-99a-5p, miR-148a-3p and miR-155-5p in regulating immunity to H. polygyrus. 
Extensive research should be focussed in delineating the role of specific miRNAs in 
cell types critical for- and in the context of immunity to intestinal helminth infections. 
This is crucial to overcome the limitation of whole tissue miRNA sequencing, 
especially with the same miRNA being expressed in multiple cell types with the 
potential of mediating different functions. Currently, the miRNA repertoire and 
function has only been studied succinctly in T cells, within antihelminth immunity 
(Okoye et al., 2014, Kelada et al., 2013).  
A potentially exciting area of investigation is the role of miRNAs in host-pathogen 
interactions. Recent studies have elegantly illustrated the transfer of H. polygyrus-
derived miRNAs to the host as a mechanism to downregulate antihelminth immune 
responses (Buck et al., 2014). Whether the opposite is also true, with host-derived 
miRNAs transferred to helminths is unclear. For example, it is interesting to speculate 
that host-derived miRNAs, upregulated in resistant mice, are released, transferred 
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and taken up into intestinal helminths to impair parasite health through miRNA-
mRNA target inhibition, leading to expulsion. 
A greater understanding the of miRNAs in immunity to intestinal helminth infections 
may uncover novel antihelminth biological pathways and improve our understanding 
of antihelminth immunity. 
  





Figure 4.1 Inducible Dicer deletion perturbs mature miRNA biogenesis in the small 
intestine 
(A) R26CreERT2/yfpDicerfl/fl mice were treated with 2mg of tamoxifen or vehicle control on 5 
consecutive days (1mg i.p. and 1mg oral gavage) and the small intestine was harvested 
3 days after the final treatment (Day 7). (B) Dicer expression in the duodenal tissue at 
day 7. (C) miRNA species Let-7b, Let-7d, Let-7f and miR-155 expression in the duodenal 
tissue at day 7. Data represented as mean ± SEM, n=4. All data is representative of at 
least two independent experiments. * = p<0.05, ** = p<0.01 determined using an 
unpaired two-tailed t test 
  




Figure 4.2 Inducible Dicer deletion in the small intestine does not promote 
resistance to H. polygyrus 
(A) R26CreERT2/yfpDicerfl/fl mice were treated with 2mg of tamoxifen or vehicle control on 5 
consecutive days from day -5 to -1 (1mg i.p. and 1mg oral gavage). Mice were then orally 
infected with 200 L3 H. polygyrus larvae on day 0 and the small intestine was harvested 
14 days-post infection. (B) Dicer expression in the duodenal tissue at day 14. (C) Luminal 
H. polygyrus worms in the small intestine 14 days-post infection. (D) Faecal egg counts 
14 days-post H. polygyrus infection. Data represented as mean ± SEM, n=8-9. All data 
is representative of at least two independent experiments. ns = not significant, **** = p< 
0.0001 determined using an unpaired two-tailed t test  
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Figure 4.3 miRNA sequencing of intestinal tissue identified miRNAs associated 
with resistance to H. polygyrus 
(A) C57BL/6 mice were orally infected with 200 L3 H. polygyrus larvae on day 0. A cohort 
of mice was sacrificed 7 days-post 1o H. polygyrus infection (H.p. 1o). Remaining mice 
were drug treated (Rx) on days 14 and 15. Two cohorts of mice were then harvest on 
day 42 or Day 63 (Rx (D42) and Rx (D63), respectively). Another two cohorts of mice 
were then 2o challenge infected with H. polygyrus on day 35 or day 56 and harvested 7 
days-post 2o infection (H.p. 2o (D42) and H.p. 2o (D63), respectively). RNA was harvested 
from the duodenum at each time point. (B) The number of miRNAs significantly 
differentially expressed in H.p. 1o, Rx (D42), Rx (D63), H.p.2o (D42) and H.p.2o (D63) 
(up- and downregulated, relative to naïve, p<0.05). (C) Common and differentially 
expressed miRNAs in H.p. 1o, H.p.2o (D42) and H.p.2o (D63) (relative to naïve, p<0.05). 
(D) Expression profile of candidate miRNAs implicated in resistant to H. polygyrus 
identified in (C). n=4.  
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Figure 4.4 qRT-PCR validation of candidate miRNAs implicated in resistance to H. 
polygyrus 
(A) miR-99a-5p, miR-148a-3p and miR-155-5p; (B) miR-30-5p, miR-96-5p; miR-146b-
5p, miR-47-3p, miR-183-5p and miR194-1-3p; (C) miR-328-3p expression in small 
intestine from RNA sequencing data, n=4. Significance confirmed by qPCR, n=8. Data 
represented as mean ± SEM. * = p<0.05, ** = p< 0.01 determined using a one-way 
ANOVA with Dunnett’s multiple comparison analysis.   




Figure 4.5 Complementary mRNA sequencing and in silico analysis identified 
candidate miRNA putative mRNA targets 
(A) IPA analysis and identification of miR-99a-5p, miR-148a-3p and miR-155-5p 
expression-paired putative mRNA targets significantly expressed in H.p.2o (D42) and 
H.p.2o (D63) (relative to naïve, p<0.05). Data from mRNA sequencing (shown in Figure 
3.1) complementary to miRNA sequencing (shown in Figure 4.3). (B) Expression profile 
of candidate miRNA and expression-paired putative mRNA targets identified in (A) (1.5 
fold change filter, relative to naïve, p<0.05). 
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Figure 4.6 Individual candidate miRNA inhibition does not abrogate resistance to 
2o H. polygyrus infection 
(A) C57BL/6 mice were orally infected with 200 L3 H. polygyrus larvae on day 0 (H.p. 
1o). Mice were then drug treated (Rx) on days 14 and 15 and 2o challenge infected on 
day 35 (H.p. 2o). Mice were treated with miRNA inhibitors, negative control inhibitor or 
vehicle only on days 33, 35, 37 and 40. Mice were then sacrificed on day 49 (14 days-
post 2o infection). (B) miR-99a-5p, miR-148a-5p and miR-55-5p expression in the small 
intestine following treatment with miRNA inhibitor (miR-99a-5pΔ, miR-148a-5pΔ or miR-
55-5pΔ), negative control inhibitor (control) or vehicle only. (C) Luminal H. polygyrus adult 
worms in the small intestine and (D) faecal egg burden on day 49 following treatment 
with miRNA inhibitor (miR-99a-5pΔ, miR-148a-5pΔ or miR-55-5pΔ), negative control 
inhibitor (control) or vehicle only. Data represented as mean ± SEM, n=5. All data is 
representative of two independent experiments. * = p<0.05, ** = p< 0.01, *** = p< 0.001, 
**** = p< 0.0001 determined using a one-way ANOVA with Dunnett’s multiple 
comparison analysis.  
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Figure 4.7 Individual miRNA inhibition does not alter T cell response following 2o 
H. polygyrus infection 
The frequency of cytokine producing CD44hi CD4+ T cells in naive mice or 14 days-post 
2o H. polygyrus infection following treatment with vehicle only, negative control inhibitor 
(control) or miRNA inhibitor (miR-99a-5pΔ, miR-148a-5pΔ or miR-55-5pΔ) in the mLN (A) 
and spleen (B). Data represented as mean ± SEM, n=5. All data is representative of two 
independent experiments. ** = p< 0.01, **** = p< 0.0001 determined using a one-way 
ANOVA with Dunnett’s multiple comparison analysis. 
  




Figure 4.8 Antihelminth effector responses are intact following individual miRNA 
inhibition 
(A) H. polygyrus-specific IgG1 in the serum from mice 14 days-post 2o H. polygyrus 
infection following treatment with vehicle only, negative control inhibitor (control) or 
miRNA inhibitor (miR-99a-5pΔ, miR-148a-5pΔ or miR-55-5pΔ). Expression of Arg1 (B), 
Retnlb (C) and Gob5 (D) in the small intestine 14 days-post 2o H. polygyrus infection 
following treatment with vehicle only, negative control inhibitor (control) or miRNA 
inhibitor (miR-99a-5pΔ, miR-148a-5pΔ or miR-55-5pΔ), relative to naïve mice. Data 
represented as mean ± SEM, n=5. All data is representative of two independent 
experiments. ns = not significant, * = p<0.05, ** = p< 0.01 determined using two-way 
ANOVA withDunnett’s multiple comparison analysis or a one-way ANOVA with Dunnett’s 
multiple comparison analysis. 
  




Figure 4.9 Concurrent triple miRNA inhibition abrogates immunity to 2o H. 
polygyrus infection 
(A) miR-99a-5p, miR-148a-5p and miR-55-5p expression in the small intestine following 
vehicle, control inhibitor (control) or triple miRNA inhibitor (miRNA3Δ) treatment. (B) 
Luminal H. polygyrus adult worms in the small intestine and (C) faecal egg burden on 
day 49 (14 days-post 2o infection) following treatment vehicle, control inhibitor (control) 
or triple miRNA inhibitor (miRNA3Δ) treatment. Data represented as mean ± SEM, n=5. 
Data is representative of one experiment. ** = p< 0.01, **** = p< 0.0001 determined using 
a one-way ANOVA with Dunnett’s multiple comparison analysis. 
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Figure 4.10 Concurrent triple miRNA inhibition alters the T cell response following 
2o H. polygyrus infection 
The frequency of cytokine producing CD44hi CD4+ T cells in naive mice or 14 days-post 
2o H. polygyrus infection following treatment with vehicle only, negative control inhibitor 
(control) or triple miRNA inhibitor (miRNA3Δ) in the mLN (A) and spleen (B). (C) ex vivo 
H. polygyrus antigen-specific cytokine production from the mLN 14 days-post 2o 
infection. Data represented as mean ± SEM, n=5. Data is from one experiment. * = 
p<0.05, ** = p< 0.01, **** = p< 0.0001 determined using a one-way ANOVA with 
Dunnett’s multiple comparison analysis. 
  




Figure 4.11 Concurrent triple miRNA inhibition inhibits mucin responses to H. 
polygyrus 
(A) H. polygyrus-specific IgG1 in the serum from mice 14 days-post 2o H. polygyrus 
infection following treatment with vehicle only, negative control inhibitor (control) or triple 
miRNA inhibitors (miRNA3Δ). Expression of Arg1 (B), Retnlb (C), Ccl24 (D), Pla2g1b (E), 
Muc1 (F) and Muc16 (G) in the small intestine of naïve mice or 14 days-post 2o H. 
polygyrus infection following treatment with vehicle only, negative control inhibitor 
(control) or triple miRNA inhibitors (miRNA3Δ) determined by RNA sequencing. Data 
represented as mean ± SEM, n=5. Data is representative of one experiment. ns = not 
significant, * = p<0.05 determined using two-way ANOVA with Dunnett’s multiple 
comparison analysis or by RNA sequencing analysis. 
  




Figure 4.12 Transcriptome analysis identified an increased antimicrobial 
signalling signature following triple miRNA inhibition 
(A) Predicted activated upstream regulators of the transcriptome of mice following triple 
miRNA inhibitor treatment (miRNA3Δ) (compared to control inhibitor treatment) 14 days-
post 2o H. polygyrus infection. (B) Fold change of the differentially expressed genes 
responsible for the predicated activation of the upstream regulators in (A) following 
miRNA3Δ (compared to control inhibitor treatment, p<0.05, 1.5 fold change filter). 
Expression of the antimicrobial response genes Irg1 (C), Tnfa (D) and Lyz2 (E) in the 
small intestine of naïve mice or 14 days-post 2o H. polygyrus infection following treatment 
with vehicle only, negative control inhibitor (control) or triple miRNA inhibitors (miRNA3Δ) 
determined by RNA sequencing. Data represented as mean ± SEM, n=5. Data is 
representative of one experiment. * = p<0.05 determined by RNA sequencing analysis. 
  




Figure 4.13 Hypotheses as to how miRNAs miR-99a-5p, miR148a-3p and miR-155-
5p regulate antimicrobial signalling 
(A) Indirect miRNA inhibition of antimicrobial signalling hypothesis. (B) Direct miRNA 
inhibition of antimicrobial signalling hypothesis.
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Chapter 5. General discussion 
Intestinal helminth infections are highly prevalent, infecting approximately a third of 
the world’s population, and are responsible for significant health and economic 
burdens (Bartsch et al., 2016, Fitzpatrick, 2013, Bethony et al., 2006). With a small 
number of chemotherapeutic drugs available, evidence of drug-resistant helminths 
(Kaplan and Vidyashankar, 2012) and stalling vaccine efforts, it is imperative to 
improve our understanding of antihelminth immunity to identify new therapeutic 
avenues. Utilising next generation RNA sequencing, it is within this context that we 
have identified both two novel mechanisms of antihelminth immunity. 
 
5.1 H. polygyrus: a suitable model for the study of antihelminth 
immunity? 
The well-established H. polygyrus model of intestinal helminth infection was used in 
this thesis to identify novel mechanisms of antihelminth immunity. H. polygyrus is 
from the same phylogenetic order as the human hookworm parasites N. americanus 
and A. duodenale, as well as the ruminant parasites H. contortus and T. 
circumcincta, (Gouy de Bellocq et al., 2001) making H. polygyrus a suitable model 
of STH. Furthermore, H. polygyrus is a naturally occurring intestinal helminth of the 
mouse, establishing chronic infection in many inbred mouse strains (Ehrenford, 
1954). In addition, H. polygyrus does allow for the study of intestinal antihelminth 
immunity in isolation, without the complexity of multiple organs. It is therefore a useful 
model for focussing on mechanisms of chronicity and resistance within the small 
intestine. Importantly, susceptible mice can acquire resistance to H. polygyrus 
following drug-cure of a 1o infection, expelling subsequent 2o challenge infections 
(Finkelman et al., 1997). This facet of the H. polygyrus model was essential in our 
investigation of novel antihelminth mechanisms, providing the comparison of 
susceptibility and resistance in the same genetic strain of mice. 
However, there are caveats in utilising H. polygyrus for the study of antihelminth 
immunity. H. polygyrus is a strictly enteric parasite, like both ruminant helminths H. 
contortus and T. circumcincta, transmitted by the faecal-oral route (Ehrenford, 1954). 
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However, N. americanus and A. duodenale infect humans through skin penetration 
and migrate to the lung before entering the small intestine, much like the lifecycle of 
N. brasiliensis. Therefore, the strictly enteric H. polygyrus mouse model does not 
fully replicate the infective lifecycle of its human helminth relatives, suggesting that 
N. brasiliensis maybe a better model to study human STH. However, N. brasiliensis 
does not establish chronic infections in mice (Camberis et al., 2003), preventing its 
use to model chronic infection. Currently, there is not a naturally occurring mouse 
intestinal helminth which mimics the infective lifecycle of both N. americanus and A. 
duodenale and establishes chronic infection. A further caveat of the using H. 
polygyrus to model STH is the ability to acquire resistance. The ability of mice to 
acquire resistance to 2o challenge infection following chemotherapeutic drug-cure of 
1o infection is rarely observed in human helminth infection. Although in the study of 
endemic populations identified that some individuals exhibit a greater degree of 
resistance that others, with 70% of the worm burden occurring in only 15% of the 
infected individuals (Hotez et al., 2008). Indeed, the generation of antihelminth 
immune memory takes years to develop and rarely achieves sterile immunity 
(McSorley and Maizels, 2012), unlike the classic immune memory-mediated 
protection observed against viral and bacterial pathogens (Farrell et al., 2017).  
Nevertheless, investigating the mechanisms of acquired immunity to H. polygyrus, 
and other intestinal helminths, may uncover novel mechanism of immunity that could 
be translated into human antihelminth immunity, vaccine development and drug 
design. This is exemplified in this thesis, where we identified an endogenous 
anthelmintic, PLA2g1B. Whether PLA2g1B mediates the killing and expulsion of 
human and ruminant intestinal helminths remains to be tested.  
It would be of great interest to employ a similar transcriptomic comparison strategy 
in other intestinal helminth models to identify compare and contrast mechanisms of 
antihelminth immunity. Utilising T. muris, which infects the cecum and colon, may 
uncover novel antihelminth mechanisms specific to whipworms and the large 
intestine. For example, Pla2g1b-deficiency compromised immunity to small intestine 
dwelling helminths, N. brasiliensis and H. polygyrus, but not the cecum dwelling T. 
muris. Specifically, the comparison of the cecum transcriptome of C57BL/6 mice 
following a low dose (susceptible) versus a high dose infection (resistant) may 
identify transcriptional changes associated with resistance. Furthermore, these 
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resistant-specific transcriptional changes could be cross-referenced to those 
identified here, both mRNA and miRNA, to determine both conserved and helminth 
species-specific mechanisms of antihelminth immunity. 
 
5.2 Cooperation of type 2 immunity and the microbiota for 
functional antihelminth immunity? 
Our understanding of immunity to intestinal helminths places type 2 immunity at 
forefront of protection, with type 1 immune responses contributing to susceptibility 
and chronic infection (Grencis, 2015, Allen and Maizels, 2011). The type 2 cytokines, 
IL-4 and IL-13, are critical in mediating many of the immunological and 
pathophysiological antihelminth effector immune responses (Urban et al., 1991b, 
Else and Grencis, 1996).  
For protective immunity to H. polygyrus, CD4+ T cell production of IL-4 and IL-13 is 
essential in mediating IL-4Rα-induced effector response (Urban et al., 1991a, Urban 
et al., 1991b). The IL-4Rα-dependent induction of Arg1-expressing aaMϕs (Anthony 
et al., 2006), Relmβ production from goblet cells (Herbert et al., 2009) and the 
production of antigen-specific IgG1 (McCoy et al., 2008) are critical for protection. In 
Chapter 3 we demonstrated that the memory type 2 immune response is ineffective 
in mediating protection to 2o H. polygyrus infection in the absence of PLA2g1B. 
Furthermore, PLA2g1B, when added to L3 larvae in vitro, was able to provide 
protection against 1o H. polygyrus infection in the absence of a memory type 2 
response. However, in vivo the induction and anthelmintic effect of PLA2g1B required 
a functional immune system, suggesting a cooperation between the type 2 immune 
response and the direct anthelmintic properties of PLA2g1B for functional protection. 
Interestingly, our data indicated that Pla2g1b expression in IECs was regulated by 
pathways distinct from type 2 immunity. Instead, Pla2g1b expression required 
intestinal microbiota, uncoupling a critical mediator of antihelminth immunity from 
type 2 immunity. The role of the microbiota in influencing immunity is not a new 
concept. Specific bacterial species and products have previously been demonstrated 
to shape distinct immune responses. For example, the generation of local Th17 cells 
in the intestine is dependent upon the presence of segmented filamentous bacterium 
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(Ivanov et al., 2009) and microbiota-derived butyrate is essential for the 
differentiation of colonic Tregs, thus regulating intestinal homeostasis (Furusawa et 
al., 2013). The exact mechanism in which Pla2g1b is regulated, beyond that 
described above, remains unclear. However, it is exciting to speculate that the 
current notion of antihelminth immunity maybe expanded beyond type 2 immune-
mediated mechanisms, incorporating other immune and non-immune aspects, such 
as microbiota-mediated shaping of stromal immunity. 
Contrary to the above postulation, increased microbial detection may in fact have a 
detrimental effect on functional antihelminth immunity. Indeed, previous studies 
demonstrated that Myd88-deficient mice, which have compromised antimicrobial 
recognition, were more resistant to a 1o H. polygyrus infection (Reynolds et al., 
2014a). Furthermore, we demonstrated that simultaneous inhibition of miR-99a-5p, 
miR-148a-3p and miR-155-5p resulted in increased activation of LPS-TLR4-MyD88 
signalling cascades and abrogated resistance to 2o H. polygyrus infection. These 
data can be extrapolated to suggest that resistant mice upregulate expression of 
miR-99a-5p, miR-148a-3p and miR-155-5p to inhibit antagonistic antimicrobial 
signalling to allow for unimpeded protective antihelminth immunity following 2o 
challenge infection.  
These two notions can be reconciled when considering the time and space of 
microbial interaction. The intestinal microbiota could be a positive influence on 
antihelminth immunity when the epithelial barrier function is not compromised. For 
example, following drug-cure of a 1o H. polygyrus infection where the microbiota is 
required for the expression of Pla2g1b. However, upon infection, H. polygyrus larvae 
penetrate through the mucosal barrier of the small intestine, potentially allowing for 
the commensal microbes to translocate into the intestinal tissue, thus inducing the 
MyD88 signalling cascade and associated antimicrobial inflammatory responses. In 
this setting, the inflammatory response induced by the intestinal microbes may 
antagonise antihelminth immunity, preventing killing and expulsion (Reynolds et al., 
2014a). 
Although, type 2 immune responses are essential for antihelminth immunity, a 
coordinated response with the stromal compartment is essential. The influence of 
the microbiota with respect to antihelminth immunity is still poorly understood. 
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Nevertheless, as we show here, the microbiota was required for induction of the 
endogenous anthelmintic enzyme PLA2g1B but it may also antagonise expulsion 
mechanisms. Identifying ‘protective’ components of the microbiota or their products 
that promote PLA2g1b may open up new areas of probiotic-related studies in the 
treatment of intestinal helminths 
 
5.3 Tissue memory? 
The design of our RNA sequencing experiments incorporated two control groups of 
drug-treated, resistant mice that were not given a 2o challenge infection after drug 
clearance of the 1o infection. These groups were denoted as Rx (D42) and Rx (D63), 
representing mice 28 days- and 49 days-post drug-mediated parasite clearance. 
Although not analysed in detail within this thesis, the mRNA and miRNA 
transcriptional profiles of groups Rx (D42) and Rx (D63) were markedly different from 
naïve mice (Figure 3.1.C. and Figure 4.3.B, respectively). Specifically, there was an 
increase in differentially expressed mRNA and miRNAs in these groups (Rx (D42) 
and Rx (D63)) compared to 1o H. polygyrus infection (relative to naïve, p<0.05). 
These observations suggested that there was a new transcriptional ‘baseline’ in the 
small intestine in resistant mice, prior to 2o challenge infection, which was maintained 
for up to 49 days-post drug-cure. Indeed, expression of Pla2g1b, miR-99a-5p and 
miR-148a-3p was upregulated in resistant mice, prior to 2o challenge infection, and 
were required for protection against 2o infection. Are these changes in the 
transcriptome of the small intestine therefore conferring tissue/stromal memory, 
distinct from classical adaptive immunological memory, providing protection against 
subsequent infection? If so, how is this tissue memory maintained? Is it through the 
alteration of the intestinal microbiota? Or is it mediated by the seeding of immune 
cells in situ, such as memory lymphocyte clusters (MLCs) (Iijima and Iwasaki, 2014, 
Schenkel et al., 2014). Furthermore, would this helminth-induced tissue memory alter 
the response to other pathogens? 
A recent study has suggested that tissue or stromal memory exists in the skin, with 
inflammatory insults inducing epithelial stem cell memory for at least 180 days, 
hastening barrier restoration after subsequent tissue damage (Naik et al., 2017). In 
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this study, stromal memory was independent of macrophages or T cells, instead the 
1o inflammatory insult induced intrinsic epigenetic changes in epithelial stem cells. In 
addition, mechanisms of local immunological memory have been demonstrated, 
involving the formation of macrophage-T cell MLCs (Iijima and Iwasaki, 2014, Ariotti 
et al., 2014, Schenkel et al., 2014). Whether MLCs influence or require tissue-derived 
factors, representing tissue memory, and whether local MLCs are induced following 
drug-cure of 1o H. polygyrus infection is unclear and warrants further study. 
 
5.4 Lessons learnt and future applications 
Throughout this thesis we have utilised RNA sequencing approaches in an attempt 
to identify novel mechanisms of antihelminth immunity. To this end, we identified 
PLA2g1B as an endogenous anthelmintic, critical for immunity to both H. polygyrus 
and N. brasiliensis. We also identified a critical miRNA regulatory node, including 
miR-99a-5p, miR-148a-3p and miR-155-5p, which was critical for protective 
immunity to H. polygyrus.  
For the defence against many classes of pathogens, the host has evolved 
endogenous molecules to directly impair and kill the invading pathogen, such as 
cathelicidins, defensins, histatins, lysozyme and lactoferrin (Zelechowska et al., 
2016). We can now add the direct anthelmintic activity of PLA2g1B to this arsenal of 
host-derived defence molecules. Further work should be focussed on elucidating the 
role of phospholipids in intestinal helminth health and infection, as well as 
investigating the precise mechanism by which Pla2g1b expression is regulated in the 
host intestine. Following these two lines of research could allow these finding to be 
translated into potential therapeutics; in the generation of a new class of synthetic 
anthelmintic drugs, which target critical phospholipids required for helminth health, 
or by inducing host Pla2g1b expression in the intestine, alongside vaccine efforts, to 
promote long lasting immunity. Care must be taken in manipulating host expression 
of Pla2g1b as mouse studies have demonstrated that PLA2g1B can promote obesity, 
diabetes and atherosclerosis upon high calorie diet. Therefore, increasing Pla2g1b 
expression to aid antihelminth immunity may also promote diet-associated diseases. 
These postulations fall into an emerging field of research, the interplay between 
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metabolic syndromes and immunity. Human helminth infections have an inversely 
association with metabolic syndromes, such as type 2 diabetes and cardiovascular 
disease (Wiria et al., 2014), and animal models of STH suggest that helminth 
infection can improve insulin sensitivity following high fat diet (Wu et al., 2011). 
Further studies are needed to fully elucidate the relationship between intestinal 
helminth infection and metabolic syndromes. It would be interesting to study the 
interplay between the interplay between diet-induced obesity H. polygyrus infection, 
specifically investigating the role of PLA2g1B in mediating both obesity and 
antihelminth immunity. 
Over the past 16 years, since the discovery of miRNAs in mammals, the wave of 
excitement around miRNA-mediated gene regulation has peaked and slowly 
subsided. This may be, in part, due to the complex nature of miRNAs, far beyond the 
notion that a single miRNA regulates a single mRNA target, in regulating a suite of 
genes, much like transcription factors. As a result, miRNAs have been demonstrated 
to regulate several critical aspects of immunity, however their role in antihelminth 
immunity is relatively understudied. Here we identified three miRNAs, miR-99a-5p, 
miR-148a-3p and miR-155-5p, which act concurrently to promote resistance to H. 
polygyrus. Individual pharmacological inhibition of each miRNA did not abrogate 
immunity to 2o challenge H. polygyrus infection, possibly highlighting a discrepancy 
between pharmacological transient inhibition and genetic constitutive knockout 
studies. Of significance, simultaneous inhibition of all three miRNAs did abrogate 
resistance. This may highlight an additional level of complexity of miRNA-mediated 
gene regulation, suggesting that miRNA species act in synergy to induce distinct 
biological functions. Further investigation into the localisation of these miRNAs in 
specific cell types would allow for comprehensive elucidation of the mRNA targets 
and mechanism of miRNA-mediated antihelminth immunity. These miRNAs are likely 
to be expressed in multiple cell types making this avenue of investigation particularly 
complex and difficult, requiring cell-specific targeted approaches to untangle the role 
of distinct miRNAs in specific cell types. 
In conclusion, we have identified novel mechanisms of antihelminth immunity, the 
endogenous anthelmintic PLA2g1B and a miRNA module critical in regulating the 
antihelminth immune response. These findings advance our understanding of 
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antihelminth immunity and help open up new areas of study in the ongoing quest for 
new therapeutics and avenues for the treatment of STH. 
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Figure 5.1 Working model: Expression of Pla2g1b and miRNAs miR-99a-5p, miR-
148a-3p and miR-155-5p are upregulated in resistant mice and are essential for 
immunity to H. polygyrus. 
C57BL/6 mice are susceptible to 1o H. polygyrus infection: Infective L3 larvae penetrate 
and embed into the small intestine where they undergo two developmental moults before 
emerging as adult L5 worms in the intestinal lumen. 
Acquired tissue memory: Following drug-cure of 1o infection, a memory Th2 cells and 
memory B cells are established. In addition, the expression of miRNAs miR-99a-5p and 
miR-148a-3p are increased in the intestinal tissue (Observation 1). Pla2g1b expression 
is also upregulated in intestinal epithelial cells (Observation 2), mediated by both the 
immune compartment and/or the intestinal microbiota.  
PLA2g1B and miRNAs miR-99a-5p, miR-148a-3p and miR-155-5p are required for 
resistance to 2o challenge infection: PLA2g1B directly cleaves phospholipids from 
invading L3 larvae (Observation 3). Anthelmintic PLA2g1B acts in cooperation with type 
2 immunity to promote helminth trapping and killing. Expression of miR-155-5p is 
increased in the intestinal tissue following 2o infection. Upregulation of miRNAs miR-99a-
5p, miR-148a-3p and miR-155-5p is required to supress the antagonistic antimicrobial 
response (Observation 4) and promote functional type 2 immunity, resulting in helminth 
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